

ENDOGENOUS SERUM TESTOSTERONE IN MAN: AGEING, THE METABOLIC SYNDROME, FUNCTIONAL DECLINE AND THE ROLE OF SUPPLEMENTATION

Matthew Timothy Haren

B.App.Sc (Human Movement), B.Health.Sc(Hons)

Departments of Medicine and Public Health

Faculty of Health Sciences

The University of Adelaide

Adelaide, South Australia

Australia

Thesis submitted in total fulfillment of the Degree of Doctor of Philosophy (PhD)

February 2005



REFERENCES

1. Mooradian, A.D., J.E. Morley, and S.G. Korenman, *Biological actions of androgens*. *Endocr Rev*, 1987. 8(1): p. 1-28.
2. Nankin, H.R. and J.H. Calkins, *Decreased bioavailable testosterone in aging normal and impotent men*. *J Clin Endocrinol Metab*, 1986. 63(6): p. 1418-20.
3. Sih, R., et al., *Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial*. *J Clin Endocrinol Metab*, 1997. 82(6): p. 1661-7.
4. Mendel, C.M., *Rates of dissociation of sex steroid hormones from human sex hormone-binding globulin: a reassessment*. *J Steroid Biochem Mol Biol*, 1990. 37(2): p. 251-5.
5. Manni, A., et al., *Bioavailability of albumin-bound testosterone*. *J Clin Endocrinol Metab*, 1985. 61(4): p. 705-10.
6. Gray, J.M., et al., *Effects of testosterone on body weight and adipose tissue: role of aromatization*. *Physiol Behav*, 1979. 23(3): p. 465-9.
7. Hryb, D.J., et al., *Solubilization and partial characterization of the sex hormone-binding globulin receptor from human prostate*. *J Biol Chem*, 1989. 264(10): p. 5378-83.
8. Hryb, D.J., et al., *The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones*. *J Biol Chem*, 1990. 265(11): p. 6048-54.

9. Nakhla, A.M., M.S. Khan, and W. Rosner, *Biologically active steroids activate receptor-bound human sex hormone-binding globulin to cause LNCaP cells to accumulate adenosine 3',5'-monophosphate*. J Clin Endocrinol Metab, 1990. 71(2): p. 398-404.
10. Schweikert, H.U., et al., *Testosterone metabolism in human bone*. Acta Endocrinol (Copenh), 1980. 95(2): p. 258-64.
11. Vittek, J., et al., *The metabolism of 7alpha-3H-testosterone by rat mandibular bone*. Endocrinology, 1974. 94(2): p. 325-9.
12. Selby, C., *Sex hormone binding globulin: origin, function and clinical significance*. Ann Clin Biochem, 1990. 27 (Pt 6): p. 532-41.
13. Morley, J.E., P. Patrick, and H.M. Perry, 3rd, *Evaluation of assays available to measure free testosterone*. Metabolism, 2002. 51(5): p. 554-9.
14. Vermeulen, A., L. Verdonck, and J.M. Kaufman, *A critical evaluation of simple methods for the estimation of free testosterone in serum*. J Clin Endocrinol Metab, 1999. 84(10): p. 3666-72.
15. Mathur, R.S., et al., *Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females*. Fertil Steril, 1981. 35(1): p. 29-35.
16. Kapoor, P., B.M. Luttrell, and D. Williams, *The free androgen index is not valid for adult males*. J Steroid Biochem Mol Biol, 1993. 45(4): p. 325-6.
17. O'Connor, S., et al., *The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation*. J Steroid Biochem, 1973. 4(4): p. 331-9.

18. Khaw, K.T. and E. Barrett Connor, *Lower endogenous androgens predict central adiposity in men*. *Ann Epidemiol*, 1992. 2(5): p. 675-82.
19. Scopacasa, F., et al., *Bone density and bone-related biochemical variables in normal men: a longitudinal study*. *J Gerontol A Biol Sci Med Sci*, 2002. 57(6): p. M385-91.
20. Barrett-Connor, E., et al., *A prospective, population-based study of androstenedione, estrogens, and prostatic cancer*. *Cancer Res*, 1990. 50(1): p. 169-73.
21. Contoreggi, C.S., et al., *Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men*. *J Androl*, 1990. 11(5): p. 460-70.
22. De Pergola, G., et al., *Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men*. *Metabolism*, 1997. 46(11): p. 1287-93.
23. Duell, P.B. and E.L. Bierman, *The relationship between sex hormones and high-density lipoprotein cholesterol levels in healthy adult men*. *Arch Intern Med*, 1990. 150(11): p. 2317-20.
24. Feldman, H.A., et al., *Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study*. *J Clin Endocrinol Metab*, 2002. 87(2): p. 589-98.
25. Goemaere, S., et al., *Inverse association between bone turnover rate and bone mineral density in community-dwelling men >70 years of age: no major role of sex steroid status*. *Bone*, 2001. 29(3): p. 286-91.

26. Goodman-Gruen, D. and E. Barrett-Connor, *Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women*. *Diabetes Care*, 2000. 23(7): p. 912-8.
27. Haffner, S.M., et al., *Obesity, body fat distribution and sex hormones in men*. *Int J Obes Relat Metab Disord*, 1993. 17(11): p. 643-9.
28. Harris, J.A., P.A. Vernon, and D.I. Boomsma, *The heritability of testosterone: a study of Dutch adolescent twins and their parents*. *Behav Genet*, 1998. 28(3): p. 165-71.
29. Henriksen, G.L., et al., *Serum dioxin, testosterone, and gonadotropins in veterans of Operation Ranch Hand*. *Epidemiology*, 1996. 7(4): p. 352-7.
30. Kalish, L.A., W.S. McDougal, and J.B. McKinlay, *Family history and the risk of prostate cancer*. *Urology*, 2000. 56(5): p. 803-6.
31. Kiratli, B.J., et al., *Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer*. *Urology*, 2001. 57(1): p. 127-32.
32. Kontoleon, P.E., et al., *Hormonal profile in patients with congestive heart failure*. *Int J Cardiol*, 2003. 87(2-3): p. 179-83.
33. Lima, N., et al., *Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat*. *Int J Obes Relat Metab Disord*, 2000. 24(11): p. 1433-7.
34. Luukkaa, V., et al., *Inverse correlation between serum testosterone and leptin in men*. *J Clin Endocrinol Metab*, 1998. 83(9): p. 3243-6.

35. Morley, J.E., et al., *Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men*. *Metabolism*, 1997. 46(4): p. 410-3.
36. Ng, T.P., et al., *Male endocrine functions in workers with moderate exposure to lead*. *Br J Ind Med*, 1991. 48(7): p. 485-91.
37. Phillips, G.B., K. Yano, and G.N. Stemmermann, *Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones*. *J Clin Epidemiol*, 1988. 41(12): p. 1151-6.
38. Pickles, T., et al., *Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma*. *Cancer*, 2002. 94(2): p. 362-7.
39. Rosmond, R., et al., *A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern*. *J Intern Med*, 2003. 254(4): p. 386-90.
40. Shaneyfelt, T., et al., *Hormonal predictors of prostate cancer: a meta-analysis*. *J Clin Oncol*, 2000. 18(4): p. 847-53.
41. Shores, M.M., et al., *Increased incidence of diagnosed depressive illness in hypogonadal older men*. *Arch Gen Psychiatry*, 2004. 61(2): p. 162-7.
42. Stellato, R.K., et al., *Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study*. *Diabetes Care*, 2000. 23(4): p. 490-4.
43. Tominaga, A., et al., *Effects of surgery on testosterone secretion in male patients with pituitary adenomas*. *Endocr J*, 1996. 43(3): p. 307-12.

44. Van Den Saffele, J.K., et al., *Serum leptin levels in healthy ageing men: are decreased serum testosterone and increased adiposity in elderly men the consequence of leptin deficiency?* Clin Endocrinol (Oxf), 1999. 51(1): p. 81-8.
45. Yarnell, J.W., et al., *Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study.* Arterioscler Thromb, 1993. 13(4): p. 517-20.
46. Yu, M.W., et al., *Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma.* J Natl Cancer Inst, 2000. 92(24): p. 2023-8.
47. Zmuda, J.M., et al., *Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants.* Am J Epidemiol, 1997. 146(8): p. 609-17.
48. Nomura, A.M., et al., *Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States).* Cancer Causes Control, 1998. 9(4): p. 425-32.
49. Tibblin, G., et al., *The pituitary-gonadal axis and health in elderly men: a study of men born in 1913.* Diabetes, 1996. 45(11): p. 1605-9.
50. Barrett-Connor, E., D.G. Von Muhlen, and D. Kritz-Silverstein, *Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study.* J Clin Endocrinol Metab, 1999. 84(2): p. 573-7.
51. Basaria, S., et al., *Long-term effects of androgen deprivation therapy in prostate cancer patients.* Clin Endocrinol (Oxf), 2002. 56(6): p. 779-86.

52. Behre, H.M., J. Bohmeyer, and E. Nieschlag, *Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls*. Clin Endocrinol (Oxf), 1994. 40(3): p. 341-9.
53. Bonnefoy, M., et al., *Physical activity and dehydroepiandrosterone sulphate, insulin-like growth factor I and testosterone in healthy active elderly people*. Age Ageing, 1998. 27(6): p. 745-51.
54. Ferrini, R.L. and E. Barrett-Connor, *Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men*. Am J Epidemiol, 1998. 147(8): p. 750-4.
55. Iannuzzi-Sucich, M., K.M. Prestwood, and A.M. Kenny, *Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women*. J Gerontol A Biol Sci Med Sci, 2002. 57(12): p. M772-7.
56. Kiel, D.P., et al., *Sex hormones and lipoproteins in men*. Am J Med, 1989. 87(1): p. 35-9.
57. Denti, L., et al., *Aging-related decline of gonadal function in healthy men: correlation with body composition and lipoproteins*. J Am Geriatr Soc, 2000. 48(1): p. 51-8.
58. Field, A.E., et al., *The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men*. J Clin Endocrinol Metab, 1994. 79(5): p. 1310-6.
59. Gray, A., et al., *Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study*. J Clin Endocrinol Metab, 1991. 73(5): p. 1016-25.

60. Baumgartner, R.N., et al., *Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes*. *Obes Res*, 1999. 7(2): p. 141-9.
61. Kamischke, A., et al., *Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy*. *Eur Respir J*, 1998. 11(1): p. 41-5.
62. Yuan, J.M., et al., *A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China*. *Int J Cancer*, 1995. 63(4): p. 491-3.
63. Mitchell, R., et al., *Age related changes in the pituitary-testicular axis in normal men; lower serum testosterone results from decreased bioactive LH drive*. *Clin Endocrinol (Oxf)*, 1995. 42(5): p. 501-7.
64. Kaiser, F.E., et al., *Impotence and aging: clinical and hormonal factors*. *J Am Geriatr Soc*, 1988. 36(6): p. 511-9.
65. Maas, D., A. Jochen, and B. Lalande, *Age-related changes in male gonadal function. Implications for therapy*. *Drugs Aging*, 1997. 11(1): p. 45-60.
66. Tenover, J.S., et al., *The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate*. *J Clin Endocrinol Metab*, 1987. 65(6): p. 1118-26.
67. Harman, S.M., et al., *Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging*. *J Clin Endocrinol Metab*, 2001. 86(2): p. 724-31.
68. Morley, J.E., *Androgens and aging*. *Maturitas*, 2001. 38(1): p. 61-71; discussion 71-3.

69. Longcope, C., et al., *Androgens, estrogens, and sex hormone-binding globulin in middle-aged men*. J Clin Endocrinol Metab, 1990. 71(6): p. 1442-6.
70. Nahoul, K. and M. Roger, *Age-related decline of plasma bioavailable testosterone in adult men*. J Steroid Biochem, 1990. 35(2): p. 293-9.
71. Simon, D., et al., *The influence of aging on plasma sex hormones in men: the Telecom Study*. Am J Epidemiol, 1992. 135(7): p. 783-91.
72. Morley, J.E., et al., *Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone*. Proc Natl Acad Sci U S A, 1997. 94(14): p. 7537-42.
73. Baker, H.W. and B. Hudson, *Changes in the pituitary-testicular axis with age*. Monogr Endocrinol, 1983. 25: p. 71-83.
74. Leifke, E., et al., *Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort*. Clin Endocrinol (Oxf), 2000. 53(6): p. 689-95.
75. Maruyama, Y., et al., *Variation with age in the levels of sex-steroid-binding plasma protein as determined by radioimmunoassay*. Acta Endocrinol (Copenh), 1984. 106(3): p. 428-32.
76. Morley, J.E., et al., *Validation of a screening questionnaire for androgen deficiency in aging males*. Metabolism, 2000. 49(9): p. 1239-42.
77. Tenover, J.L., *Testosterone and the aging male*. J Androl, 1997. 18(2): p. 103-6.

78. Schiavi, R.C., et al., *Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction*. Arch Sex Behav, 1997. 26(3): p. 231-41.
79. Schiavi, R.C., et al., *The relationship between pituitary-gonadal function and sexual behavior in healthy aging men*. Psychosom Med, 1991. 53(4): p. 363-74.
80. Sternbach, H., *Age-associated testosterone decline in men: clinical issues for psychiatry*. Am J Psychiatry, 1998. 155(10): p. 1310-8.
81. Gladkova, A.I., *[The regulation of male sexual behavior by the sex hormones]*. Usp Fiziol Nauk, 1999. 30(1): p. 97-105.
82. Burris, A.S., et al., *A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men*. J Androl, 1992. 13(4): p. 297-304.
83. Yesavage, J.A., et al., *Plasma testosterone levels, depression, sexuality, and age*. Biol Psychiatry, 1985. 20(2): p. 222-5.
84. Barrett-Connor, E., D. Goodman-Gruen, and B. Patay, *Endogenous sex hormones and cognitive function in older men*. J Clin Endocrinol Metab, 1999. 84(10): p. 3681-5.
85. Janowsky, J.S., S.K. Oviatt, and E.S. Orwoll, *Testosterone influences spatial cognition in older men*. Behav Neurosci, 1994. 108(2): p. 325-32.
86. Moffat, S.D. and E. Hampson, *A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference*. Psychoneuroendocrinology, 1996. 21(3): p. 323-37.

87. Tchernof, A., et al., *Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables*. *Atherosclerosis*, 1997. 133(2): p. 235-44.
88. Zumoff, B., et al., *Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity*. *J Clin Endocrinol Metab*, 1990. 71(4): p. 929-31.
89. Tchernof, A., et al., *Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones*. *J Endocrinol*, 1996. 150(Suppl): p. S155-64.
90. Marin, P. and S. Arver, *Androgens and abdominal obesity*. *Baillieres Clin Endocrinol Metab*, 1998. 12(3): p. 441-51.
91. Lovejoy, J.C., et al., *Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men*. *Int J Obes Relat Metab Disord*, 1995. 19(9): p. 614-24.
92. Elbers, J.M., et al., *Long-term testosterone administration increases visceral fat in female to male transsexuals*. *J Clin Endocrinol Metab*, 1997. 82(7): p. 2044-7.
93. Clague, J.E., F.C. Wu, and M.A. Horan, *Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men*. *Int J Androl*, 1999. 22(4): p. 261-5.
94. Baumgartner, R.N., et al., *Predictors of skeletal muscle mass in elderly men and women*. *Mech Ageing Dev*, 1999. 107(2): p. 123-36.

95. Murphy, S., et al., *Sex hormones and bone mineral density in elderly men*. Bone Miner, 1993. 20(2): p. 133-40.
96. Gillberg, P., A.G. Johansson, and S. Ljunghall, *Decreased estradiol levels and free androgen index and elevated sex hormone-binding globulin levels in male idiopathic osteoporosis*. Calcif Tissue Int, 1999. 64(3): p. 209-13.
97. Kenny, A.M., et al., *Bone density, bone turnover, and hormone levels in men over age 75*. J Gerontol A Biol Sci Med Sci, 1998. 53(6): p. M419-25.
98. Vanderschueren, D., et al., *Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model*. Bone, 2000. 27(5): p. 611-7.
99. Falahati-Nini, A., et al., *Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men*. J Clin Invest, 2000. 106(12): p. 1553-60.
100. Center, J.R., et al., *Hormonal and biochemical parameters in the determination of osteoporosis in elderly men*. J Clin Endocrinol Metab, 1999. 84(10): p. 3626-35.
101. Heller, R.F., et al., *Coronary heart disease in 'low risk' men*. Atherosclerosis, 1983. 49(2): p. 187-93.
102. Hamalainen, E., et al., *Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men*. Metabolism, 1986. 35(6): p. 535-41.

103. Nanjee, M.N., et al., *Relationships of plasma lipoprotein concentrations to unbound, albumin-bound and sex hormone-binding globulin-bound fractions of gonadal steroids in men*. Eur J Clin Invest, 1989. 19(3): p. 241-5.
104. Barrett-Connor, E. and K.T. Khaw, *Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study*. Circulation, 1988. 78(3): p. 539-45.
105. Simon, D., et al., *Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study*. J Clin Endocrinol Metab, 1997. 82(2): p. 682-5.
106. van Kesteren, P.J., et al., *Mortality and morbidity in transsexual subjects treated with cross-sex hormones*. Clin Endocrinol (Oxf), 1997. 47(3): p. 337-42.
107. Gann, P.H., et al., *Prospective study of sex hormone levels and risk of prostate cancer*. J Natl Cancer Inst, 1996. 88(16): p. 1118-26.
108. Eaton, N.E., et al., *Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies*. Br J Cancer, 1999. 80(7): p. 930-4.
109. Haren, M.T., et al. *The calculation of bioavailable testosterone*. in *VIIIth International Congress of Andrology*. 2001. Montreal, Quebec, Canada: Medimond.
110. Smith, K.W., H.A. Feldman, and J.B. McKinlay, *Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men*. Clin Endocrinol (Oxf), 2000. 53(6): p. 703-11.
111. Snyder, P.J., et al., *Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age*. J Clin Endocrinol Metab, 1999. 84(8): p. 2647-53.

112. Hajjar, R.R., F.E. Kaiser, and J.E. Morley, *Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis*. J Clin Endocrinol Metab, 1997. 82(11): p. 3793-6.
113. Wang, C., et al., *Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group*. J Clin Endocrinol Metab, 2000. 85(8): p. 2839-53.
114. Arver, S., et al., *Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men*. Clin Endocrinol (Oxf), 1997. 47(6): p. 727-37.
115. Morley, J.E., et al., *Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study*. J Am Geriatr Soc, 1993. 41(2): p. 149-52.
116. Urban, R.J., et al., *Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis*. Am J Physiol, 1995. 269(5 Pt 1): p. E820-6.
117. Snyder, P.J., et al., *Effect of testosterone treatment on bone mineral density in men over 65 years of age*. J Clin Endocrinol Metab, 1999. 84(6): p. 1966-72.
118. Katznelson, L., et al., *Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism*. J Clin Endocrinol Metab, 1996. 81(12): p. 4358-65.
119. Bhasin, S., et al., *Testosterone replacement increases fat-free mass and muscle size in hypogonadal men*. J Clin Endocrinol Metab, 1997. 82(2): p. 407-13.

120. Brodsky, I.G., P. Balagopal, and K.S. Nair, *Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study*. J Clin Endocrinol Metab, 1996. 81(10): p. 3469-75.
121. Wang, C., et al., *Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study*. J Clin Endocrinol Metab, 1996. 81(10): p. 3578-83.
122. Douglas, T.H., et al., *Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men*. J Surg Oncol, 1995. 59(4): p. 246-50.
123. Jin, B., A.J. Conway, and D.J. Handelsman, *Effects of androgen deficiency and replacement on prostate zonal volumes*. Clin Endocrinol (Oxf), 2001. 54(4): p. 437-45.
124. Ellyin, F. *The long-term beneficial effects of low dose testosterone in the aging male*. in *77th Annual Meeting o the Endocrine Society (USA)*. 1995.
125. Lambert, C.P., et al., *Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial*. J Clin Endocrinol Metab, 2002. 87(5): p. 2100-6.
126. Snyder, P.J., et al., *Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age*. Am J Med, 2001. 111(4): p. 255-60.
127. Kenny, A.M., et al., *Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels*. J Gerontol A Biol Sci Med Sci, 2002. 57(7): p. M460-5.

128. Steidle, C., et al., *AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function*. J Clin Endocrinol Metab, 2003. 88(6): p. 2673-81.
129. Seidman, S.N., et al., *Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial*. J Clin Psychiatry, 2001. 62(6): p. 406-12.
130. Morley, J.E., et al., *Testosterone and frailty*
Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. Clin Geriatr Med, 1997. 13(4): p. 685-95.
131. Marin, P., et al., *The effects of testosterone treatment on body composition and metabolism in middle-aged obese men*. Int J Obes Relat Metab Disord, 1992. 16(12): p. 991-7.
132. Tenover, J.S., *Effects of testosterone supplementation in the aging male*. J Clin Endocrinol Metab, 1992. 75(4): p. 1092-8.
133. Bakhshi, V., et al., *Testosterone improves rehabilitation outcomes in ill older men*. J Am Geriatr Soc, 2000. 48(5): p. 550-3.
134. Ferrando, A.A., et al., *Testosterone administration to older men improves muscle function: molecular and physiological mechanisms*. Am J Physiol Endocrinol Metab, 2002. 282(3): p. E601-7.
135. Kenny, A.M., et al., *Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels*. J Gerontol A Biol Sci Med Sci, 2001. 56(5): p. M266-72.

136. Park, N.C., et al., *Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency*. *Aging Male*, 2003. 6(2): p. 86-93.
137. Crawford, B.A., et al., *Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment*. *J Clin Endocrinol Metab*, 2003. 88(7): p. 3167-76.
138. English, K.M., et al., *Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study*. *Circulation*, 2000. 102(16): p. 1906-11.
139. Aversa, A., et al., *Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction*. *Clin Endocrinol (Oxf)*, 2003. 58(5): p. 632-8.
140. Gluud, C., P. Wantzin, and J. Eriksen, *No effect of oral testosterone treatment on sexual dysfunction in alcoholic cirrhotic men*. *Gastroenterology*, 1988. 95(6): p. 1582-7.
141. Cherrier, M.M., et al., *Testosterone supplementation improves spatial and verbal memory in healthy older men*. *Neurology*, 2001. 57(1): p. 80-8.
142. O'Carroll, R. and J. Bancroft, *Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study*. *Br J Psychiatry*, 1984. 145: p. 146-51.
143. Holmang, S., et al., *Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men*. *Prostate*, 1993. 23(2): p. 99-106.

144. Uyanik, B.S., et al., *Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study.* Jpn Heart J, 1997. 38(1): p. 73-82.
145. Wu, S.Z. and X.Z. Weng, *Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients.* Chin Med J (Engl), 1993. 106(6): p. 415-8.
146. Anderson, R.A., J. Bancroft, and F.C. Wu, *The effects of exogenous testosterone on sexuality and mood of normal men.* J Clin Endocrinol Metab, 1992. 75(6): p. 1503-7.
147. Morales, A., et al., *Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes.* J Urol, 1997. 157(3): p. 849-54.
148. Haddad, G., et al. *Testosterone treatment improves body composition and muscle strength in hypogonadal men.* in *76th Annual Meeting of the Endocrine Society.* 1994.
149. Alexander, G.M., et al., *Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities.* Horm Behav, 1998. 33(2): p. 85-94.
150. Norton, K. and T. Olds, *Anthropometrica. A textbook of body measurements for sport and health courses.* 1996, Sydney: UNSW Press.
151. Barry, M.J., et al., *The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.* J Urol, 1992. 148(5): p. 1549-57; discussion 1564.
152. Greenleaf, C.L., R.B. Margolis, and G.J. Erker, *Application of the Trail Making Test in differentiating neuropsychological impairment of elderly persons.* Percept Mot Skills, 1985. 61(3 Pt 2): p. 1283-9.

153. Arbuthnott, K. and J. Frank, *Trail making test, part B as a measure of executive control: validation using a set-switching paradigm*. J Clin Exp Neuropsychol, 2000. 22(4): p. 518-28.
154. Crowe, S.F., *The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on parts A and B of the Trail Making Test*. J Clin Psychol, 1998. 54(5): p. 585-91.
155. Stratford, P.W., G.R. Norman, and G.M. McIntosh, *Generalisability of grip strength measurements in patients with tennis elbow*. Physical Therapy, 1989. 69: p. 276-281.
156. Diessel, E., et al., *Evaluation of a new body composition phantom for quality control and cross-calibration of DXA devices*. J Appl Physiol, 2000. 89(2): p. 599-605.
157. Pardridge, W.M., *Serum bioavailability of sex steroid hormones*. Clin Endocrinol Metab, 1986. 15(2): p. 259-78.
158. Pardridge, W.M. and L.J. Mietus, *Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone*. J Clin Invest, 1979. 64(1): p. 145-54.
159. Gouchie, C. and D. Kimura, *The relationship between testosterone levels and cognitive ability patterns*. Psychoneuroendocrinology, 1991. 16(4): p. 323-34.
160. Wittert, G.A., et al. *Proceedings of the USA Endocrine Society*. in *USA Endocrine Society*. 2000. Toronto, CANADA.
161. Rabijewski, M., M. Adamkiewicz, and S. Zgliczynski, *[The influence of testosterone replacement therapy on well-being, bone mineral density and lipids in elderly men]*. Pol Arch Med Wewn, 1998. 100(3): p. 212-21.

162. Mathers, C. *Keynote Address: Health differentials between Australian males and females: A statistical profile.* in *National men's health Conference.* 1996. Melbourne.
163. Connell, R., et al., *Men's Health: A research agenda and background report.* Department of Health and Aged Care, 1999. Canberra.
164. *National Health Survey 2001: Summary of Results.* 2001, Australian Bureau of Statistics.
165. MacDonald, J. and D. Crawford, *Recent developments concerning men's health in Australia.* Australian Journal of Primary Health, 2002. 8(1): p. 77-82.
166. Fletcher, R., *Testosterone poisoning or terminal neglect? The Men's Health Issue.* Parliamentary Research Service, 1995. Research Paper No. 22.
167. Matsumoto, A.M., *Andropause: clinical implications of the decline in serum testosterone levels with aging in men.* J Gerontol A Biol Sci Med Sci, 2002. 57(2): p. M76-99.
168. Tamimi, R., et al., *Testosterone and oestradiol in relation to tobacco smoking, body mass index, energy consumption and nutrient intake among adult men.* Eur J Cancer Prev, 2001. 10(3): p. 275-80.
169. Anderson, K.E., et al., *Diet-hormone interactions: protein/carbohydrate ratio alters reciprocally the plasma levels of testosterone and cortisol and their respective binding globulins in man.* Life Sci, 1987. 40(18): p. 1761-8.
170. Campbell, L.V., D.G. Carey, and D.J. Chisholm, *Measurement of central adiposity. A bet each way?* Diabetes Care, 1996. 19(9): p. 1033-4.

171. Ware, J.E. and C.D. Sherbourne, *The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection*. *Medical Care*, 1992. 30: p. 473-483.
172. Ware, J.E., et al., *SF-36 Health Survey: manual and interpretation guide*. 1993, The Health Institute, New England Medical Centre: Boston, Massachusetts.
173. McCallum, J., *The new 'SF-36' Health Status Measure: Australian validity tests*. 1994, National Centre for Epidemiology and Population Health, The Australian National University: Canberra, ACT.
174. McCallum, J., *The SF-36 in an Australian sample: validation*. *Australian Journal of Public Health*, 1995. 19: p. 160-166.
175. Sanson-Fisher, R.W. and J.J. Perkins, *Adaptation and validation of the SF-36 health survey for use in Australia*. *Journal of Clinical Epidemiology*, 1998. 51(11): p. 961-967.
176. McHorney, J.E., J.E. Ware, and A.E. Raczec, *The MOS 36-item short form health survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups*. *Medical Care*, 1994. 32: p. 247-263.
177. Brazier, J.E., et al., *Validating the SF-36 health survey questionnaire: new outcome measure for primary health care*. *British Medical Journal*, 1992. 305: p. 160-164.
178. Beck, A.T. and R.W. Beck, *Screening depressed patients in family practice*. *Postgrad Med*, 1972. 52: p. 81-85.
179. Beck, A.T., *Depression: causes and treatment*. 1970, Philadelphia: University of Pennsylvania Press.

180. Reynolds, W.M. and J.W. Gould, *A psychometric investigation of the standard and short form Beck Depression Inventory*. J Consult Clin Psychol, 1981. 49(2): p. 306-7.
181. Steer, R.A., A.T. Beck, and G. Brown, *Sex differences on the revised Beck Depression Inventory for outpatients with affective disorders*. J Pers Assess, 1989. 53(4): p. 693-702.
182. Gallagher, D., G. Nies, and L.W. Thompson, *Reliability of the Beck Depression Inventory with older adults*. Journal of Consulting and Clinical Psychology, 1982. 50: p. 152-153.
183. Marsella, A.J. and M.D. Murray, *Diagnostic type, gender and consistency vs. specificity in behavior*. J Clin Psychol, 1974. 30(4): p. 484-8.
184. Beck, A.T., et al., *Differentiating anxiety and depression: a test of the cognitive content-specificity hypothesis*. J Abnorm Psychol, 1987. 96(3): p. 179-83.
185. Armstrong, T., A. Bauman, and J. Davies, *Physical activity patterns of Australian adults. Results of the 1999 Physical Activity Survey*. 2000, Australian Institute of Health and Welfare: Canberra.
186. Hodge, A., et al., *The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation*. Aust N Z J Public Health, 2000. 24(6): p. 576-83.
187. Spector, I.P., M.P. Carey, and L. Steinberg, *The sexual desire inventory: development, factor structure, and evidence of reliability*. J Sex Marital Ther, 1996. 22(3): p. 175-90.
188. Rosen, R.C., et al., *The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction*. Urology, 1997. 49(6): p. 822-30.

189. Feldman, H.A., et al., *Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study*. J Clin Epidemiol, 1994. 47(5): p. 457-67.
190. Maislin, G., A.I. Pack, and N.B. Kribbs, *A survey screen for prediction of apnea*. Sleep, 1995. 18: p. 158-166.
191. Spreen, O. and E. Strauss, *A compendium of neuropsychological tests*. 2nd Edition ed. 1998, New York: Oxford UniPress.
192. Lezak, M., *Neuropsychological assessment*. 3rd Edition ed. 1995, New York: Oxford University Press.
193. Fuld, P.A., et al., *Object-memory evaluation for prospective detection of dementia in normal functioning elderly: predictive and normative data*. J Clin Exp Neuropsychol, 1990. 12(4): p. 520-8.
194. Barnes, G.W. and G.J. Lucas, *Cerebral dysfunction vs. psychogenesis in Halstead-Reitan tests*. The Journal of Nervous and Mental Disease, 1974. 158: p. 50-60.
195. Reitan, R.M. and D. Wolfson, *A selective and critical review of neuropsychological deficits and the frontal lobes*. Neuropsychol Rev, 1994. 4(3): p. 161-98.
196. Reitan, R.M. and D. Wolfson, *Differential relationships of age and education to WAIS subtest scores among brain-damaged and control groups*. Arch Clin Neuropsychol, 1996. 11(4): p. 303-11.
197. Leckliter, I.N. and J.D. Matarazzo, *The influence of age, education, IQ, gender, and alcohol abuse on Halstead-Reitan Neuropsychological Test Battery performance*. J Clin Psychol, 1989. 45(4): p. 484-512.

198. Haaland, K.Y., et al., *Recovery of simple motor skills after head injury*. J Clin Exp Neuropsychol, 1994. 16(3): p. 448-56.
199. Massman, P.J. and R.S. Doody, *Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning*. J Clin Exp Neuropsychol, 1996. 18(1): p. 110-21.
200. Ott, B.R., S.A. Elias, and M.C. Lannon, *Quantitative assessment of movement in Alzheimer's disease*. J Geriatr Psychiatry Neurol, 1995. 8(1): p. 71-5.
201. Bornstein, R.A., *Normative data on selected neuropsychological measures from a non-clinical sample*. Journal of Clinical Psychology, 1985. 41: p. 651-659.
202. Carlier, M., et al., *Hand performance of French children on a finger tapping test in relation to handedness, sex and age*. Percept Mot Skills, 1993. 76: p. 931-940.
203. Finlayson, M.A. and R.M. Reitan, *Handedness in relation to measures of motor and tactile-perceptual functions in normal children*. Percept Mot Skills, 1976. 42(43): p. 475-81.
204. Taylor, A., et al., *Summary of key biomedical findings, policy implications and research recommendations*. 2002, Population Research and Outcome Studies Unit, Department of Human Services: Adelaide.
205. Dal Grande, E. and A. Taylor, *Quality of life in South Australia as measured by SF-36: population norms for 2002, trends from 1994 to 2002 and impact of chronic diseases and health risk factors on quality of life*. 2004, Population Research and Outcome Studies Unit, Department of Human Services, South Australia: Adelaide.

206. Logie, H., R. Hogan, and A. Peut, *Longitudinal studies of ageing: Implications for future studies*. 2004, Australian Institute of Health and Welfare: Canberra.
207. Dunstan, D.W., et al., *The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)--methods and response rates*. *Diabetes Res Clin Pract*, 2002. 57(2): p. 119-29.
208. Cape, R.D. and S.J. Gibson, *The influence of clinical problems, age and social support on outcomes for elderly persons referred to regional aged care assessment teams*. *Aust N Z J Med*, 1994. 24(4): p. 378-85.
209. McCallum, J., et al., *The continuum of care for older people*. *Aust Health Rev*, 1995. 18(2): p. 40-55.
210. McCallum, J., et al., *Hospital and Home. A longitudinal study of hospital, residential and community service use by older people living in Dubbo, NSW*. 1994, Office on Ageing: Sydney.
211. Cameron, A.J., et al., *Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab)*. *Med J Aust*, 2003. 178(9): p. 427-32.
212. Booth, M.L., et al., *The relationship between body mass index and waist circumference: implications for estimates of the population prevalence of overweight*. *Int J Obes Relat Metab Disord*, 2000. 24(8): p. 1058-61.
213. Simons, L.A., et al., *Dubbo Study of the elderly: hypertension and lipid levels*. *Atherosclerosis*, 1992. 92(1): p. 59-65.

214. Lindstrom, M., S.O. Isacsson, and J. Merlo, *Increasing prevalence of overweight, obesity and physical inactivity: two population-based studies 1986 and 1994*. Eur J Public Health, 2003. 13(4): p. 306-12.
215. Pasquet, P., et al., *Prevalence of overweight and obesity for urban adults in Cameroon*. Ann Hum Biol, 2003. 30(5): p. 551-62.
216. Sibai, A.M., et al., *Prevalence and covariates of obesity in Lebanon: findings from the first epidemiological study*. Obes Res, 2003. 11(11): p. 1353-61.
217. Mokdad, A.H., et al., *Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001*. Jama, 2003. 289(1): p. 76-9.
218. Erem, C., et al., *Prevalence of obesity and associated risk factors in a Turkish population (Istanbul city, Turkey)*. Obes Res, 2004. 12(7): p. 1117-27.
219. Simons, L.A., et al., *Multiple medication use in the elderly. Use of prescription and non-prescription drugs in an Australian community setting*. Med J Aust, 1992. 157(4): p. 242-6.
220. Simons, L.A., et al., *Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly*. Aust N Z J Med, 1996. 26(1): p. 66-74.
221. Simons, L.A., et al., *Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly*. Atherosclerosis, 1995. 117(1): p. 107-18.
222. Giles, G.G. and D.R. English, *The Melbourne Collaborative Cohort Study*. IARC Sci Publ, 2002. 156: p. 69-70.

223. Haren, M.T., et al., *Defining 'relative' androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health?* *Climacteric*, 2002. 5(1): p. 15-25.
224. van den Beld, A.W., et al., *Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men.* *J Clin Endocrinol Metab*, 2000. 85(9): p. 3276-82.
225. Perry, H.M., 3rd, et al., *Testosterone and leptin in older African-American men: relationship to age, strength, function, and season.* *Metabolism*, 2000. 49(8): p. 1085-91.
226. Schatzl, G., et al., *Serum androgen levels in men: impact of health status and age.* *Urology*, 2003. 61(3): p. 629-33.
227. Gapstur, S.M., et al., *Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study.* *Cancer Epidemiol Biomarkers Prev*, 2002. 11(10 Pt 1): p. 1041-7.
228. Bonnefoy, M., et al., *Lack of correlation between 6-month fluctuations in habitual physical activity and testosterone concentrations in elderly subjects.* *J Sports Med Phys Fitness*, 2001. 41(1): p. 78-82.
229. Lindholm, J., et al., *Coronary risk factors and plasma sex hormones.* *Am J Med*, 1982. 73(5): p. 648-51.
230. Dai, W.S., et al., *Cigarette smoking and serum sex hormones in men.* *Am J Epidemiol*, 1988. 128(4): p. 796-805.

231. English, K.M., et al., *Effect of cigarette smoking on levels of bioavailable testosterone in healthy men*. Clin Sci (Lond), 2001. 100(6): p. 661-5.
232. Shono, N., et al., *The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men*. J Atheroscler Thromb, 1996. 3(1): p. 45-51.
233. Simon, D., et al., *Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study*. Diabetologia, 1992. 35(2): p. 173-7.
234. Nagata, C., et al., *Relationships between types of fat consumed and serum estrogen and androgen concentrations in Japanese men*. Nutr Cancer, 2000. 38(2): p. 163-7.
235. Sparrow, D., R. Bosse, and J.W. Rowe, *The influence of age, alcohol consumption, and body build on gonadal function in men*. J Clin Endocrinol Metab, 1980. 51(3): p. 508-12.
236. Goodman Gruen, D. and E. Barrett Connor, *Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women*. Diabetes Care, 2000. 23(7): p. 912-8.
237. Oh, J.Y., et al., *Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study*. Diabetes Care, 2002. 25(1): p. 55-60.
238. Mohr, B.A., et al., *Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study*. Urology, 2001. 57(5): p. 930-5.
239. Vatten, L.J., et al., *Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway*. Cancer Epidemiol Biomarkers Prev, 1997. 6(11): p. 967-9.

240. Heikkila, R., et al., *Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study*. *Cancer*, 1999. 86(2): p. 312-5.
241. Carter, H.B., et al., *Longitudinal evaluation of serum androgen levels in men with and without prostate cancer*. *Prostate*, 1995. 27(1): p. 25-31.
242. Nomura, A.M., et al., *Serum androgens and prostate cancer*. *Cancer Epidemiol Biomarkers Prev*, 1996. 5(8): p. 621-5.
243. Joseph, M.A., et al., *Relationship of serum sex-steroid hormones and prostate volume in African American men*. *Prostate*, 2002. 53(4): p. 322-9.
244. Gann, P.H., et al., *A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia*. *Prostate*, 1995. 26(1): p. 40-9.
245. Burnham, T.C., et al., *Men in committed, romantic relationships have lower testosterone*. *Horm Behav*, 2003. 44(2): p. 119-22.
246. Gray, P.B., et al., *Social variables predict between-subject but not day-to-day variation in the testosterone of US men*. *Psychoneuroendocrinology*, 2004. 29(9): p. 1153-62.
247. Gray, P.B., *Marriage, parenting, and testosterone variation among Kenyan Swahili men*. *Am J Phys Anthropol*, 2003. 122(3): p. 279-86.
248. Schultheiss, O.C., A. Dargel, and W. Rohde, *Implicit motives and gonadal steroid hormones: effects of menstrual cycle phase, oral contraceptive use, and relationship status*. *Horm Behav*, 2003. 43(2): p. 293-301.

249. Cohan, C.L., A. Booth, and D.A. Granger, *Gender moderates the relationship between testosterone and marital interaction*. J Fam Psychol, 2003. 17(1): p. 29-40.
250. Dai, W.S., et al., *The epidemiology of plasma testosterone levels in middle-aged men*. Am J Epidemiol, 1981. 114(6): p. 804-16.
251. Muller, M., et al., *Endogenous sex hormones in men aged 40-80 years*. Eur J Endocrinol, 2003. 149(6): p. 583-9.
252. Hsieh, C.C., et al., *Predictors of sex hormone levels among the elderly: a study in Greece*. J Clin Epidemiol, 1998. 51(10): p. 837-41.
253. Persky, H., et al., *The effect of alcohol and smoking on testosterone function and aggression in chronic alcoholics*. Am J Psychiatry, 1977. 134(6): p. 621-5.
254. Ruusa, J., B. Bergman, and M.L. Sundell, *Sex hormones during alcohol withdrawal: a longitudinal study of 29 male alcoholics during detoxification*. Alcohol Alcohol, 1997. 32(5): p. 591-7.
255. Van Thiel, D.H., et al., *Effect of liver transplantation on the hypothalamic-pituitary-gonadal axis of chronic alcoholic men with advanced liver disease*. Alcohol Clin Exp Res, 1990. 14(3): p. 478-81.
256. Vermeulen, A., S. Goemaere, and J.M. Kaufman, *Testosterone, body composition and aging*. J Endocrinol Invest, 1999. 22(5 Suppl): p. 110-6.
257. Winters, S.J., et al., *Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men*. Metabolism, 2001. 50(10): p. 1242-7.

258. Tchernof, A., et al., *Reduced testosterone and adrenal C19 steroid levels in obese men.* Metabolism, 1995. 44(4): p. 513-9.
259. Khaw, K.T. and E. Barrett-Connor, *Lower endogenous androgens predict central adiposity in men.* Ann Epidemiol, 1992. 2(5): p. 675-82.
260. Steinberger, E., *Hormonal control of mammalian spermatogenesis.* Physiol Rev, 1971. 51(1): p. 1-22.
261. Vermeulen, A., J.M. Kaufman, and V.A. Giagulli, *Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.* J Clin Endocrinol Metab, 1996. 81(5): p. 1821-6.
262. Tchernof, A., et al., *The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.* Diabetes Care, 1996. 19(6): p. 629-37.
263. Roubenoff, R., *Sarcopenic obesity: the confluence of two epidemics.* Obes Res, 2004. 12(6): p. 887-8.
264. Morley, J.E., et al., *Sarcopenia.* J Lab Clin Med, 2001. 137(4): p. 231-43.
265. Marcell, T.J., et al., *Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men.* Am J Physiol Endocrinol Metab, 2001. 281(6): p. E1159-64.
266. Morley, J.E., *Anorexia, sarcopenia, and aging.* Nutrition, 2001. 17(7-8): p. 660-3.

267. Roubenoff, R., et al., *Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study*. Am J Med, 2003. 115(6): p. 429-35.
268. McKoy, G., et al., *Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation*. J Physiol, 1999. 516 (Pt 2): p. 583-92.
269. Morley, J.E. and D. Kraenzle, *Causes of weight loss in a community nursing home*. J Am Geriatr Soc, 1994. 42(6): p. 583-5.
270. Wilson, M.M., et al., *Prevalence and causes of undernutrition in medical outpatients*. Am J Med, 1998. 104(1): p. 56-63.
271. Morley, J.E., *Anorexia and weight loss in older persons*. J Gerontol A Biol Sci Med Sci, 2003. 58(2): p. 131-7.
272. Chapman, I.M., et al., *The anorexia of ageing*. Biogerontology, 2002. 3(1-2): p. 67-71.
273. MacIntosh, C.G., et al., *Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility*. Am J Clin Nutr, 1999. 69(5): p. 999-1006.
274. MacIntosh, C.G., et al., *Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging*. J Clin Endocrinol Metab, 2001. 86(12): p. 5830-7.
275. Brown, W.J., et al., *Test-retest reliability of four physical activity measures used in population surveys*. J Sci Med Sport, 2004. 7(2): p. 205-15.

276. Pinnock, C.B., A.M. Stapleton, and V.R. Marshall, *Erectile dysfunction in the community: a prevalence study*. Med J Aust, 1999. 171(7): p. 353-7.
277. Chew, K.K., et al., *Erectile dysfunction in general medicine practice: prevalence and clinical correlates*. Int J Impot Res, 2000. 12(1): p. 41-5.
278. Kantor, J., et al., *Prevalence of erectile dysfunction and active depression: an analytic cross-sectional study of general medical patients*. Am J Epidemiol, 2002. 156(11): p. 1035-42.
279. Traish, A.M., et al., *Effects of castration and androgen replacement on erectile function in a rabbit model*. Endocrinology, 1999. 140(4): p. 1861-8.
280. Araujo, A.B., et al., *The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study*. Psychosom Med, 1998. 60(4): p. 458-65.
281. Seidman, S.N., et al., *Low testosterone levels in elderly men with dysthymic disorder*. Am J Psychiatry, 2002. 159(3): p. 456-9.
282. Boyle, P., et al., *The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study*. BJU Int, 2003. 92(7): p. 719-25.
283. Aversa, A., et al., *Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction*. Clin Endocrinol (Oxf), 2000. 53(4): p. 517-22.
284. Becker, A.J., et al., *Cavernous and systemic testosterone plasma levels during different penile conditions in healthy males and patients with erectile dysfunction*. Urology, 2001. 58(3): p. 435-40.

285. Zvara, P., et al., *Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model*. *Int J Impot Res*, 1995. 7(4): p. 209-19.
286. Reilly, C.M., et al., *Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway*. *J Androl*, 1997. 18(6): p. 588-94.
287. Schiavi, R.C., et al., *The relationship between pituitary-gonadal function and sexual behavior in healthy aging men*. *Psychosom Med*, 1991. 53(4): p. 363-74.
288. Sadowsky, M., et al., *Sexual activity and sex hormone levels in aging men*. *Int Psychogeriatr*, 1993. 5(2): p. 181-6.
289. Ansong, K.S. and R.B. Punwaney, *An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive*. *J Urol*, 1999. 162(3 Pt 1): p. 719-21.
290. Krause, W. and H.H. Muller, *Relation of sexual dysfunction to hormone levels, diseases and drugs used in andrological patients*. *Urol Int*, 2000. 64(3): p. 143-8.
291. Pinnock, C. and V.R. Marshall, *Troublesome lower urinary tract symptoms in the community: a prevalence study*. *Med J Aust*, 1997. 167(2): p. 72-5.
292. Haidinger, G., et al., *Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology*. *Eur Urol*, 2000. 37(4): p. 413-20.
293. Napalkov, P., P. Maisonneuve, and P. Boyle, *Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia*. *Urology*, 1995. 46(3 Suppl A): p. 41-6.

294. Meikle, A.W., et al., *Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins*. J Clin Endocrinol Metab, 1997. 82(2): p. 571-5.
295. Suzuki, K., et al., *Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration*. Scand J Urol Nephrol, 1995. 29(1): p. 65-8.
296. Wadie, B.S., H.E. Ebrahim el, and M.A. Gomha, *The relationship of detrusor instability and symptoms with objective parameters used for diagnosing bladder outlet obstruction: a prospective study*. J Urol, 2002. 168(1): p. 132-4.
297. Hall, R., P.L. Andrews, and C.H. Hoyle, *Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder*. Eur J Pharmacol, 2002. 449(3): p. 301-9.
298. Meigs, J.B., et al., *Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men*. J Clin Epidemiol, 2001. 54(9): p. 935-44.
299. Rosen, R., et al., *Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)*. Eur Urol, 2003. 44(6): p. 637-49.
300. Moffat, S.D., et al., *Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men*. J Clin Endocrinol Metab, 2002. 87(11): p. 5001-7.
301. Yaffe, K., et al., *Sex hormones and cognitive function in older men*. J Am Geriatr Soc, 2002. 50(4): p. 707-12.

302. Kenny, A.M., et al., *Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels*. J Gerontol A Biol Sci Med Sci, 2002. 57(5): p. M321-5.
303. Janowsky, J.S., B. Chavez, and E. Orwoll, *Sex steroids modify working memory*. J Cogn Neurosci, 2000. 12(3): p. 407-14.
304. Flood, J.F. and J.E. Morley, *Learning and memory in the SAMP8 mouse*. Neurosci Biobehav Rev, 1998. 22(1): p. 1-20.
305. Flood, J.F., et al., *Age-related decrease of plasma testosterone in SAMP8 mice: replacement improves age-related impairment of learning and memory*. Physiol Behav, 1995. 57(4): p. 669-73.
306. Morley, J.E., et al., *Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory*. Peptides, 2000. 21(12): p. 1761-7.
307. Pike, C.J., *Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons*. Brain Res, 2001. 919(1): p. 160-5.
308. Moffat, S.D., et al., *Free testosterone and risk for Alzheimer disease in older men*. Neurology, 2004. 62(2): p. 188-93.
309. Hogervorst, E., et al., *Serum total testosterone is lower in men with Alzheimer's disease*. Neuro Endocrinol Lett, 2001. 22(3): p. 163-8.
310. Chait, A., H.T. Robertson, and J.D. Brunzell, *Chylomicronemia syndrome in diabetes mellitus*. Diabetes Care, 1981. 4(3): p. 343-8.

311. Rogers, R.L., et al., *Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion*. *Angiology*, 1989. 40(4 Pt 1): p. 260-9.
312. Bruce, D.G., et al., *Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study*. *Diabetes Res Clin Pract*, 2003. 61(1): p. 59-67.
313. Flood, J.F., A.D. Mooradian, and J.E. Morley, *Characteristics of learning and memory in streptozocin-induced diabetic mice*. *Diabetes*, 1990. 39(11): p. 1391-8.
314. Mooradian, A.D., et al., *Cortical function in elderly non-insulin dependent diabetic patients. Behavioral and electrophysiologic studies*. *Arch Intern Med*, 1988. 148(11): p. 2369-72.
315. Meneilly, G.S., et al., *The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes*. *J Gerontol*, 1993. 48(4): p. M117-21.
316. Hassing, L.B., et al., *Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study*. *J Int Neuropsychol Soc*, 2004. 10(4): p. 599-607.
317. Farr, S.A., et al., *DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice*. *Life Sci*, 2004. 75(23): p. 2775-85.
318. Banks, W.A., et al., *Triglycerides induce leptin resistance at the blood-brain barrier*. *Diabetes*, 2004. 53(5): p. 1253-60.
319. Shanley, L.J., A.J. Irving, and J. Harvey, *Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity*. *J Neurosci*, 2001. 21(24): p. RC186.

320. Cohen, P.G., *Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection.* Med Hypotheses, 2001. 56(6): p. 702-8.
321. Rasgon, N. and L. Jarvik, *Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis.* J Gerontol A Biol Sci Med Sci, 2004. 59(2): p. 178-83; discussion 184-92.
322. Morley, J.E., *The metabolic syndrome and aging.* J Gerontol A Biol Sci Med Sci, 2004. 59(2): p. 139-42.
323. Watson, G.S. and S. Craft, *The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.* CNS Drugs, 2003. 17(1): p. 27-45.
324. Abbatecola, A.M., et al., *Insulin resistance and executive dysfunction in older persons.* J Am Geriatr Soc, 2004. 52(10): p. 1713-8.
325. Fried, L.P., et al., *Frailty in older adults: evidence for a phenotype.* J Gerontol A Biol Sci Med Sci, 2001. 56(3): p. M146-56.
326. Gillick, M., *Pinning down frailty.* J Gerontol A Biol Sci Med Sci, 2001. 56(3): p. M134-5.
327. Morley, J.E. and H.M. Perry, 3rd, *Androgen deficiency in aging men: role of testosterone replacement therapy.* J Lab Clin Med, 2000. 135(5): p. 370-8.
328. Bhasin, S., et al., *The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.* N Engl J Med, 1996. 335(1): p. 1-7.
329. Roy, T.A., et al., *Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men.* Am J Physiol Endocrinol Metab, 2002. 283(2): p. E284-94.

330. Yesavage, J.A., *Geriatric depression scale: consistency of depressive symptoms over time*. Percept Mot Skills, 1991. 73(3 Pt 1): p. 1032.
331. Mayhew, T.P., et al., *Performance characteristics of the Kin-Com dynamometer*. Phys Ther, 1994. 74(11): p. 1047-54.
332. Vellas, B., et al., *The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients*. Nutrition, 1999. 15(2): p. 116-22.
333. Donini, L.M., et al., *MNA predictive value in the follow-up of geriatric patients*. J Nutr Health Aging, 2003. 7(5): p. 282-93.
334. Morley, J.E., *Anorexia, body composition, and ageing*. Curr Opin Clin Nutr Metab Care, 2001. 4(1): p. 9-13.
335. Brannian, J.D., P. Long, and D.O. Kreger, *Is the free androgen index a useful clinical marker in male patients?* S D J Med, 1998. 51(12): p. 449-51.
336. Cantrill, J.A., et al., *Which testosterone replacement therapy?* Clin Endocrinol (Oxf), 1984. 21(2): p. 97-107.
337. Bagchus, W.M., et al., *Important effect of food on the bioavailability of oral testosterone undecanoate*. Pharmacotherapy, 2003. 23(3): p. 319-25.
338. Tax, L., *Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone*. Eur J Drug Metab Pharmacokinet, 1987. 12(3): p. 225-6.

339. Tauber, U., et al., *Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone*. Eur J Drug Metab Pharmacokinet, 1986. 11(2): p. 145-9.
340. Bhasin, S., et al., *Testosterone dose-response relationships in healthy young men*. Am J Physiol Endocrinol Metab, 2001. 281(6): p. E1172-81.
341. Kwon, I.S., et al., *Relationship between muscle strength and the time taken to complete a standardized walk-turn-walk test*. J Gerontol A Biol Sci Med Sci, 2001. 56(9): p. B398-404.
342. Urban, R.J., *Effects of testosterone and growth hormone on muscle function*. J Lab Clin Med, 1999. 134(1): p. 7-10.
343. Grounds, M.D., *Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling*. Biogerontology, 2002. 3(1-2): p. 19-24.
344. Chakravarthy, M.V., F.W. Booth, and E.E. Spangenburg, *The molecular responses of skeletal muscle satellite cells to continuous expression of IGF-1: implications for the rescue of induced muscular atrophy in aged rats*. Int J Sport Nutr Exerc Metab, 2001. 11 Suppl: p. S44-8.
345. Alzghoul, M.B., et al., *Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo*. Faseb J, 2004. 18(1): p. 221-3.
346. Harridge, S.D., *Ageing and local growth factors in muscle*. Scand J Med Sci Sports, 2003. 13(1): p. 34-9.
347. Musaro, A., et al., *Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle*. Nat Genet, 2001. 27(2): p. 195-200.

348. Anderson, F.H., R.M. Francis, and K. Faulkner, *Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors*. Bone, 1996. 18(2): p. 171-7.
349. Snyder, P.J., et al., *Effects of testosterone replacement in hypogonadal men*. J Clin Endocrinol Metab, 2000. 85(8): p. 2670-7.
350. Whitsel, E.A., et al., *Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis*. Am J Med, 2001. 111(4): p. 261-9.
351. Wu, S.Z., X.Z. Weng, and X.X. Yao, *[Antianginal and lipid lowering effects of oral androgenic preparation (Andriol) on elderly male patients with coronary heart disease]*. Zhonghua Nei Ke Za Zhi, 1993. 32(4): p. 235-8.
352. Morley, J.E. and H.M. Perry, 3rd, *Andropause: an old concept in new clothing*. Clin Geriatr Med, 2003. 19(3): p. 507-28.
353. Ghanem, H., et al. *Hormone Replacement Therapy for PADAM: Outcome and Safety (Middle East Multicentre Study)*. in *The VIIIth International Congress of Andrology*. 2001. Montreal, Quebec, Canada: Medimond.
354. Moore, C., et al., *The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency*. Eur Urol, 2004. 46(1): p. 80-7.
355. Daig, I., et al., *The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics*. Health Qual Life Outcomes, 2003. 1(1): p. 77.

356. Tariq, S.H., et al., *Erectile dysfunction: etiology and treatment in young and old patients*. Clin Geriatr Med, 2003. 19(3): p. 539-51.
357. Kunelius, P., et al., *The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study*. J Clin Endocrinol Metab, 2002. 87(4): p. 1467-72.
358. Jain, P., A.W. Rademaker, and K.T. McVary, *Testosterone supplementation for erectile dysfunction: results of a meta-analysis*. J Urol, 2000. 164(2): p. 371-5.
359. Novak, A., M. Brod, and J. Elbers, *Andropause and quality of life: findings from patient focus groups and clinical experts*. Maturitas, 2002. 43(4): p. 231-7.
360. Ng, M.K., et al., *Prospective study of effect of androgens on serum inflammatory markers in men*. Arterioscler Thromb Vasc Biol, 2002. 22(7): p. 1136-41.
361. Tan, R.S. and S.J. Pu, *Is it andropause? Recognizing androgen deficiency in aging men*. Postgrad Med, 2004. 115(1): p. 62-6.
362. Gray, A., et al., *An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis*. J Clin Epidemiol, 1991. 44(7): p. 671-84.
363. Morley, J.E., *Andropause, testosterone therapy, and quality of life in aging men*. Cleve Clin J Med, 2000. 67(12): p. 880-2.
364. McCredie, M., et al., *Prevalence of urinary symptoms in urban Australian men aged 40-69*. J Epidemiol Biostat, 2001. 6(2): p. 211-8.

365. Anthony, J.C., et al., *Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients*. Psychol Med, 1982. 12(2): p. 397-408.
366. Boll, T.J. and R.M. Reitan, *Effect of age on performance of the Trail Making Test*. Percept Mot Skills, 1973. 36(3): p. 691-4.
367. Gordon, N.G., *The Trail Making Test in neuropsychological diagnosis*. J Clin Psychol, 1972. 28(2): p. 167-9.
368. Ferrucci, L., et al., *Relationship between health status, fluid intelligence and disability in a non demented elderly population*. Aging (Milano), 1993. 5(6): p. 435-43.
369. Villardita, C., et al., *Neuropsychological test performances and normal aging*. Arch Gerontol Geriatr, 1985. 4(4): p. 311-9.
370. Folstein, M.F., S.E. Folstein, and P.R. McHugh, *"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician*. J Psychiatr Res, 1975. 12(3): p. 189-98.
371. Alexander, G.M., et al., *Androgen-behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli*. Horm Behav, 1997. 31(2): p. 110-9.
372. Su, T.P., et al., *Neuropsychiatric effects of anabolic steroids in male normal volunteers*. Jama, 1993. 269(21): p. 2760-4.
373. Raivio, T., et al., *Novel assay for determination of androgen bioactivity in human serum*. J Clin Endocrinol Metab, 2001. 86(4): p. 1539-44.

374. Mangelsdorf, D.J., et al., *The nuclear receptor superfamily: the second decade*. Cell, 1995. 83(6): p. 835-9.
375. Langley, E., Z.X. Zhou, and E.M. Wilson, *Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer*. J Biol Chem, 1995. 270(50): p. 29983-90.
376. Doesburg, P., et al., *Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor*. Biochemistry, 1997. 36(5): p. 1052-64.
377. Ikonen, T., J.J. Palvimo, and O.A. Janne, *Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators*. J Biol Chem, 1997. 272(47): p. 29821-8.
378. Kempainen, J.A., et al., *Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone*. Mol Endocrinol, 1999. 13(3): p. 440-54.
379. Nakhla, A.M., et al., *Sex hormone-binding globulin receptor signal transduction proceeds via a G protein*. Steroids, 1999. 64(3): p. 213-6.
380. Rennie, P.S., et al., *Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene*. Mol Endocrinol, 1993. 7(1): p. 23-36.
381. Kubota, S., et al., *Cell-type-specific trans-activation of herpes simplex virus thymidine kinase promoter by the human T-cell leukemia virus type I Tax protein*. DNA Cell Biol, 2001. 20(9): p. 563-8.

382. Mori, M., K. Suzuki, and B. Tamaoki, *Testosterone metabolism in rooster comb*. *Biochim Biophys Acta*, 1974. 337(1): p. 118-28.
383. Hansen, J.R. and K.F. Stoa, *Metabolism in vitro of testosterone in rooster comb*. *Steroids Lipids Res*, 1973. 4(5): p. 277-84.
384. Sadighi, M., et al., *Effects of testosterone either alone or with IGF-I on growth of cells derived from the proliferation zone of regenerating antlers in vitro*. *Growth Horm IGF Res*, 2001. 11(4): p. 240-6.
385. Leader-Williams, N., *Age-related changes in the testicular and antler cycles of reindeer, Rangifer tarandus*. *J Reprod Fertil*, 1979. 57(1): p. 117-26.
386. Goss, R.J. and J.K. Rosen, *The effect of latitude and photoperiod on the growth of antlers*. *J Reprod Fertil Suppl*, 1973. 19: p. 111-8.
387. Goss, R.J., *Inhibition of growth and shedding of antlers by sex hormones*. *Nature*, 1968. 220(162): p. 83-5.
388. Woodruff, M.W. and W.O. Umiker, *The effect of estrogen and androgen on the rat prostate gland and testes*. *J Urol*, 1960. 84: p. 162-6.
389. Fleet, J.C., et al., *Gene expression profiling of Caco-2 BBe cells suggests a role for specific signaling pathways during intestinal differentiation*. *Physiol Genomics*, 2003. 13(1): p. 57-68.
390. Takaishi, H., et al., *Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B*. *Proc Natl Acad Sci U S A*, 1999. 96(21): p. 11836-41.

391. Thomas, P.B., K.E. Risinger, and C.M. Klinge, *Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells and comparison of estrogen-responsive gene transcription in cells adapted to serum-free media*. J Steroid Biochem Mol Biol, 2003. 86(1): p. 41-55.
392. Tyulmenkov, V.V., S.C. Jernigan, and C.M. Klinge, *Comparison of transcriptional synergy of estrogen receptors alpha and beta from multiple tandem estrogen response elements*. Mol Cell Endocrinol, 2000. 165(1-2): p. 151-61.
393. Moilanen, A.M., et al., *A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins*. J Biol Chem, 1999. 274(6): p. 3700-4.
394. Roy, P., et al., *Screening of some anti-androgenic endocrine disruptors using a recombinant cell-based in vitro bioassay*. J Steroid Biochem Mol Biol, 2004. 88(2): p. 157-66.
395. Satoh, K., et al., *Study on anti-androgenic effects of bisphenol a diglycidyl ether (BADGE), bisphenol F diglycidyl ether (BFDGE) and their derivatives using cells stably transfected with human androgen receptor, AR-EcoScreen*. Food Chem Toxicol, 2004. 42(6): p. 983-93.
396. Raivio, T., et al., *Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men*. J Androl, 2002. 23(6): p. 919-21.

APPENDICES

I.	Computer Assisted Telephone Interview Recruitment Questionnaire	A-1
II.	Mailed questionnaire package	A-7
III.	Clinic questionnaire (Questionnaire B)	A-38
IV.	Chapter 5.1 Bivariate analyses tables	A-47
V.	Chapter 5.2 Bivariate analyses tables.....	A-102
VI.	Chapter 5.3 Bivariate analyses.....	A-139
VII.	Chapter 5.4 Bivariate analyses tables	A-166

NOTE:

Appendices I-III are included in the print copy of the thesis held in the University of Adelaide Library.

IV. Chapter 5.1 Bivariate analyses tables

	Mean	S.E.	95% CI		Adj. Wald test	
Overall	16.19	0.27	15.65	16.73		
Age group: 35 – 44 years	17.27	0.51	16.26	18.27		
45 – 54	16.83	0.53	15.80	17.87	F(1, 566) = 0.35	P = 0.55
55 – 64	15.24	0.46	14.34	16.14	F(2, 565) = 4.94	P = 0.007
65 – 74	15.22	0.66	13.93	16.51	F(3, 564) = 4.1	P = 0.007
75 – 79	12.96	1.33	10.35	15.57	F(4, 563) = 4.46	P = 0.0015
School leaving age: 13 or younger	15.37	1.46	12.51	18.23		
14	14.69	0.79	13.13	16.25	F(1, 555) = 0.17	P = 0.68
15	15.98	0.63	14.74	17.23	F(2, 554) = 0.81	P = 0.45
16	16.39	0.56	15.28	17.49	F(3, 553) = 1.06	P = 0.36
17	17.43	0.52	16.40	18.46	F(4, 552) = 2.35	P = 0.053
18 or older	15.53	0.64	14.27	16.80	F(5, 551) = 2.14	P = 0.059
Highest post-secondary	15.98	0.56	14.87	17.08		
Non bachelor qualification	16.12	0.35	15.44	16.80	F(1, 566) = 0.05	P = 0.83
Bachelor degree or higher	17.14	0.62	15.92	18.36	F(2, 565) = 1.21	P = 0.30
Gross annual household income:	15.60	0.69	14.24	16.96		
\$20,001 - \$40,000	16.69	0.57	15.58	17.80	F(1, 561) = 1.46	P = 0.23
\$40,001 - \$60,000	16.83	0.59	15.66	18.00	F(2, 560) = 1.04	P = 0.36

	Mean	S.E.	95% CI		Adj. Wald test	
\$60,001 - \$80,000	14.96	0.59	13.81	16.11	F(3, 559) = 2.28 P = 0.078	
More than \$80,000	16.27	0.50	15.29	17.24	F(4, 558) = 1.74 P = 0.14	
Work status: Employed	16.54	0.31	15.94	17.15		
Retired	15.00	0.57	13.87	16.13	F(1, 566) = 5.61 P = 0.018	
Other (1)	17.21	1.12	15.01	19.41	F(2, 565) = 3.18 P = 0.042	
Country of birth: Australia	16.12	0.35	15.44	16.80		
UK (2)	16.59	0.51	15.58	17.60	F(1, 566) = 0.57 P = 0.45	
Other	16.04	0.76	14.55	17.53	F(2, 565) = 0.32 P = 0.72	
Receive DSS pension: Yes	16.26	0.64	15.01	17.51		
No	16.17	0.28	15.61	16.72	F(1, 566) = 0.02 P = 0.89	
Marital status: Married/ living with	15.60	0.28	15.05	16.15		
Separated/ divorced	19.05	0.92	17.23	20.87	F(1, 566) = 12.74 P = 0.0004	
Widowed	14.73	2.71	9.40	20.06	F(2, 565) = 6.45 P = 0.0017	
Never married	19.45	1.13	17.23	21.66	F(3, 564) = 7.42 P = 0.0001	

Table IV.I Mean serum total testosterone levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Mean	S.E.	95% CI		Adj. Wald test
Overall	5.16	0.12	4.93	5.38	
Age group: 35 – 44 years	6.29	0.16	5.98	6.61	
45 – 54	5.64	0.30	5.06	6.23	F(1, 566) = 3.70 P = 0.055
55 – 64	4.43	0.12	4.19	4.67	F(2, 565) = 43.77 P < 0.0001
65 – 74	3.64	0.13	3.39	3.89	F(3, 564) = 61.31 P < 0.0001
75 – 79	3.01	0.36	2.31	3.71	F(4, 563) = 50.85 P < 0.0001
School leaving age: 13 or younger	3.93	0.31	3.32	4.54	
14	3.77	0.19	3.40	4.14	F(1, 555) = 0.19 P = 0.67
15	4.88	0.20	4.50	5.27	F(2, 554) = 8.95 P = 0.0001
16	5.44	0.32	4.81	6.08	F(3, 553) = 9.94 P < 0.0001
17	5.80	0.19	5.42	6.18	F(4, 552) = 17.07 P < 0.0001
18 or older	5.45	0.26	4.93	5.97	F(5, 551) = 14.78 P < 0.0001
Highest post-secondary	4.94	0.19	4.57	5.30	
Non bachelor qualification	5.17	0.16	4.85	5.48	F(1, 566) = 0.88 P = 0.35
Bachelor degree or higher	5.68	0.27	5.15	6.22	F(2, 565) = 2.58 P = 0.077
Gross annual household income:	4.33	0.21	3.93	4.74	
\$20,001 - \$40,000	4.91	0.18	4.55	5.27	F(1, 561) = 4.40 P = 0.036
\$40,001 - \$60,000	5.84	0.33	5.19	6.49	F(2, 560) = 7.65 P = 0.0005
\$60,001 - \$80,000	5.31	0.20	4.91	5.71	F(3, 559) = 6.44 P = 0.0003
More than \$80,000	5.37	0.22	4.94	5.80	F(4, 558) = 5.52 P = 0.0002

	Mean	S.E.	95% CI		Adj. Wald test
Work status: Employed	5.65	0.11	5.44	5.86	
Retired	3.93	0.30	3.35	4.52	F(1, 566) = 29.48 P < 0.0001
Other (1)	5.36	0.28	4.81	5.91	F(2, 565) = 14.76 P < 0.0001
Country of birth: Australia	5.21	0.15	4.91	5.51	
UK (2)	5.10	0.19	4.73	5.48	F(1, 566) = 0.18 P = 0.68
Other	4.99	0.27	4.46	5.52	F(2, 565) = 0.26 P = 0.77
Receive DSS pension: Yes	4.47	0.30	3.89	5.05	
No	5.45	0.10	5.24	5.65	F(1, 566) = 9.81 P = 0.0018
Marital status: Married/ living	4.99	0.13	4.74	5.24	
Separated/ divorced	5.67	0.30	5.08	6.26	F(1, 566) = 4.34 P = 0.038
Widowed	4.11	0.79	2.56	5.66	F(2, 565) = 2.93 P = 0.054
Never married	6.76	0.30	6.17	7.35	F(3, 564) = 10.97 P < 0.0001

Table IV.II Mean serum BT levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Mean	S.E.	95% CI		Adj. Wald test
Overall	4.14	0.10	3.93	4.34	
Age group: 35 – 44 years	5.06	0.15	4.76	5.36	
45 – 54	4.61	0.28	4.06	5.15	F(1, 566) = 2.06 P = 0.15
55 – 64	3.50	0.10	3.29	3.70	F(2, 565) = 38.24 P < 0.0001
65 – 74	2.92	0.12	2.68	3.16	F(3, 564) = 45.61 P < 0.0001
75 – 79	2.13	0.21	1.71	2.54	F(4, 563) = 46.42 P < 0.0001
School leaving age: 13 or younger	3.02	0.26	2.49	3.54	
14	2.82	0.15	2.53	3.12	F(1, 555) = 0.40 P = 0.53
15	3.94	0.17	3.60	4.28	F(2, 554) = 12.59 P < 0.0001
16	4.48	0.30	3.89	5.06	F(3, 553) = 13.33 P < 0.0001
17	4.71	0.17	4.37	5.05	F(4, 552) = 21.02 P < 0.0001
18 or older	4.25	0.25	3.77	4.74	F(5, 551) = 17.62 P < 0.0001
Highest post-secondary qualification: None	3.95	0.16	3.64	4.26	
Non bachelor qualification	4.12	0.15	3.83	4.41	F(1, 566) = 0.64 P = 0.43
Bachelor degree or higher	4.72	0.29	4.15	5.28	F(2, 565) = 2.74 P = 0.065
Gross annual household income:					
Up to \$20,000	3.43	0.18	3.07	3.79	
\$20,001 - \$40,000	3.72	0.15	3.43	4.02	F(1, 561) = 1.57 P = 0.21
\$40,001 - \$60,000	4.85	0.31	4.25	5.45	F(2, 560) = 7.98 P = 0.0004

	Mean	S.E.	95% CI		Adj. Wald test
\$60,001 - \$80,000	4.39	0.19	4.01	4.76	F(3, 559) = 8.00 P < 0.0001
More than \$80,000	4.34	0.19	3.96	4.72	F(4, 558) = 6.97 P < 0.0001
Work status: Employed	4.54	0.10	4.35	4.74	
Retired	3.13	0.27	2.60	3.67	F(1, 566) = 23.56 P < 0.0001
Other (1)	4.28	0.25	3.79	4.78	F(2, 565) = 11.82 P < 0.0001
Country of birth: Australia	4.20	0.14	3.92	4.47	
UK (2)	4.03	0.17	3.71	4.35	F(1, 566) = 0.58 P = 0.45
Other	3.99	0.23	3.54	4.44	F(2, 565) = 0.43 P = 0.65
Receive DSS pension: Yes	3.54	0.27	3.02	4.06	
No	4.39	0.09	4.20	4.57	F(1, 566) = 8.92 P = 0.0029
Marital status: Married/ living with a partner	4.02	0.12	3.79	4.25	
Separated/ divorced	4.36	0.27	3.83	4.90	F(1, 566) = 1.33 P = 0.25
Widowed	3.52	0.76	2.03	5.01	F(2, 565) = 0.93 P = 0.39
Never married	5.36	0.34	4.68	6.04	F(3, 564) = 4.89 P = 0.0023

Table IV.III Mean calculated BT levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Mean	S.E.	95% CI]		Adj. Wald test
Overall	348.10	6.02	336.27	359.92	
Age group: 35 – 44 years	398.91	9.64	379.97	417.85	
45 – 54	375.11	13.70	348.19	402.03	F(1, 566) = 2.01 P = 0.16
55 – 64	313.69	7.76	298.45	328.94	F(2, 565) = 25.33 P < 0.0001
65 – 74	283.96	10.15	264.03	303.89	F(3, 564) = 28.29 P < 0.0001
75 – 79	223.26	21.33	181.36	265.15	F(4, 563) = 27.80 P < 0.0001
School leaving age: 13 or younger	288.77	19.73	250.02	327.53	
14	273.98	13.08	248.27	299.68	F(1, 555) = 0.39 P = 0.53
15	338.02	11.97	314.51	361.52	F(2, 554) = 6.94 P = 0.001
16	364.26	14.47	335.84	392.68	F(3, 553) = 8.81 P < 0.0001
17	387.06	10.79	365.87	408.25	F(4, 552) = 13.44 P < 0.0001
18 or older	345.65	14.62	316.93	374.36	F(5, 551) = 10.76 P < 0.0001
Highest post-secondary	338.38	11.05	316.68	360.08	
Non bachelor qualification	346.89	7.94	331.29	362.48	F(1, 566) = 0.39 P = 0.53
Bachelor degree or higher	379.63	15.64	348.90	410.35	F(2, 565) = 2.41 P = 0.09
Gross annual household income:	310.39	13.62	283.63	337.16	
\$20,001 - \$40,000	334.58	10.38	314.20	354.97	F(1, 561) = 1.99 P = 0.16
\$40,001 - \$60,000	382.42	15.26	352.43	412.40	F(2, 560) = 6.33 P = 0.0019
\$60,001 - \$80,000	350.48	12.15	326.61	374.35	F(3, 559) = 4.45 P = 0.0042

	Mean	S.E.	95% CI]		Adj. Wald test	
More than \$80,000	361.25	11.22	339.21	383.29	F(4, 558) = 3.91	P = 0.0038
Work status: Employed	371.12	6.26	358.83	383.41		
Retired	288.47	13.76	261.43	315.50	F(1, 566) = 29.84	P < 0.0001
Other (1)	364.13	18.82	327.17	401.09	F(2, 565) = 14.96	P < 0.0001
Country of birth: Australia	348.65	7.66	333.61	363.70		
UK (2)	351.35	11.18	329.38	373.32	F(1, 566) = 0.04	P = 0.84
Other	341.47	15.97	310.10	372.85	F(2, 565) = 0.13	P = 0.88
Receive DSS pension: Yes	317.84	14.32	289.71	345.97		
No	360.77	5.96	349.07	372.48	F(1, 566) = 7.66	P = 0.0058
Marital status: Married/ living with	338.12	6.40	325.56	350.68		
Separated/ divorced	383.60	19.42	345.46	421.75	F(1, 566) = 4.96	P = 0.026
Widowed	307.38	56.52	196.37	418.39	F(2, 565) = 2.66	P = 0.071
Never married	428.04	20.06	388.64	467.44	F(3, 564) = 7.36	P = 0.0001

Table IV.IV Mean calculated FT levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Mean	S.E.	95% CI		Adj. Wald test
Overall	32.37	0.67	31.06	33.68	
Age group: 35 – 44 years	28.11	1.23	25.69	30.54	
45 – 54	30.28	0.99	28.33	32.24	F(1, 566) = 1.87 P = 0.17
55 – 64	33.00	1.06	30.91	35.09	F(2, 565) = 4.60 P = 0.01
65 – 74	39.32	1.75	35.89	42.75	F(3, 564) = 10.30 P < 0.0001
75 – 79	45.11	3.23	38.77	51.46	F(4, 563) = 11.89 P < 0.0001
School leaving age: 13 or younger	38.47	3.50	31.60	45.35	
14	40.49	2.20	36.17	44.81	F(1, 555) = 0.24 P = 0.63
15	32.77	1.54	29.73	35.80	F(2, 554) = 4.48 P = 0.012
16	30.18	1.15	27.92	32.45	F(3, 553) = 6.64 P = 0.0002
17	30.42	1.14	28.18	32.66	F(4, 552) = 5.71 P = 0.0002
18 or older	30.77	2.01	26.82	34.72	F(5, 551) = 4.62 P = 0.0004
Highest post-secondary	33.27	1.36	30.59	35.95	
Non bachelor qualification	32.04	0.81	30.45	33.62	F(1, 566) = 0.60 P = 0.44
Bachelor degree or higher	31.86	2.13	27.68	36.05	F(2, 565) = 0.33 P = 0.72
Gross annual household income:	37.35	1.67	34.06	40.64	
\$20,001 - \$40,000	35.97	1.43	33.15	38.78	F(1, 561) = 0.39 P = 0.53
\$40,001 - \$60,000	29.59	1.23	27.17	32.01	F(2, 560) = 9.12 P = 0.0001
\$60,001 - \$80,000	26.30	1.43	23.49	29.10	F(3, 559) = 12.44 P < 0.0001

	Mean	S.E.	95% CI		Adj. Wald test
More than \$80,000	30.25	1.14	28.02	32.49	F(4, 558) = 9.62 P < 0.0001
Work status: Employed	29.53	0.72	28.12	30.93	
Retired	39.02	1.34	36.39	41.65	F(1, 566) = 39.06 P < 0.0001
Other (1)	32.38	2.58	27.31	37.45	F(2, 565) = 19.54 P < 0.0001
Country of birth: Australia	32.04	0.86	30.34	33.73	
UK (2)	33.24	1.36	30.58	35.91	F(1, 566) = 0.57 P = 0.45
Other	32.87	1.42	30.07	35.66	F(2, 565) = 0.33 P = 0.72
Receive DSS pension: Yes	38.69	1.44	35.86	41.52	
No	29.73	0.67	28.41	31.06	F(1, 566) = 31.72 P < 0.0001
Marital status: Married/ living with	31.62	0.70	30.24	33.00	
Separated/ divorced	37.85	2.04	33.84	41.86	F(1, 566) = 8.34 P = 0.004
Widowed	33.01	1.90	29.27	36.74	F(2, 565) = 4.23 P = 0.015
Never married	32.85	3.82	25.35	40.35	F(3, 564) = 2.82 P = 0.038

Table IV.V Mean SHBG levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

Total T		
	Coeff (95% CI)	P
LH	-	-
FSH	-0.079 (-0.148 - -0.01)	0.025
BT		
LH	-0.083 (-0.121 - -0.045)	<0.0001
FSH	-0.078 (-0.098 - -0.056)	<0.0001
cBT		
LH	-0.069 (-0.105 - -0.033)	<0.0001
FSH	-0.066 (-0.084 - -0.048)	<0.0001
FT		
LH	-4.168 (-6.867 - -1.470)	0.003
FSH	-4.024 (-5.217 - -2.832)	<0.0001
SHBG		
LH	1.047 (0.659 - 1.434)	<0.0001
FSH	0.62 (0.374 - 0.865)	<0.0001

Table IV.VI Statistically significant non-age-adjusted associations between serum testosterone and SHBG levels and the serum levels of LH and FSH in 568 men recruited from randomly selected households in North-west Adelaide. Data presented are regression coefficients with 95% confidence intervals and P values.

	Mean	S.E.	95% CI		Adj. Wald test
Angina: No	16.28	0.27	15.74	16.81	
Yes	14.85	1.60	11.71	17.98	F(1, 566) = 0.78 P = 0.38
Anxiety: No	16.19	0.27	15.66	16.72	
Yes	16.24	1.32	13.65	18.84	F(1, 566) = 0.00 P = 0.97
Asthma: No	16.18	0.28	15.63	16.73	
Yes	16.32	1.06	14.24	18.40	F(1, 566) = 0.02 P = 0.89
Depression: No	16.19	0.27	15.65	16.73	
Yes	16.22	1.10	14.05	18.38	F(1, 566) = 0.00 P = 0.98
Diabetes: No	16.46	0.28	15.90	17.01	
Yes	13.13	0.86	11.44	14.82	F(1, 566) = 13.44 P = 0.0003
Enlarged prostate: No	16.23	0.28	15.67	16.79	
Yes	15.81	1.02	13.80	17.82	F(1, 566) = 0.15 P = 0.69
High cholesterol: No	16.69	0.33	16.04	17.34	
Yes	15.04	0.48	14.09	15.98	F(1, 566) = 8.02 P = 0.0048
High BP: No	16.72	0.33	16.07	17.37	
Yes	14.70	0.46	13.80	15.60	F(1, 566) = 12.82 P = 0.0004
Insomnia: No	16.32	0.29	15.76	16.89	
Yes	15.04	0.88	13.32	16.76	F(1, 566) = 1.95 P = 0.16
Osteoarthritis: No	16.22	0.29	15.66	16.79	
Yes	15.82	0.93	14.00	17.64	F(1, 566) = 0.17 P = 0.68
Rheumatoid arthritis: No	16.15	0.28	15.60	16.70	
Yes	17.09	1.23	14.68	19.50	F(1, 566) = 0.56 P = 0.46
Thyroid problems: No	16.24	0.28	15.69	16.78	
Yes	13.06	2.37	8.40	17.72	F(1, 566) = 1.77 P = 0.18
Prostate cancer: No	16.28	0.27	15.74	16.81	

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	12.04	2.48	7.16	16.91	F(1, 566) = 2.89	P = 0.09
Prostate removal: No	16.25	0.28	15.70	16.80		
Yes	13.89	1.23	11.48	16.30	F(1, 566) = 3.53	P = 0.061
TURP: No	16.22	0.28	15.68	16.77		
Yes	15.14	1.32	12.55	17.73	F(1, 566) = 0.65	P = 0.42
Vasectomy: No	16.07	0.31	15.46	16.68		
Yes	16.54	0.57	15.42	17.66	F(1, 566) = 0.53	P = 0.47
Penile surgery: No	16.13	0.28	15.59	16.68		
Yes	18.54	1.80	15.00	22.08	F(1, 566) = 1.75	P = 0.18
Bladder surgery: No	16.24	0.28	15.69	16.79		
Yes	14.36	0.96	12.47	16.25	F(1, 566) = 3.50	P = 0.062
Digestive health condition:	16.02	0.28	15.47	16.56		
Yes	17.73	1.08	15.60	19.86	F(1, 566) = 2.34	P = 0.13
Circulatory health condition:	16.23	0.29	15.66	16.79		
Yes	15.72	0.92	13.92	17.52	F(1, 566) = 0.28	P = 0.60
Musculoskeletal health	16.28	0.30	15.69	16.87		
Yes	15.63	0.64	14.37	16.88	F(1, 566) = 0.85	P = 0.36
Neurological health	16.15	0.28	15.60	16.70		
Yes	17.67	1.00	15.71	19.63	F(1, 566) = 2.16	P = 0.14
Psychological health	16.12	0.26	15.60	16.63		
Yes	18.27	2.96	12.45	24.09	F(1, 566) = 0.52	P = 0.47
Respiratory health condition:	16.10	0.28	15.54	16.66		
Yes	17.93	0.94	16.08	19.78	F(1, 566) = 3.45	P = 0.06
Metabolic, Endo. Nut. Health	16.26	0.28	15.71	16.81		
Yes	13.45	1.10	11.29	15.61	F(1, 566) = 6.12	P = 0.014

	Mean	S.E.	95% CI		Adj. Wald test	
Urological health condition:	16.19	0.28	15.65	16.74		
Yes	16.13	1.09	13.99	18.26	F(1, 566) = 0.00	P = 0.95
Medication, general	16.28	0.30	15.70	16.87		
Yes	15.75	0.69	14.40	17.10	F(1, 566) = 0.5	P = 0.48
Medication, digestive: No	16.26	0.28	15.71	16.81		
Yes	15.78	0.94	13.94	17.61	F(1, 566) = 0.24	P = 0.62
Medication, circulatory: No	16.52	0.32	15.90	17.15		
Yes	15.31	0.53	14.26	16.35	F(1, 566) = 3.86	P = 0.05
Medication, musculoskeletal:	16.32	0.29	15.74	16.90		
Yes	15.48	0.75	14.01	16.94	F(1, 566) = 1.11	P = 0.29
Medication, neurological: No	16.26	0.29	15.70	16.82		
Yes	15.36	0.92	13.56	17.16	F(1, 566) = 0.88	P = 0.35
Medication, psychological:	16.09	0.26	15.57	16.61		
Yes	17.22	1.48	14.32	20.11	F(1, 566) = 0.56	P = 0.45
Medication, respiratory: No	16.25	0.30	15.67	16.84		
Yes	15.76	0.67	14.45	17.08	F(1, 566) = 0.45	P = 0.50
Medication, metabolic endo.	16.63	0.31	16.03	17.24		
Yes	14.61	0.59	13.46	15.76	F(1, 566) = 9.36	P = 0.0023
Medication, urological: No	16.20	0.28	15.66	16.74		
Yes	15.51	2.01	11.56	19.45	F(1, 566) = 0.12	P = 0.73
Medication, male genital: No	16.21	0.27	15.67	16.74		
Yes	15.75	2.10	11.64	19.87	F(1, 566) = 0.05	P = 0.83

Table IV.VII Comparisons of mean serum TT concentrations between men with and without chronic diseases, men who have had urogenital surgery and men who have not and men using and not using medications. Data presented are means \pm standard error and 95% confidence intervals.

	Mean	S.E.	95% CI		Adj. Wald test
Angina: No	5.16	0.09	4.97	5.34	
Yes	5.16	1.23	2.74	7.58	F(1, 566) = 0.00 P = 0.999
Anxiety: No	5.10	0.10	4.91	5.29	
Yes	5.72	0.82	4.12	7.33	F(1, 566) = 0.57 P = 0.45
Asthma: No	5.16	0.12	4.92	5.40	
Yes	5.14	0.35	4.45	5.83	F(1, 566) = 0.00 P = 0.96
Depression: No	5.07	0.10	4.88	5.26	
Yes	5.79	0.66	4.49	7.09	F(1, 566) = 1.16 P = 0.28
Diabetes: No	5.28	0.12	5.04	5.52	
Yes	3.77	0.30	3.17	4.36	F(1, 566) = 21.44 P < 0.0001
Enlarged prostate: No	5.26	0.12	5.02	5.49	
Yes	4.12	0.31	3.51	4.73	F(1, 566) = 11.51 P = 0.0007
High cholesterol: No	5.22	0.11	5.01	5.44	
Yes	5.00	0.29	4.44	5.57	F(1, 566) = 0.50 P = 0.48
High BP: No	5.40	0.14	5.12	5.67	
Yes	4.48	0.18	4.14	4.83	F(1, 566) = 16.34 P = 0.0001
Insomnia: No	5.22	0.12	4.98	5.47	
Yes	4.57	0.28	4.02	5.11	F(1, 566) = 4.65 P = 0.032
Osteoarthritis: No	5.22	0.12	4.98	5.46	
Yes	4.42	0.32	3.79	5.04	F(1, 566) = 5.58 P = 0.019
Rheumatoid arthritis: No	5.18	0.12	4.95	5.41	
Yes	4.71	0.47	3.79	5.63	F(1, 566) = 0.95 P = 0.33
Thyroid problems: No	5.17	0.12	4.94	5.40	
Yes	4.40	0.70	3.03	5.78	F(1, 566) = 1.16 P = 0.28
Prostate cancer: No	5.21	0.12	4.98	5.44	

	Mean	S.E.	95% CI		Adj. Wald test
Yes	2.58	0.50	1.59	3.56	F(1, 566) = 26.08 P < 0.0001
Prostate removal: No	5.20	0.12	4.97	5.43	
Yes	3.34	0.28	2.79	3.90	F(1, 566) = 36.74 P < 0.0001
TURP: No	5.21	0.12	4.97	5.44	
Yes	3.59	0.25	3.11	4.08	F(1, 566) = 34.99 P < 0.0001
Vasectomy: No	5.08	0.11	4.86	5.29	
Yes	5.39	0.31	4.77	6.00	F(1, 566) = 0.87 P = 0.35
Penile surgery: No	5.15	0.12	4.92	5.38	
Yes	5.49	0.72	4.09	6.90	F(1, 566) = 0.22 P = 0.64
Bladder surgery: No	5.19	0.12	4.95	5.42	
Yes	4.06	0.29	3.50	4.62	F(1, 566) = 13.28 P = 0.0003
Digestive health condition:	5.05	0.10	4.86	5.24	
Yes	6.14	0.73	4.71	7.57	F(1, 566) = 2.23 P = 0.14
Circulatory health condition:	5.20	0.12	4.96	5.44	
Yes	4.53	0.26	4.01	5.05	F(1, 566) = 5.38 P = 0.021
Musculoskeletal health	5.19	0.13	4.94	5.44	
Yes	4.94	0.21	4.53	5.35	F(1, 566) = 1.05 P = 0.31
Neurological health	5.17	0.12	4.94	5.40	
Yes	4.71	0.28	4.16	5.26	F(1, 566) = 2.28 P = 0.13
Psychological health	5.10	0.09	4.92	5.29	
Yes	6.63	2.02	2.66	10.59	F(1, 566) = 0.57 P = 0.45
Respiratory health condition:	5.16	0.12	4.92	5.40	
Yes	5.11	0.33	4.46	5.76	F(1, 566) = 0.02 P = 0.89
Metabolic, Endo. Nut. Health	5.18	0.12	4.95	5.41	
Yes	4.43	0.43	3.59	5.27	F(1, 566) = 2.84 P = 0.09

	Mean	S.E.	95% CI		Adj. Wald test
Urological health condition:	5.16	0.12	4.93	5.39	
Yes	4.91	0.63	3.68	6.14	F(1, 566) = 0.16 P = 0.69
Medication, general	5.29	0.13	5.03	5.55	
Yes	4.53	0.19	4.16	4.89	F(1, 566) = 11.18 P = 0.0009
Medication, digestive: No	5.20	0.10	5.01	5.40	
Yes	4.88	0.56	3.78	5.98	F(1, 566) = 0.32 P = 0.57
Medication, circulatory: No	5.45	0.11	5.25	5.66	
Yes	4.37	0.30	3.77	4.96	F(1, 566) = 11.55 P = 0.0007
Medication, musculoskeletal:	5.24	0.10	5.04	5.44	
Yes	4.73	0.50	3.75	5.70	F(1, 566) = 1.01 P = 0.31
Medication, neurological: No	5.19	0.12	4.95	5.44	
Yes	4.71	0.25	4.22	5.19	F(1, 566) = 3.12 P = 0.078
Medication, psychological:	5.13	0.09	4.94	5.31	
Yes	5.47	0.86	3.78	7.17	F(1, 566) = 0.16 P = 0.69
Medication, respiratory: No	5.18	0.13	4.93	5.43	
Yes	5.03	0.24	4.55	5.51	F(1, 566) = 0.29 P = 0.59
Medication, metabolic endo.	5.37	0.10	5.17	5.57	
Yes	4.40	0.37	3.68	5.12	F(1, 566) = 6.51 P = 0.011
Medication, urological: No	5.16	0.12	4.93	5.39	
Yes	4.64	0.43	3.80	5.48	F(1, 566) = 1.39 P = 0.24
Medication, male genital: No	5.22	0.12	4.99	5.45	
Yes	3.65	0.41	2.85	4.45	F(1, 566) = 13.77 P = 0.0002

Table IV.VIII Comparisons of mean serum BT concentrations between men with and without chronic diseases, men who have had urogenital surgery and men who have not and men using and not using medications. Data presented are means \pm standard error and 95% confidence intervals.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	4.13	0.08	3.96	4.29		
Yes	4.27	1.13	2.05	6.50	F(1, 566) = 0.02	P = 0.90
Anxiety: No	4.08	0.08	3.91	4.24		
Yes	4.74	0.76	3.24	6.24	F(1, 566) = 0.74	P = 0.39
Asthma: No	4.15	0.11	3.93	4.37		
Yes	4.04	0.32	3.42	4.66	F(1, 566) = 0.10	P = 0.75
Depression: No	4.06	0.08	3.89	4.23		
Yes	4.73	0.62	3.51	5.95	F(1, 566) = 1.13	P = 0.29
Diabetes: No	4.24	0.11	4.03	4.46		
Yes	2.92	0.29	2.36	3.48	F(1, 566) = 18.53	P < 0.0001
Enlarged prostate: No	4.22	0.11	4.00	4.43		
Yes	3.27	0.28	2.72	3.83	F(1, 566) = 9.74	P = 0.0019
High cholesterol: No	4.17	0.10	3.98	4.37		
Yes	4.05	0.26	3.54	4.57	F(1, 566) = 0.18	P = 0.67
High BP: No	4.34	0.13	4.09	4.60		
Yes	3.55	0.16	3.24	3.86	F(1, 566) = 15.07	P = 0.0001
Insomnia: No	4.19	0.11	3.97	4.41		
Yes	3.69	0.27	3.17	4.22	F(1, 566) = 2.85	P = 0.09
Osteoarthritis: No	4.19	0.11	3.97	4.40		
Yes	3.59	0.27	3.06	4.12	F(1, 566) = 4.12	P = 0.043
Rheumatoid arthritis: No	4.16	0.11	3.94	4.37		
Yes	3.76	0.38	3.01	4.51	F(1, 566) = 0.98	P = 0.32
Thyroid problems: No	4.14	0.11	3.94	4.35		
Yes	3.70	0.61	2.49	4.90	F(1, 566) = 0.52	P = 0.47
Prostate cancer: No	4.19	0.11	3.98	4.39		

	Mean	S.E.	95% CI		Adj. Wald test
Yes	1.79	0.39	1.02	2.55	F(1, 566) = 35.47 P < 0.0001
Prostate removal: No	4.18	0.11	3.97	4.39	
Yes	2.28	0.23	1.84	2.73	F(1, 566) = 58.17 P < 0.0001
TURP: No	4.18	0.11	3.97	4.39	
Yes	2.67	0.20	2.29	3.06	F(1, 566) = 45.33 P < 0.0001
Vasectomy: No	4.03	0.10	3.84	4.22	
Yes	4.45	0.30	3.87	5.03	F(1, 566) = 1.84 P = 0.18
Penile surgery: No	4.13	0.11	3.92	4.34	
Yes	4.28	0.58	3.14	5.42	F(1, 566) = 0.06 P = 0.80
Bladder surgery: No	4.16	0.11	3.95	4.37	
Yes	3.26	0.22	2.84	3.69	F(1, 566) = 13.62 P = 0.0002
Digestive health condition:	4.04	0.09	3.87	4.21	
Yes	5.01	0.67	3.69	6.34	F(1, 566) = 2.07 P = 0.15
Circulatory health condition:	4.17	0.11	3.95	4.39	
Yes	3.65	0.25	3.17	4.14	F(1, 566) = 3.68 P = 0.056
Musculoskeletal health	4.16	0.12	3.93	4.39	
Yes	3.98	0.20	3.60	4.36	F(1, 566) = 0.62 P = 0.43
Neurological health	4.15	0.11	3.94	4.36	
Yes	3.72	0.24	3.25	4.19	F(1, 566) = 2.69 P = 0.10
Psychological health	4.10	0.08	3.93	4.26	
Yes	5.22	1.88	1.54	8.91	F(1, 566) = 0.36 P = 0.55
Respiratory health condition:	4.13	0.11	3.92	4.35	
Yes	4.19	0.28	3.63	4.74	F(1, 566) = 0.03 P = 0.87
Metabolic, Endo. Nut. Health	4.15	0.11	3.94	4.36	
Yes	3.75	0.37	3.03	4.46	F(1, 566) = 1.11 P = 0.29

	Mean	S.E.	95% CI		Adj. Wald test
Urological health condition:	4.14	0.11	3.93	4.35	
Yes	4.09	0.59	2.92	5.25	F(1, 566) = 0.01 P = 0.93
Medication, general	4.26	0.12	4.03	4.50	
Yes	3.53	0.18	3.18	3.88	F(1, 566) = 11.43 P = 0.0008
Medication, digestive: No	4.17	0.09	4.00	4.35	
Yes	3.91	0.51	2.91	4.92	F(1, 566) = 0.25 P = 0.62
Medication, circulatory: No	4.39	0.10	4.20	4.58	
Yes	3.47	0.27	2.93	4.01	F(1, 566) = 9.86 P = 0.0018
Medication, musculoskeletal:	4.19	0.09	4.01	4.37	
Yes	3.86	0.46	2.96	4.76	F(1, 566) = 0.49 P = 0.49
Medication, neurological: No	4.17	0.11	3.95	4.39	
Yes	3.74	0.22	3.30	4.18	F(1, 566) = 2.96 P = 0.086
Medication, psychological:	4.10	0.08	3.94	4.27	
Yes	4.50	0.80	2.92	6.07	F(1, 566) = 0.24 P = 0.63
Medication, respiratory: No	4.15	0.12	3.92	4.37	
Yes	4.08	0.21	3.66	4.49	F(1, 566) = 0.08 P = 0.77
Medication, metabolic endo.	4.30	0.09	4.11	4.48	
Yes	3.57	0.34	2.91	4.23	F(1, 566) = 4.36 P = 0.037
Medication, urological: No	4.14	0.11	3.93	4.35	
Yes	4.01	0.64	2.76	5.27	F(1, 566) = 0.04 P = 0.85
Medication, male genital: No	4.19	0.11	3.98	4.40	
Yes	2.71	0.34	2.05	3.38	F(1, 566) = 17.29 P < 0.0001

Table IV.IX Comparisons of mean cBT concentrations between men with and without chronic diseases, men who have had urogenital surgery and men who have not and men using and not using medications. Data presented are means \pm standard error and 95% confidence intervals.

	Mean	S.E.	95% CI		Adj. Wald test
Angina: No	349.30	5.47	338.55	360.05	
Yes	329.61	51.34	228.76	430.46	F(1, 566) = 0.15 P = 0.70
Anxiety: No	346.51	5.52	335.66	357.35	
Yes	363.64	35.96	293.01	434.27	F(1, 566) = 0.22 P = 0.64
Asthma: No	348.69	6.25	336.42	360.95	
Yes	342.70	21.53	300.42	384.99	F(1, 566) = 0.07 P = 0.79
Depression: No	345.90	5.59	334.91	356.88	
Yes	364.89	29.55	306.84	422.94	F(1, 566) = 0.40 P = 0.53
Diabetes: No	355.50	6.25	343.22	367.77	
Yes	262.15	17.54	227.70	296.61	F(1, 566) = 25.12 P < 0.0001
Enlarged prostate: No	352.11	6.26	339.81	364.40	
Yes	305.45	20.38	265.41	345.48	F(1, 566) = 4.79 P = 0.029
High cholesterol: No	354.28	6.43	341.66	366.90	
Yes	333.69	13.28	307.60	359.78	F(1, 566) = 1.95 P = 0.16
High BP: No	362.22	7.11	348.25	376.19	
Yes	308.40	10.39	288.00	328.79	F(1, 566) = 18.26 P < 0.0001
Insomnia: No	351.44	6.34	338.98	363.90	
Yes	318.42	18.16	282.76	354.08	F(1, 566) = 2.95 P = 0.086
Osteoarthritis: No	350.49	6.32	338.08	362.91	
Yes	321.17	18.83	284.19	358.15	F(1, 566) = 2.18 P = 0.14
Rheumatoid arthritis: No	348.59	6.19	336.43	360.75	
Yes	338.09	25.35	288.30	387.89	F(1, 566) = 0.16 P = 0.69
Thyroid problems: No	348.78	6.06	336.87	360.68	
Yes	299.27	46.24	208.46	390.09	F(1, 566) = 1.13 P = 0.29
Prostate cancer: No	351.30	5.98	339.56	363.04	

	Mean	S.E.	95% CI		Adj. Wald test
Yes	192.26	38.94	115.77	268.75	F(1, 566) = 16.30 P = 0.0001
Prostate removal: No	350.81	6.07	338.88	362.74	
Yes	239.09	20.75	198.32	279.85	F(1, 566) = 26.74 P < 0.0001
TURP: No	350.42	6.14	338.36	362.49	
Yes	272.02	18.63	235.43	308.61	F(1, 566) = 15.96 P = 0.0001
Vasectomy: No	342.93	6.34	330.48	355.37	
Yes	362.85	14.51	334.35	391.36	F(1, 566) = 1.58 P = 0.21
Penile surgery: No	347.30	6.08	335.36	359.25	
Yes	379.63	40.25	300.57	458.68	F(1, 566) = 0.63 P = 0.43
Bladder surgery: No	349.39	6.14	337.32	361.46	
Yes	296.46	15.31	266.40	326.52	F(1, 566) = 10.29 P = 0.0014
Digestive health condition: No	342.97	5.68	331.82	354.12	
Yes	393.22	30.59	333.14	453.30	F(1, 566) = 2.61 P = 0.11
Circulatory health condition: No	349.97	6.36	337.49	362.46	
Yes	321.80	14.71	292.90	350.70	F(1, 566) = 3.09 P = 0.08
Musculoskeletal health: No	349.81	6.69	336.67	362.95	
Yes	336.62	11.80	313.44	359.80	F(1, 566) = 0.94 P = 0.33
Neurological health: No	348.22	6.19	336.05	360.38	
Yes	344.21	11.99	320.66	367.76	F(1, 566) = 0.09 P = 0.77
Psychological health: No	346.93	5.46	336.21	357.64	
Yes	380.23	82.73	217.73	542.73	F(1, 566) = 0.16 P = 0.69
Respiratory health condition: No	347.03	6.25	334.74	359.31	
Yes	368.55	18.58	332.06	405.04	F(1, 566) = 1.21 P = 0.27
Metabolic, Endo. Nut. Health: No	349.06	6.13	337.03	361.10	
Yes	309.75	24.91	260.82	358.69	F(1, 566) = 2.35 P = 0.13

	Mean	S.E.	95% CI		Adj. Wald test
Urological health condition:	348.17	6.11	336.16	360.18	
Yes	344.70	30.71	284.38	405.01	F(1, 566) = 0.01 P = 0.91
Medication, general	354.98	6.75	341.71	368.24	
Yes	314.72	12.19	290.78	338.65	F(1, 566) = 8.34 P = 0.004
Medication, digestive: No	351.20	5.79	339.82	362.57	
Yes	328.66	24.23	281.07	376.25	F(1, 566) = 0.82 P = 0.37
Medication, circulatory: No	363.34	6.33	350.91	375.76	
Yes	307.45	13.48	280.98	333.93	F(1, 566) = 14.08 P = 0.0002
Medication, musculoskeletal:	352.02	5.98	340.27	363.77	
Yes	326.50	21.03	285.20	367.80	F(1, 566) = 1.36 P = 0.24
Medication, neurological: No	350.11	6.39	337.55	362.67	
Yes	323.07	13.74	296.09	350.05	F(1, 566) = 3.19 P = 0.07
Medication, psychological:	347.00	5.48	336.23	357.78	
Yes	359.29	37.81	285.02	433.56	F(1, 566) = 0.10 P = 0.75
Medication, respiratory: No	348.80	6.62	335.80	361.79	
Yes	343.23	13.38	316.95	369.50	F(1, 566) = 0.14 P = 0.71
Medication, metabolic endo.	359.95	6.05	348.08	371.83	
Yes	305.66	16.30	273.64	337.68	F(1, 566) = 9.74 P = 0.0019
Medication, urological: No	348.26	6.07	336.34	360.18	
Yes	334.05	41.89	251.78	416.32	F(1, 566) = 0.11 P = 0.74
Medication, male genital: No	351.14	6.07	339.22	363.06	
Yes	272.91	32.58	208.92	336.90	F(1, 566) = 5.57 P = 0.019

Table IV.X Comparisons of mean FT concentrations between men with and without chronic diseases, men who have had urogenital surgery and men who have not and men using and not using medications. Data presented are means \pm standard error and 95% confidence intervals.

	Mean	S.E.	95% CI		Adj. Wald test
Angina: No	32.38	0.69	31.02	33.75	
Yes	32.14	2.34	27.55	36.73	F(1, 566) = 0.01 P = 0.92
Anxiety: No	32.35	0.66	31.04	33.65	
Yes	32.60	3.08	26.56	38.64	F(1, 566) = 0.01 P = 0.94
Asthma: No	32.13	0.68	30.80	33.46	
Yes	34.54	2.70	29.23	39.84	F(1, 566) = 0.74 P = 0.39
Depression: No	32.46	0.67	31.14	33.78	
Yes	31.71	2.61	26.59	36.83	F(1, 566) = 0.08 P = 0.78
Diabetes: No	32.12	0.69	30.76	33.47	
Yes	35.29	2.53	30.32	40.27	F(1, 566) = 1.46 P = 0.23
Enlarged prostate: No	31.67	0.67	30.34	32.99	
Yes	39.84	2.63	34.67	45.01	F(1, 566) = 9.06 P = 0.0027
High cholesterol: No	33.32	0.86	31.63	35.01	
Yes	30.16	0.92	28.34	31.97	F(1, 566) = 6.28 P = 0.013
High BP: No	31.81	0.76	30.32	33.29	
Yes	33.95	1.37	31.26	36.65	F(1, 566) = 1.88 P = 0.17
Insomnia: No	32.25	0.70	30.88	33.62	
Yes	33.41	2.25	29.00	37.83	F(1, 566) = 0.24 P = 0.62
Osteoarthritis: No	32.14	0.71	30.75	33.53	
Yes	34.93	1.80	31.39	38.47	F(1, 566) = 2.07 P = 0.15
Rheumatoid arthritis: No	32.10	0.67	30.78	33.43	
Yes	37.76	3.47	30.95	44.57	F(1, 566) = 2.57 P = 0.11
Thyroid problems: No	32.42	0.67	31.10	33.74	

	Mean	S.E.	95% CI		Adj. Wald test
Yes	28.74	5.51	17.91	39.57	F(1, 566) = 0.44 P = 0.51
Prostate cancer: No	32.01	0.66	30.71	33.30	
Yes	50.10	5.88	38.55	61.64	F(1, 566) = 9.36 P = 0.0023
Prostate removal: No	32.05	0.66	30.74	33.35	
Yes	45.26	4.99	35.46	55.05	F(1, 566) = 6.89 P = 0.0089
TURP: No	32.12	0.68	30.80	33.45	
Yes	40.38	3.20	34.08	46.67	F(1, 566) = 6.35 P = 0.012
Vasectomy: No	32.77	0.81	31.19	34.35	
Yes	31.23	1.13	29.01	33.45	F(1, 566) = 1.23 P = 0.27
Penile surgery: No	32.29	0.68	30.95	33.62	
Yes	35.60	2.49	30.71	40.48	F(1, 566) = 1.65 P = 0.20
Bladder surgery: No	32.36	0.68	31.03	33.69	
Yes	32.71	3.40	26.03	39.39	F(1, 566) = 0.01 P = 0.92
Digestive health condition:	32.45	0.70	31.07	33.83	
Yes	31.66	2.11	27.51	35.80	F(1, 566) = 0.13 P = 0.72
Circulatory health condition:	32.27	0.69	30.92	33.63	
Yes	33.76	2.56	28.73	38.78	F(1, 566) = 0.31 P = 0.57
Musculoskeletal health	32.52	0.72	31.11	33.94	
Yes	31.33	1.76	27.88	34.79	F(1, 566) = 0.39 P = 0.53
Neurological health	32.20	0.67	30.87	33.52	
Yes	37.93	3.82	30.43	45.43	F(1, 566) = 2.18 P = 0.14
Psychological health	32.19	0.64	30.93	33.44	
Yes	37.32	7.11	23.36	51.27	F(1, 566) = 0.52 P = 0.47

	Mean	S.E.	95% CI		Adj. Wald test
Respiratory health condition:	32.21	0.69	30.86	33.55	
Yes	35.45	2.87	29.81	41.09	F(1, 566) = 1.20 P = 0.27
Metabolic, Endo. Nut. Health	32.50	0.68	31.17	33.84	
Yes	27.06	2.42	22.32	31.80	F(1, 566) = 4.71 P = 0.031
Urological health condition:	32.36	0.68	31.03	33.68	
Yes	32.98	4.11	24.92	41.04	F(1, 566) = 0.02 P = 0.88
Medication, general	31.59	0.68	30.26	32.93	
Yes	36.13	2.03	32.14	40.12	F(1, 566) = 4.48 P = 0.035
Medication, digestive: No	31.98	0.69	30.63	33.33	
Yes	34.81	2.16	30.56	39.06	F(1, 566) = 1.55 P = 0.21
Medication, circulatory: No	31.02	0.78	29.49	32.55	
Yes	35.96	1.21	33.58	38.35	F(1, 566) = 11.73 P = 0.0007
Medication, musculoskeletal:	32.28	0.74	30.82	33.74	
Yes	32.87	1.46	30.01	35.73	F(1, 566) = 0.13 P = 0.72
Medication, neurological: No	32.39	0.69	31.04	33.74	
Yes	32.07	2.68	26.80	37.33	F(1, 566) = 0.01 P = 0.91
Medication, psychological:	32.00	0.66	30.70	33.29	
Yes	36.19	3.19	29.92	42.46	F(1, 566) = 1.65 P = 0.20
Medication, respiratory: No	32.61	0.73	31.17	34.04	
Yes	30.71	1.52	27.72	33.71	F(1, 566) = 1.25 P = 0.26
Medication, metabolic endo.	32.01	0.77	30.50	33.53	
Yes	33.65	1.28	31.13	36.16	F(1, 566) = 1.19 P = 0.28
Medication, urological: No	32.37	0.67	31.06	33.69	

	Mean	S.E.	95% CI		Adj. Wald test
Yes	32.00	6.45	19.34	44.66	F(1, 566) = 0.00 P = 0.95
Medication, male genital: No	31.84	0.66	30.54	33.14	
Yes	45.44	3.78	38.02	52.87	F(1, 566) = 12.55 P = 0.0004

Table IV.XI Comparisons of mean SHBG concentrations between men with and without chronic diseases, men who have had urogenital surgery and men who have not and men using and not using medications. Data presented are means \pm standard error and 95% confidence intervals.

Chi-squared tables

Age > 60 v BT < 3.1

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60	BT < 3.1		Total
	No	Yes	
No	.6589 [.617, .6984]	.0398 [.0274, .0576]	.6987 [.6578, .7367]
Yes	.1954 [.1639, .2313]	.1059 [.0821, .1356]	.3013 [.2633, .3422]
Total	.8543 [.822, .8816]	.1457 [.1184, .178]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	83.2981	
Design-based	F(1, 566)	=	89.1191	P = 0.0000

Married/ live-in partner v BT < 3.1

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Married/ Live-in Partner	BT < 3.1		Total
	No	Yes	
No	.172 [.1401, .2094]	.0217 [.0117, .0397]	.1937 [.1601, .2324]
Yes	.6823 [.6398, .7219]	.124 [.0992, .1541]	.8063 [.7676, .8399]
Total	.8543 [.822, .8816]	.1457 [.1184, .178]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	1.2528	
Design-based	F(1, 566)	=	1.0543	P = 0.3049

Waist > 102 v BT < 3.1

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Waist > 102	BT < 3.1		Total
	No	Yes	
No	.5594 [.5156,.6023]	.0604 [.0433,.0836]	.6198 [.5768,.661]
Yes	.2949 [.2566,.3362]	.0853 [.0646,.1119]	.3802 [.339,.4232]
Total	.8543 [.822,.8816]	.1457 [.1184,.178]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	17.3402	
Design-based	F(1, 566)	=	16.5890	P = 0.0001

Triglycerides > 2 v BT < 3.1

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Triglycerides > 2	BT < 3.1		Total
	No	Yes	
No	.6449 [.6021,.6855]	.107 [.0836,.1359]	.7519 [.7121,.7878]
Yes	.2094 [.1758,.2475]	.0387 [.0255,.0584]	.2481 [.2122,.2879]
Total	.8543 [.822,.8816]	.1457 [.1184,.178]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	0.1639	
Design-based	F(1, 566)	=	0.1584	P = 0.6908

Alcohol intake 75%'ile v BT < 3.1

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Alc 75%'ile	BT < 3.1		Total
	No	Yes	
No	.6281 [.585,.6693]	.1123 [.0883,.1418]	.7404 [.6998,.7774]

Yes	.2262 [.191, .2657]	.0334 [.0213, .0518]	.2596 [.2226, .3002]
Total	.8543 [.822, .8816]	.1457 [.1184, .178]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	0.4681	
Design-based	F(1, 566)	=	0.4569	P = 0.4994

Alcohol intake 90%'ile v BT < 3.1

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Alc 90%'ile	BT < 3.1		Total
	No	Yes	
No	.7646 [.7259, .7993]	.1339 [.1075, .1655]	.8985 [.8685, .9223]
Yes	.0897 [.0671, .119]	.0118 [.0061, .0228]	.1015 [.0777, .1315]
Total	.8543 [.822, .8816]	.1457 [.1184, .178]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	0.4474	
Design-based	F(1, 566)	=	0.5369	P = 0.4640

Age > 60 v Total T < 8

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60	Total T < 8		Total
	No	Yes	
No	.678 [.6365, .7169]	.0207 [.012, .0355]	.6987 [.6578, .7367]
Yes	.2724 [.2359, .3122]	.0289 [.0174, .0475]	.3013 [.2633, .3422]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 11.1104
 Design-based F(1, 566) = 11.1414 P = 0.0009

Married/ live-in partner v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Married/ Live-in Partner	Total T < 8		Total
	No	Yes	
No	.1845 [.1516, .2227]	.0092 [.0037, .0226]	.1937 [.1601, .2324]
Yes	.7659 [.7257, .8018]	.0404 [.0269, .0602]	.8063 [.7676, .8399]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 0.0139
 Design-based F(1, 566) = 0.0126 P = 0.9105

Waist > 102 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Waist > 102	Total T < 8		Total
	No	Yes	
No	.6061 [.563, .6477]	.0137 [.0069, .0271]	.6198 [.5768, .661]
Yes	.3443 [.3042, .3867]	.0359 [.0231, .0554]	.3802 [.339, .4232]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 14.8469
 Design-based F(1, 566) = 15.0457 P = 0.0001

Triglycerides > 2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Triglycerides > 2	Total T < 8		Total
	No	Yes	
No	.7246 [.6839, .7619]	.0273 [.0166, .0444]	.7519 [.7121, .7878]
Yes	.2258 [.1912, .2646]	.0223 [.0127, .0389]	.2481 [.2122, .2879]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 6.4791
 Design-based F(1, 566) = 6.2605 P = 0.0126

SHBG > 35 b Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

SHBG > 35	Total T < 8		Total
	No	Yes	
No	.632 [.5889, .673]	.0397 [.0265, .0592]	.6717 [.6293, .7114]
Yes	.3185 [.2792, .3605]	.0098 [.004, .0242]	.3283 [.2886, .3707]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 2.2640
 Design-based F(1, 566) = 1.9599 P = 0.1621

HbA1c > 6.2 v Total T < 8

```

pweight: wt           Number of obs   =   568
Strata:  nwregion     Number of strata =     2
PSU:     <observations> Number of PSUs  =   568
                               Population size =   568
    
```

HbA1c > 6.2	Total T < 8		Total
	No	Yes	
No	.8636 [.832,.89]	.032 [.0202,.0501]	.8955 [.8668,.9186]
Yes	.0869 [.066,.1136]	.0176 [.0093,.0332]	.1045 [.0814,.1332]
Total	.9504 [.9288,.9657]	.0496 [.0343,.0712]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

```

Pearson:
Uncorrected  chi2(1)      =   19.9133
Design-based F(1, 566)   =   19.0852    P = 0.0000
    
```

Non-smoker v Total T < 8

```

pweight: wt           Number of obs   =   568
Strata:  nwregion     Number of strata =     2
PSU:     <observations> Number of PSUs  =   568
                               Population size =   568
    
```

Non-smoker	Total T < 8		Total
	No	Yes	
No	.1998 [.1662,.2382]	.0053 [.0017,.0169]	.2051 [.1711,.2438]
Yes	.7507 [.7103,.7871]	.0443 [.0299,.065]	.7949 [.7562,.8289]
Total	.9504 [.9288,.9657]	.0496 [.0343,.0712]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

```

Pearson:
Uncorrected  chi2(1)      =   1.7371
Design-based F(1, 566)   =   1.6327    P = 0.2019
    
```

Age > 60 v Total T < 12

```

pweight: wt           Number of obs   =   568
    
```


Waist > 102	Total T < 12		Total
	No	Yes	
No	.4973 [.4535,.5413]	.1225 [.0962,.1546]	.6198 [.5768,.661]
Yes	.2394 [.204,.2789]	.1408 [.1134,.1734]	.3802 [.339,.4232]
Total	.7368 [.6964,.7735]	.2632 [.2265,.3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	20.5733	
Design-based	F(1, 566)	=	18.1615	P = 0.0000

Triglycerides > 2 v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Triglycerides > 2	Total T < 12		Total
	No	Yes	
No	.5832 [.5392,.626]	.1687 [.1379,.2047]	.7519 [.7121,.7878]
Yes	.1536 [.1241,.1885]	.0946 [.0726,.1222]	.2481 [.2122,.2879]
Total	.7368 [.6964,.7735]	.2632 [.2265,.3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	13.4322	
Design-based	F(1, 566)	=	12.0682	P = 0.0006

HbA1c > 6.2 v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

HbA1c > 6.2	Total T < 12		Total
	No	Yes	

No	.6883	.2072	.8955
	[.6465,.7273]	[.1738,.2451]	[.8668,.9186]
Yes	.0484	.0561	.1045
	[.0336,.0694]	[.0393,.0793]	[.0814,.1332]
Total	.7368	.2632	1
	[.6964,.7735]	[.2265,.3036]	

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:
Uncorrected chi2(1) = 25.5053
Design-based F(1, 566) = 24.5030 P = 0.0000

Non-smoker v Total T < 12

pweight: wt	Number of obs	=	568
Strata: nwregion	Number of strata	=	2
PSU: <observations>	Number of PSUs	=	568
	Population size	=	568

Non-smoker	Total T < 12		Total
	No	Yes	
No	.1887	.0164	.2051
	[.1558,.2267]	[.0086,.0311]	[.1711,.2438]
Yes	.5481	.2468	.7949
	[.5038,.5916]	[.2109,.2866]	[.7562,.8289]
Total	.7368	.2632	1
	[.6964,.7735]	[.2265,.3036]	

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:
Uncorrected chi2(1) = 25.3896
Design-based F(1, 566) = 24.2967 P = 0.0000

COMBINATIONS

Age > 60 + Waist > 102 v BT < 3.1

pweight: wt	Number of obs	=	568
Strata: nwregion	Number of strata	=	2
PSU: <observations>	Number of PSUs	=	568
	Population size	=	568

Age > 60 + Waist > 102	BT < 3.1		Total
	No	Yes	
No	.7921	.0837	.8758

	[.7558,.8243]	[.0635,.1095]	[.8452,.9011]
Yes	.0622	.062	.1242
	[.045,.0853]	[.0443,.0862]	[.0989,.1548]
Total	.8543	.1457	1
	[.822,.8816]	[.1184,.178]	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 80.9779
 Design-based F(1, 566) = 78.7969 P = 0.0000

Age > 60 + Waist > 102 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Age > 60		Total T < 8		
Waist > 102		No	Yes	Total
No	.8435	.0323		.8758
	[.8105,.8716]	[.0207,.05]	[.8452,.9011]	
Yes	.1069	.0173		.1242
	[.0837,.1356]	[.0088,.0336]	[.0989,.1548]	
Total	.9504	.0496		1
	[.9288,.9657]	[.0343,.0712]		

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 13.7076
 Design-based F(1, 566) = 12.6944 P = 0.0004

Age > 60 + Triglycerides > 2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Age > 60		Total T < 8		
Triglycerides > 2		No	Yes	Total
No	.8998	.0347		.9344
	[.8717,.9222]	[.0225,.0531]	[.9103,.9524]	
Yes	.0507	.0149		.0656
	[.0353,.0722]	[.0073,.0303]	[.0476,.0897]	
Total	.9504	.0496		1

[.9288,.9657] [.0343,.0712]

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 26.7841
 Design-based F(1, 566) = 24.9416 P = 0.0000

Age > 60 + HbA1c > 6.2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Age > 60		Total T < 8		Total
HbA1c > 6.2		No	Yes	
No	.9038 [.8756,.9261]	.0357 [.0231,.0547]	.9395 [.9155,.957]	
Yes	.0466 [.0315,.0685]	.0139 [.0067,.0283]	.0605 [.043,.0845]	
Total	.9504 [.9288,.9657]	.0496 [.0343,.0712]	1	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 25.0838
 Design-based F(1, 566) = 23.6974 P = 0.0000

Waist > 102 + triglycerides > 2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Waist > 102		Total T < 8		Total
Triglycerides > 2		No	Yes	
No	.8497 [.816,.8782]	.0299 [.0188,.0475]	.8796 [.848,.9054]	
Yes	.1007 [.0772,.1305]	.0196 [.0106,.036]	.1204 [.0946,.152]	
Total	.9504 [.9288,.9657]	.0496 [.0343,.0712]	1	

Key: cell proportions

[95% confidence intervals for cell proportions]

Pearson:

Uncorrected chi2(1) = 21.2799
 Design-based F(1, 566) = 20.0560 P = 0.0000

Waist > 102 + HbA1c > 6.2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

HbA1c > 6.2	Total T < 8		Total
	No	Yes	
No	.9005 [.8729, .9226]	.037 [.0242, .0562]	.9375 [.9144, .9546]
Yes	.0499 [.035, .0708]	.0126 [.0059, .0268]	.0625 [.0454, .0856]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:

Uncorrected chi2(1) = 18.4621
 Design-based F(1, 566) = 17.6316 P = 0.0000

Triglycerides > 2 + HbA1c > 6.2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

HbA1c > 6.2	Total T < 8		Total
	No	Yes	
No	.9283 [.9038, .9469]	.0422 [.0283, .0623]	.9704 [.953, .9815]
Yes	.0221 [.013, .0374]	.0074 [.0027, .0204]	.0296 [.0185, .047]
Total	.9504 [.9288, .9657]	.0496 [.0343, .0712]	1

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:

Uncorrected chi2(1) = 14.8555

Design-based F(1, 566) = 13.8087 P = 0.0002

Age > 60 + waist > 102 v Total T > 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60

Waist > 102	Total T < 12		
	No	Yes	Total
No	.6774 [.6353, .7168]	.1984 [.1655, .2359]	.8758 [.8452, .9011]
Yes	.0593 [.0425, .0823]	.0649 [.0468, .0892]	.1242 [.0989, .1548]
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	27.8526	
Design-based	F(1, 566)	=	26.4354	P = 0.0000

Age > 60 + triglycerides > 2 v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60

Triglycerides > 2	Total T < 12		
	No	Yes	Total
No	.7132 [.6721, .751]	.2213 [.1869, .2599]	.9344 [.9103, .9524]
Yes	.0236 [.014, .0395]	.042 [.0278, .0629]	.0656 [.0476, .0897]
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	29.1925	
Design-based	F(1, 566)	=	28.8942	P = 0.0000

Age > 60 + HbA1c > 6.2 v Total T < 12


```

pweight: wt          Number of obs   =   568
Strata:  nwregion    Number of strata  =     2
PSU:     <observations> Number of PSUs    =   568
                               Population size =   568

```

```

Age > 60
HbA1c > 6.2          Total T < 12
                    No           Yes           Total
No                   .7147       .2248       .9395
   [.6735,.7525]   [.1903,.2636] [.9155,.957]
Yes                   .0221       .0384       .0605
   [.0125,.0388]   [.0249,.0588] [.043,.0845]
Total                 .7368       .2632       1
   [.6964,.7735]   [.2265,.3036]

```

```

Key: cell proportions
     [95% confidence intervals for cell proportions]

```

```

Pearson:
Uncorrected chi2(1)      = 26.0280
Design-based F(1, 566)  = 24.0352   P = 0.0000

```

```

Waist > 102 + triglycerides > 2 v Total T < 12

```

```

pweight: wt          Number of obs   =   568
Strata:  nwregion    Number of strata  =     2
PSU:     <observations> Number of PSUs    =   568
                               Population size =   568

```

```

Waist > 102
Triglycerides > 2    Total T < 12
                    No           Yes           Total
No                   .6771       .2026       .8796
   [.6344,.717]   [.1692,.2405] [.848,.9054]
Yes                   .0597       .0607       .1204
   [.0411,.0859]   [.0438,.0836] [.0946,.152]
Total                 .7368       .2632       1
   [.6964,.7735]   [.2265,.3036]

```

```

Key: cell proportions
     [95% confidence intervals for cell proportions]

```

```

Pearson:
Uncorrected chi2(1)      = 23.2552
Design-based F(1, 566)  = 20.3568   P = 0.0000

```

```

Waist > 102 + HbA1c > 6.2 v Total T < 12

```

```

pweight: wt          Number of obs   =   568
Strata:  nwregion    Number of strata  =     2

```


Age > 60 Non-smoker	Total T < 12		Total
	No	Yes	
No	.5788 [.535, .6214]	.15 [.1211, .1844]	.7288 [.6889, .7653]
Yes	.1579 [.1294, .1914]	.1132 [.0887, .1435]	.2712 [.2347, .3111]
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:
Uncorrected chi2(1) = 25.9471
Design-based F(1, 566) = 23.5799 P = 0.0000

Waist > 102 + Non-smoker v Total T < 12

pweight: wt	Number of obs	=	568
Strata: nwregion	Number of strata	=	2
PSU: <observations>	Number of PSUs	=	568
	Population size	=	568

Waist > 102 Non-smoker	Total T < 12		Total
	No	Yes	
No	.5624 [.5185, .6054]	.1283 [.1016, .1608]	.6908 [.6496, .7291]
Yes	.1743 [.1443, .2091]	.1349 [.1081, .1672]	.3092 [.2709, .3504]
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:
Uncorrected chi2(1) = 39.2735
Design-based F(1, 566) = 35.4154 P = 0.0000

Triglycerides > 2 + non-smoker v Total T < 12

pweight: wt	Number of obs	=	568
Strata: nwregion	Number of strata	=	2
PSU: <observations>	Number of PSUs	=	568
	Population size	=	568

Triglycerides > 2 Non-smoker	Total T < 12		Total
	No	Yes	

No	.6388	.1724	.8112
	[.5956,.6799]	[.1414,.2085]	[.775,.8427]
Yes	.098	.0909	.1888
	[.0749,.1272]	[.0693,.1183]	[.1573,.225]
Total	.7368	.2632	1
	[.6964,.7735]	[.2265,.3036]	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 32.3921
 Design-based F(1, 566) = 29.3351 P = 0.0000

HbA1c > 6.2 + non-smoker v Total T < 12

pweight: wt	Number of obs	=	568
Strata: nwregion	Number of strata	=	2
PSU: <observations>	Number of PSUs	=	568
	Population size	=	568

HbA1c > 6.2		Total T < 12		
Non-smoker	No	Yes	Total	
No	.6942	.2147	.9089	
	[.6526,.7329]	[.1808,.2529]	[.8817,.9304]	
Yes	.0425	.0486	.0911	
	[.0289,.0622]	[.033,.0709]	[.0696,.1183]	
Total	.7368	.2632	1	
	[.6964,.7735]	[.2265,.3036]		

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 21.3776
 Design-based F(1, 566) = 20.6680 P = 0.0000

Age > 60 + waist > 102 + triglycerides > 2 v Total T < 8

pweight: wt	Number of obs	=	568
Strata: nwregion	Number of strata	=	2
PSU: <observations>	Number of PSUs	=	568
	Population size	=	568

Age > 60		Total T < 8		
Waist > 102	No	Yes	Total	
Triglycerides > 2	No	Yes	Total	
No	.9311	.0373	.9684	
	[.9067,.9494]	[.0247,.0561]	[.9494,.9804]	

Yes	.0194	.0122	.0316
	[.0108,.0346]	[.0054,.0275]	[.0196,.0506]
Total	.9504	.0496	1
	[.9288,.9657]	[.0343,.0712]	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 44.8909
 Design-based F(1, 566) = 40.8645 P = 0.0000

Age > 60 + waist > 102 + HbA1c > 6.2 v Total T < 8

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60		Total T < 8		
Waist > 102		No	Yes	Total
HbA1c > 6.2				
No	.927	.0407	.9677	
	[.9022,.9459]	[.0271,.0607]	[.9494,.9796]	
Yes	.0234	.0088	.0323	
	[.0138,.0396]	[.0036,.0218]	[.0204,.0506]	
Total	.9504	.0496	1	
	[.9288,.9657]	[.0343,.0712]		

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 20.2355
 Design-based F(1, 566) = 19.2226 P = 0.0000

Age > 60 + triglycerides > 2 + HbA1c > 6.2 v Total T < 8

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60		Total T < 8		
Triglycerides > 6.2		No	Yes	Total
HbA1c > 6.2				
No	.9367	.0422	.9789	
	[.9129,.9543]	[.0283,.0623]	[.9622,.9883]	
Yes	.0137	.0074	.0211	
	[.0067,.028]	[.0027,.0204]	[.0117,.0378]	
Total	.9504	.0496	1	

[.9288,.9657] [.0343,.0712]

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:

Uncorrected chi2(1) = 23.5913
 Design-based F(1, 566) = 21.4795 P = 0.0000

Waist > 102 + triglycerides > 2 + HbA1c > 6.2 v Total T < 8

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Waist > 102		Total T < 8		Total
Triglycerides > 2	No	Yes		
HbA1c > 6.2				
No	.9367 [.9135,.954]	.0434 [.0294,.0637]	.9801 [.9651,.9887]	
Yes	.0138 [.0072,.0259]	.0062 [.0019,.0195]	.0199 [.0113,.0349]	
Total	.9504 [.9288,.9657]	.0496 [.0343,.0712]	1	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:

Uncorrected chi2(1) = 16.5347
 Design-based F(1, 566) = 15.0963 P = 0.0001

Age > 60 + waist > 102 + triglycerides > 2 v Total T < 12

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Age > 60		Total T < 12		Total
Waist > 102	No	Yes		
Triglycerides > 2				
No	.7293 [.6885,.7664]	.2391 [.2037,.2786]	.9684 [.9494,.9804]	
Yes	.0075 [.0027,.0207]	.0241 [.014,.0411]	.0316 [.0196,.0506]	
Total	.7368 [.6964,.7735]	.2632 [.2265,.3036]	1	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 23.8072
 Design-based F(1, 566) = 21.0403 P = 0.0000

Age > 60 + wasit > 102 + HbA1c > 6.2 v Total T < 12

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Age > 60		Total T < 12		Total
Waist > 102	No	Yes		
HbA1c > 6.2				
No	.7293 [.6886, .7664]	.2385 [.2031, .2779]	.9677 [.9494, .9796]	
Yes	.0075 [.003, .0188]	.0247 [.0146, .0416]	.0323 [.0204, .0506]	
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 24.7895
 Design-based F(1, 566) = 25.4973 P = 0.0000

Age > 60 + triglycerides > 2 + HbA1c > 6.2 v Total T < 12

pweight: wt Number of obs = 568
 Strata: nwregion Number of strata = 2
 PSU: <observations> Number of PSUs = 568
 Population size = 568

Age > 60		Total T < 12		Total
Triglycerides > 2	No	Yes		
HbA1c > 6.2				
No	.7341 [.6936, .771]	.2448 [.2091, .2844]	.9789 [.9622, .9883]	
Yes	.0027 [6.6e-04, .0107]	.0185 [.0097, .0348]	.0211 [.0117, .0378]	
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1	

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 23.5229
 Design-based F(1, 566) = 28.7776 P = 0.0000

Waist > 102 + triglycerides > 2 + HbA1c > 6.2 v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Waist > 102				
Triglycerides > 2		Total T < 12		
HbA1c > 6.2	No	Yes	Total	
No	.733	.247	.9801	
	[.6926,.77]	[.2111,.2869]	[.9651,.9887]	
Yes	.0037	.0162	.0199	
	[.0012,.0117]	[.0085,.0307]	[.0113,.0349]	
Total	.7368	.2632	1	
	[.6964,.7735]	[.2265,.3036]		

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 17.9657
 Design-based F(1, 566) = 23.0865 P = 0.0000

Age > 60 + waist > 102 + non-smoker v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Age > 60				
Waist > 102		Total T < 12		
Non-smoke	No	Yes	Total	
No	.6876	.1984	.886	
	[.6458,.7266]	[.1655,.2359]	[.8564,.9101]	
Yes	.0492	.0649	.114	
	[.0341,.0704]	[.0468,.0892]	[.0899,.1436]	
Total	.7368	.2632	1	
	[.6964,.7735]	[.2265,.3036]		

Key: cell proportions
 [95% confidence intervals for cell proportions]

Pearson:
 Uncorrected chi2(1) = 35.1837
 Design-based F(1, 566) = 33.7151 P = 0.0000

Age > 60 + triglycerides > 102 + non-smoker v Total T < 12


```

pweight: wt           Number of obs   =   568
Strata:  nwregion     Number of strata =     2
PSU:     <observations> Number of PSUs  =   568
                               Population size =   568
    
```

```

Age > 60
Triglycerides > 2      Total T < 12
Non-smoker             No           Yes           Total

      No           .716           .2213          .9373
      [.675, .7538] [.1869, .2599] [.9134, .9549]

      Yes          .0207           .042           .0627
      [.0118, .0362] [.0278, .0629] [.0451, .0866]

Total                .7368           .2632           1
      [.6964, .7735] [.2265, .3036]
    
```

Key: cell proportions
 [95% confidence intervals for cell proportions]

```

Pearson:
Uncorrected  chi2(1)           =   32.3107
Design-based F(1, 566)       =   31.7371      P = 0.0000
    
```

Age > 60 + HbA1c > 6.2 + non-smoker v Total T < 12

```

pweight: wt           Number of obs   =   568
Strata:  nwregion     Number of strata =     2
PSU:     <observations> Number of PSUs  =   568
                               Population size =   568
    
```

```

Age > 60
HbA1c > 6.2          Total T < 12
Non-smoker           No           Yes           Total

      No           .7185           .2286          .9472
      [.6775, .7562] [.1938, .2676] [.9244, .9633]

      Yes          .0182           .0346          .0528
      [.0098, .0338] [.0219, .0542] [.0367, .0756]

Total                .7368           .2632           1
      [.6964, .7735] [.2265, .3036]
    
```

Key: cell proportions
 [95% confidence intervals for cell proportions]

```

Pearson:
Uncorrected  chi2(1)           =   25.0825
Design-based F(1, 566)       =   23.5328      P = 0.0000
    
```

Waist > 102 + triglycerides > 2 + non-smoker v Total T < 12

```

pweight: wt           Number of obs   =   568
Strata:  nwregion     Number of strata =     2
PSU:     <observations> Number of PSUs  =   568
    
```

Population size = 568

Waist > 102
Triglycerides > 2
Non-smoker

	Total T < 12		Total
	No	Yes	
No	.7062 [.6647, .7446]	.2052 [.1717, .2432]	.9114 [.8842, .9328]
Yes	.0305 [.0185, .0499]	.0581 [.0415, .0807]	.0886 [.0672, .1158]
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	43.7945	
Design-based	F(1, 566)	=	39.7922	P = 0.0000

Waist > 102 + HbA1c > 6.2 + non-smoker v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Waist > 102
HbA1c > 6.2
Non-smoker

	Total T < 12		Total
	No	Yes	
No	.7152 [.6742, .753]	.2283 [.1935, .2673]	.9436 [.9213, .9598]
Yes	.0215 [.0126, .0364]	.0349 [.0223, .0541]	.0564 [.0402, .0787]
Total	.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	22.1174	
Design-based	F(1, 566)	=	22.8372	P = 0.0000

Triglycerides > 2 + HbA1c > 6.2 + non-smoker v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

```

Triglycerides > 2
HbA1c > 6.2
Non-smoker
      Total T < 12
      No          Yes          Total
No      .7329     .2411     .9741
      [.6925,.7699] [.2056,.2806] [.957,.9845]
Yes     .0038     .0221     .0259
      [.0012,.012] [.0125,.0388] [.0155,.043]
Total   .7368     .2632     1
      [.6964,.7735] [.2265,.3036]

```

Key: cell proportions
[95% confidence intervals for cell proportions]

```

Pearson:
Uncorrected  chi2(1)      = 27.0848
Design-based F(1, 566)   = 33.9734      P = 0.0000

```

Age > 60 + waist > 102 + triglycerides > 2 + HbA1c > 6.2 v Total T < 12

```

pweight: wt          Number of obs   = 568
Strata:  nwregion    Number of strata = 2
PSU:     <observations> Number of PSUs   = 568
                          Population size = 568

```

```

Age > 60
Waist > 102
Triglycerides > 2      Total T < 12
HbA1c > 6.2
      No          Yes          Total
No      .7341     .2508     .9848
      [.6936,.771] [.2147,.2907] [.9703,.9923]
Yes     .0027     .0125     .0152
      [6.6e-04,.0107] [.0058,.0267] [.0077,.0297]
Total   .7368     .2632     1
      [.6964,.7735] [.2265,.3036]

```

```

{hline 50}
Key: cell proportions
      [95% confidence intervals for cell proportions]

```

```

Pearson:
Uncorrected  chi2(1)      = 14.1434
Design-based F(1, 566)   = 17.0767      P = 0.0000

```

Age > 60 + waist > 102 + triglycerides > 2 + HbA1c > 6.2 v Total T < 8

```

pweight: wt          Number of obs   = 568
Strata:  nwregion    Number of strata = 2
PSU:     <observations> Number of PSUs   = 568
                          Population size = 568

```

```

Age > 60
Waist > 102
Triglycerides > 2      Total T < 8
HbA1c > 6.2

```


Non-smoker		No	Yes	Total
No		.7345 [.694, .7713]	.2481 [.2122, .288]	.9826 [.9679, .9906]
Yes		.0023 [5.7e-04, .0093]	.0151 [.0076, .0296]	.0174 [.0094, .0321]
Total		.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

{hline 50}

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:
Uncorrected chi2(1) = 18.9538
Design-based F(1, 566) = 26.5277 P = 0.0000

Triglycerides > 2 + HbA1c > 6.2 + non-smoker + age > 60 v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

Triglycerides > 2
HbA1c > 6.2

Non-smoker		Total T < 12		Total
Age > 60		No	Yes	
No		.7355 [.6951, .7723]	.2448 [.2091, .2844]	.9803 [.9639, .9893]
Yes		.0012 [1.7e-04, .0089]	.0185 [.0097, .0348]	.0197 [.0107, .0361]
Total		.7368 [.6964, .7735]	.2632 [.2265, .3036]	1

{hline 50}

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:
Uncorrected chi2(1) = 26.6887
Design-based F(1, 566) = 36.0950 P = 0.0000

HbA1c > 6.2 + non-smoker + age > 60 + waist > 102 v Total T < 12

pweight:	wt	Number of obs	=	568
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	568
		Population size	=	568

HbA1c > 6.2
Non-smoker

Age > 60		Total T < 12		Total
Waist > 102		No	Yes	
No		.7307 [.6901, .7678]	.2385 [.2031, .2779]	.9692 [.9511, .9807]


```
          [.6964,.7735]    [.2265,.3036]
{hline 50}
Key:    cell proportions
       [95% confidence intervals for cell proportions]

Pearson:
  Uncorrected  chi2(1)      =  17.0087
  Design-based F(1, 566)   =  22.7398    P = 0.0000
```

V. Chapter 5.2 Bivariate analyses tables

	Mean	S.E.	95% CI		Adj. Wald test
Overall	58430.71	406.05	57632.99	59228.43	
Age group: 35 - 44 years	60680.33	758.38	59190.43	62170.22	
45 - 54	59308.28	709.66	57914.10	60702.46	F(1, 515) = 1.74 P = 0.19
55 - 64	58073.87	769.55	56562.03	59585.71	F(2, 514) = 2.90 P = 0.056
65 - 74	54672.83	1085.20	52540.87	56804.78	F(3, 513) = 7.27 P < 0.0001
75 - 79	53631.54	1011.99	51643.41	55619.67	F(4, 512) = 10.88 P < 0.0001
School leaving age: 13 or	57287.54	1595.48	54152.94	60422.14	
14	53504.98	1455.68	50645.04	56364.91	F(1, 505) = 3.05 P = 0.082
15	58368.15	745.32	56903.85	59832.46	F(2, 504) = 4.40 P = 0.013
16	59410.17	634.09	58164.38	60655.96	F(3, 503) = 4.74 P = 0.003
17	58601.43	914.46	56804.81	60398.05	F(4, 502) = 3.56 P = 0.007
18 or older	61026.80	1232.57	58605.21	63448.39	F(5, 501) = 3.66 P = 0.003
Highest post-secondary	57692.97	844.20	56034.47	59351.46	
Non bachelor qualification	58574.39	498.64	57594.77	59554.00	F(1, 515) = 0.80 P = 0.37
Bachelor degree or higher	59511.90	1205.11	57144.37	61879.44	F(2, 514) = 0.82 P = 0.44
Gross annual household	54971.45	1025.49	52956.74	56986.16	
\$20,001 - \$40,000	57265.45	751.16	55789.70	58741.20	F(1, 510) = 3.23 P = 0.07
\$40,001 - \$60,000	59969.60	640.37	58711.50	61227.69	F(2, 509) = 9.41 P = 0.0001

	Mean	S.E.	95% CI		Adj. Wald test	
	Mean	S.E.	95% CI		Adj. Wald test	
\$60,001 - \$80,000	60939.26	1413.08	58163.08	63715.45	F(3, 508) = 7.46	P = 0.0001
More than \$80,000	60116.72	795.99	58552.91	61680.54	F(4, 507) = 6.55	P < 0.0001
Work status: Employed	59629.77	491.48	58664.23	60595.32		
Retired	55179.74	742.61	53720.83	56638.65	F(1, 515) = 24.85	P < 0.0001
Other (1)	59982.02	1379.25	57272.37	62691.68	F(2, 514) = 13.10	P < 0.0001
Country of birth: Australia	58786.52	512.12	57780.42	59792.63		
UK (2)	58188.88	851.47	56516.10	59861.66	F(1, 515) = 0.36	P = 0.55
Other	57000.69	1016.89	55002.93	58998.44	F(2, 514) = 1.25	P = 0.29
Receive DSS pension: Yes	55292.35	795.10	53730.32	56854.38		
No	59759.56	451.15	58873.24	60645.89	F(1,515) = 23.66	P < 0.0001
Marital status: Married/	58662.91	436.14	57806.09	59519.73		
Separated/ divorced	55033.67	1594.89	51900.38	58166.96	F(1, 515) = 4.79	P = 0.029
Widowed	56820.10	1955.43	52978.49	60661.71	F(2, 514) = 2.71	P = 0.068
Never married	61006.30	1567.12	57927.58	64085.03	F(3, 513) = 2.70	P = 0.045

Table V.I A summary of whole body lean mass (grams), in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Mean	S.E.	95% CI		Adj. Wald test
Overall	32.22	0.34	31.56	32.88	
Age group: 35 - 44 years	30.54	0.73	29.11	31.96	
45 - 54	33.17	0.57	32.05	34.30	F(1, 515) = 8.10 P = 0.005
55 - 64	32.53	0.57	31.41	33.65	F(2, 514) = 4.18 P = 0.016
65 - 74	33.29	0.69	31.94	34.64	F(3, 513) = 3.32 P = 0.02
75 - 79	33.07	1.51	30.09	36.04	F(4, 512) = 2.52 P = 0.04
School leaving age: 13 or	31.27	1.60	28.14	34.41	
14	33.09	0.80	31.52	34.67	F(1, 505) = 1.04 P = 0.31
15	33.33	0.62	32.12	34.54	F(2, 504) = 0.72 P = 0.49
16	32.43	0.69	31.08	33.79	F(3, 503) = 0.68 P = 0.57
17	30.87	0.78	29.33	32.41	F(4, 502) = 1.81 P = 0.13
18 or older	32.16	0.91	30.37	33.94	F(5, 501) = 1.46 P = 0.20
Highest post-secondary	32.62	0.61	31.43	33.81	
Non bachelor qualification	32.26	0.44	31.40	33.11	F(1, 515) = 0.24 P = 0.62
Bachelor degree or higher	31.03	1.02	29.03	33.03	F(2, 514) = 0.90 P = 0.41
Gross annual household income:	32.82	0.69	31.47	34.17	
\$20,001 - \$40,000	31.49	0.77	29.98	33.01	F(1, 510) = 1.66 P = 0.20
\$40,001 - \$60,000	31.70	0.58	30.57	32.84	F(2, 509) = 1.06 P = 0.35
\$60,001 - \$80,000	33.49	1.14	31.26	35.72	F(3, 508) = 1.22 P = 0.30

	Mean	S.E.	95% CI		Adj. Wald test
More than \$80,000	32.31	0.64	31.06	33.57	F(4, 507) = 0.92 P = 0.45
Work status: Employed	31.90	0.43	31.06	32.74	
Retired	33.07	0.59	31.91	34.23	F(1, 515) = 2.58 P = 0.11
Other (1)	31.88	1.18	29.56	34.21	F(2, 514) = 1.34 P = 0.26
Country of birth: Australia	32.69	0.40	31.91	33.48	
UK (2)	30.88	0.71	29.48	32.28	F(1, 515) = 4.90 P = 0.03
Other	31.67	1.03	29.65	33.68	F(2, 514) = 2.60 P = 0.08
Receive DSS pension: Yes	32.86	0.55	31.77	33.95	
No	31.95	0.41	31.14	32.76	F(1, 515) = 1.73 P = 0.19
Marital status: Married/ living	32.52	0.35	31.84	33.21	
Separated/ divorced	29.47	1.41	26.69	32.24	F(1, 515) = 4.41 P = 0.036
Widowed	33.29	1.36	30.63	35.96	F(2, 514) = 2.43 P = 0.09
Never married	31.73	1.70	28.39	35.08	F(3, 513) = 1.66 P = 0.17

Table V.II A summary of abdominal fat percentage, in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Mean	S.E.	95% CI		Adj. Wald test
Overall	51.42	0.39	50.66	52.18	
Age group: 35 - 44 years	55.33	0.63	54.10	56.56	
45 - 54	53.77	0.57	52.64	54.89	F(1, 533) = 3.40 P = 0.066
55 - 64	50.07	0.55	48.98	51.16	F(2, 532) = 21.73 P < 0.0001
65 - 74	44.12	0.83	42.49	45.74	F(3, 531) = 46.27 P < 0.0001
75 - 79	39.73	1.24	37.29	42.16	F(4, 530) = 56.17 P < 0.0001
School leaving age: 13 or	48.12	1.98	44.23	52.01	
14	44.54	1.04	42.50	46.57	F(1, 524) = 2.57 P = 0.11
15	50.35	0.76	48.86	51.84	F(2, 523) = 10.20 P < 0.0001
16	54.18	0.74	52.73	55.63	F(3, 522) = 19.70 P < 0.0001
17	52.90	0.78	51.37	54.44	F(4, 521) = 16.39 P < 0.0001
18 or older	51.87	0.97	49.96	53.78	F(5, 520) = 13.18 P < 0.0001
Highest post-secondary	50.17	0.66	48.87	51.46	
Non bachelor qualification	51.90	0.53	50.87	52.94	F(1, 533) = 4.20 P = 0.041
Bachelor degree or higher	52.07	1.03	50.05	54.09	F(2, 532) = 2.38 P = 0.094
Gross annual household	45.78	0.75	44.30	47.26	
\$20,001 - \$40,000	49.70	0.84	48.05	51.35	F(1, 529) = 12.05 P = 0.0006
\$40,001 - \$60,000	53.38	0.73	51.95	54.80	F(2, 528) = 26.25 P < 0.0001

	Mean	S.E.	95% CI		Adj. Wald test	
\$60,001 - \$80,000	55.61	0.93	53.79	57.43	F(3, 527) = 28.38	P < 0.0001
More than \$80,000	54.21	0.62	52.99	55.42	F(4, 526) = 26.56	P < 0.0001
Work status: Employed	54.13	0.41	53.32	54.94		
Retired	44.51	0.66	43.21	45.81	F(1, 533) = 151.96	P < 0.0001
Other (1)	51.57	0.92	49.76	53.38	F(2, 532) = 75.84	P < 0.0001
Country of birth: Australia	51.86	0.47	50.93	52.79		
UK (2)	51.32	0.82	49.71	52.93	F(1, 533) = 0.33	P = 0.57
Other	49.41	1.13	47.19	51.63	F(2, 532) = 2.01	P = 0.14
Receive DSS pension: Yes	45.76	0.65	44.48	47.05		
No	53.66	0.41	52.86	54.46	F(1, 533) = 104.59	P < 0.0001
Marital status: Married/ living	51.63	0.42	50.80	52.45		
Separated/ divorced	49.79	1.36	47.12	52.45	F(1, 533) = 1.68	P = 0.20
Widowed	44.73	2.21	40.39	49.07	F(2, 532) = 5.32	P = 0.005
Never married	53.69	1.48	50.79	56.59	F(3, 531) = 4.39	P = 0.005

Table V.III A summary of maximal grip strength (combined hands), in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. (1) Includes unemployed, invalid pensioners and work-cover recipients. (2) Included England, Ireland, Scotland, Wales, Isle of Man and Channel Islands.

	Coeff.	S.E.	t	P	95% CI	
SBP	-18.07	21.45	-0.84	0.4000	-60.21	24.06
DBP	145.93	39.67	3.68	0.0000	68.01	223.86
Serum triglycerides	830.57	273.78	3.03	0.0030	292.71	1368.43
Total cholesterol	41.95	442.51	0.09	0.9250	-827.41	911.32
LDL	175.32	513.56	0.34	0.7330	-833.74	1184.38
HDL	-7119.10	1141.11	-6.24	0.0000	-9360.93	-4877.27
Serum glucose	369.88	292.32	1.27	0.2060	-204.41	944.17
HbA1c	554.92	427.89	1.30	0.1950	-285.70	1395.54
Insulin	193.49	45.35	4.27	0.0000	104.39	282.59
IGF-1	71.99	38.56	1.87	0.0620	-3.76	147.75
Energy intake	0.52	0.14	3.81	0.0000	0.25	0.79
Fat intake	42.28	11.97	3.53	0.0000	18.77	65.79
Carbohydrate intake	13.91	5.03	2.76	0.0060	4.02	23.79
Protein intake	50.32	10.06	5.00	0.0000	30.56	70.07
Alcohol intake	37.22	18.53	2.01	0.0450	0.82	73.63

Table V.IV Bivariate associations of chronic disease risk factors with whole body lean mass (grams) in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test
Sedentary	58343.80	580.06	57204.23	59483.38	
Insufficient PA	59374.51	744.36	57912.15	60836.88	F(1, 515) = 1.20 P = 0.27
Sufficient PA	58138.94	737.14	56690.78	59587.11	F(2, 514) = 0.84 P = 0.43
Current smokers	59182.30	927.67	57359.83	61004.78	
Non-smokers	58243.82	464.43	57331.40	59156.24	F(1, 515) = 0.81 P = 0.37

Table V.V The associations of whole body lean mass (grams) with level of physical activity and smoking status in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Coeff.	S.E.	t	P	95% CI	
SBP	0.133	0.020	6.68	0.0000	0.094	0.173
DBP	0.215	0.040	5.44	0.0000	0.137	0.293
Serum triglycerides	1.030	0.289	3.56	0.0000	0.462	1.599
Total cholesterol	0.834	0.300	2.78	0.0060	0.245	1.422
LDL	0.757	0.338	2.24	0.0260	0.092	1.421
HDL	-5.157	1.071	-4.81	0.0000	-7.261	-3.052
Serum glucose	1.060	0.257	4.12	0.0000	0.555	1.565
HbA1c	1.552	0.388	4.00	0.0000	0.790	2.313
Insulin	0.298	0.070	4.27	0.0000	0.161	0.434
IGF-1	-0.059	0.026	-2.24	0.0260	-0.111	-0.007
Energy intake	0.000	0.000	0.18	0.8600	0.000	0.000
Fat intake	0.014	0.009	1.47	0.1420	-0.005	0.032
Carbohydrate intake	-0.006	0.004	-1.58	0.1160	-0.014	0.002
Protein intake	0.008	0.009	0.92	0.3550	-0.009	0.026
Alcohol intake	0.003	0.015	0.23	0.8190	-0.026	0.033

Table V.VI Bivariate associations of chronic disease risk factors with abdominal fat mass percentage in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test
Sedentary	32.61	0.53	31.56	33.65	
Insufficient PA	33.15	0.69	31.79	34.51	F(1, 515) = 0.39 P = 0.53
Sufficient PA	31.42	0.53	30.38	32.46	F(2, 514) = 2.28 P = 0.10
Current smokers	30.90	0.78	29.37	32.42	
Non-smokers	32.54	0.38	31.79	33.29	F(1, 515) = 3.60 P = 0.06

Table V.VII The associations of abdominal fat mass percentage with level of physical activity and smoking status in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Coeff.	S.E.	t	P	95% CI	
SBP	-0.146	0.024	-6.10	0.0000	-0.193	-0.099
DBP	-0.047	0.044	-1.07	0.2840	-0.134	0.039
Waist circumference	0.012	0.030	0.39	0.7000	-0.047	0.070
Serum triglycerides	0.167	0.271	0.61	0.5390	-0.366	0.700
Total cholesterol	1.236	0.381	3.24	0.0010	0.487	1.985
LDL	1.612	0.424	3.80	0.0000	0.779	2.446
HDL	-3.397	1.302	-2.61	0.0090	-5.954	-0.839
Serum glucose	-1.204	0.329	-3.66	0.0000	-1.850	-0.558
HbA1c	-1.786	0.558	-3.20	0.0010	-2.881	-0.691
Insulin	-0.018	0.039	-0.47	0.6360	-0.094	0.058
IGF-1	0.146	0.032	4.54	0.0000	0.083	0.210
Energy intake	0.001	0.000	5.50	0.0000	0.000	0.001
Fat intake	0.053	0.011	4.91	0.0000	0.032	0.074
Carbohydrate intake	0.022	0.004	4.96	0.0000	0.013	0.030
Protein intake	0.053	0.010	5.50	0.0000	0.034	0.072
Alcohol intake	0.040	0.017	2.36	0.0190	0.007	0.073

Table V.VIII Bivariate associations of chronic disease risk factors with maximal handgrip strength (combined hands) in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test
Sedentary	51.23	0.57	50.10	52.36	
Insufficient PA	51.80	1.00	49.83	53.76	F(1, 533) = 0.24 P = 0.62
Sufficient PA	51.47	0.62	50.26	52.69	F(2, 532) = 0.13 P = 0.88
Current smokers	52.59	0.82	50.98	54.20	
Non-smokers	51.04	0.45	50.15	51.92	F(1, 533) = 2.76 P = 0.097

Table V.IX The associations of maximal handgrip strength (combined hands) with level of physical activity and smoking status in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Coeff.	S.E.	t	P	95% CI	
SBP	-0.293	0.060	-4.93	0.0000	-0.410	-0.176
DBP	-0.148	0.116	-1.28	0.2020	-0.377	0.080
Waist circumference	-0.397	0.082	-4.87	0.0000	-0.557	-0.237
Serum triglycerides	-0.783	0.656	-1.19	0.2330	-2.072	0.505
Total cholesterol	2.818	0.852	3.31	0.0010	1.144	4.492
LDL	4.180	1.024	4.08	0.0000	2.168	6.192
HDL	4.029	3.260	1.24	0.2170	-2.374	10.433
Serum glucose	-3.190	0.814	-3.92	0.0000	-4.790	-1.591
HbA1c	-5.446	1.165	-4.68	0.0000	-7.734	-3.159
Insulin	-0.306	0.088	-3.46	0.0010	-0.480	-0.132
IGF-1	0.309	0.077	4.00	0.0000	0.157	0.461
Energy intake	0.000	0.000	1.20	0.2290	0.000	0.001
Fat intake	0.017	0.027	0.62	0.5380	-0.037	0.071
Carbohydrate intake	0.021	0.011	1.90	0.0580	-0.001	0.042
Protein intake	0.017	0.025	0.67	0.5020	-0.032	0.066
Alcohol intake	0.035	0.043	0.81	0.4200	-0.050	0.120

Table V.X Bivariate associations of chronic disease risk factors with physical function in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test
Sedentary	75.78	1.44	72.96	78.60	
Insufficient PA	79.63	2.30	75.12	84.14	F(1, 566) = 2.02 P = 0.16
Sufficient PA	82.25	1.27	79.76	84.73	F(2, 565) = 5.71 P = 0.004
Current smokers	77.05	2.16	72.81	81.29	
Non-smokers	79.31	1.01	77.34	81.29	F(1, 566) = 0.90 P = 0.34

Table V.XI The associations of physical function with level of physical activity and smoking status in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Coeff.	S.E.	t	P	95% CI	
SBP	-0.316	0.093	-3.40	0.0010	-0.499	-0.133
DBP	-0.117	0.198	-0.59	0.5540	-0.506	0.271
Waist circumference	-0.509	0.134	-3.79	0.0000	-0.772	-0.245
Serum triglycerides	-2.048	1.313	-1.56	0.1190	-4.627	0.530
Total cholesterol	5.241	1.613	3.25	0.0010	2.073	8.408
LDL	6.309	1.941	3.25	0.0010	2.495	10.122
HDL	16.599	6.200	2.68	0.0080	4.420	28.777
Serum glucose	-4.617	1.477	-3.13	0.0020	-7.518	-1.717
HbA1c	-7.770	2.131	-3.65	0.0000	-11.957	-3.584
Insulin	-0.566	0.173	-3.26	0.0010	-0.906	-0.225
IGF-1	0.253	0.138	1.84	0.0660	-0.017	0.524
Energy intake	0.001	0.000	1.98	0.0480	0.000	0.002
Fat intake	0.067	0.041	1.63	0.1040	-0.014	0.148
Carbohydrate intake	0.036	0.018	2.01	0.0450	0.001	0.072
Protein intake	0.064	0.037	1.71	0.0880	-0.009	0.137
Alcohol intake	0.049	0.074	0.67	0.5050	-0.096	0.194

Table V.XII Bivariate associations of chronic disease risk factors with limitations to usual role activities because of physical problems in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test
Sedentary	75.90	2.50	70.99	80.80	
Insufficient PA	76.44	4.03	68.52	84.36	F(1, 566) = 0.01 P = 0.91
Sufficient PA	79.51	2.44	74.71	84.31	F(2, 565) = 0.58 P = 0.56
Current smokers	72.50	3.82	65.00	80.00	
Non-smokers	78.49	1.79	74.98	82.01	F(1, 566) = 2.03 P = 0.16

Table V.XIII The associations of limitations to usual role activities because of physical problems with level of physical activity and smoking status in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Coeff.	S.E.	t	P	95% CI	
SBP	-0.147	0.066	-2.23	0.026	-0.276	-0.018
DBP	-0.077	0.138	-0.56	0.576	-0.349	0.194
Waist circumference	-0.296	0.092	-3.23	0.001	-0.477	-0.116
Serum triglycerides	-2.107	0.811	-2.60	0.010	-3.700	-0.513
Total cholesterol	0.353	1.076	0.33	0.743	-1.761	2.466
LDL	2.226	1.162	1.92	0.056	-0.057	4.509
HDL	7.555	3.596	2.10	0.036	0.493	14.618
Serum glucose	-2.100	0.925	-2.27	0.024	-3.918	-0.283
HbA1c	-3.412	1.351	-2.52	0.012	-6.066	-0.758
Insulin	-0.183	0.121	-1.52	0.130	-0.421	0.054
IGF-1	0.106	0.094	1.13	0.260	-0.078	0.290
Energy intake	0.000	0.000	0.30	0.767	-0.001	0.001
Fat intake	-0.005	0.030	-0.17	0.866	-0.064	0.054
Carbohydrate intake	0.011	0.013	0.88	0.377	-0.014	0.036
Protein intake	-0.003	0.026	-0.11	0.909	-0.053	0.048
Alcohol intake	-0.010	0.052	-0.19	0.853	-0.113	0.093

Table V.XIV Bivariate associations of chronic disease risk factors with bodily pain in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test
Sedentary	71.39	1.68	68.09	74.69	
Insufficient PA	75.30	2.59	70.22	80.38	F(1, 566) = 1.61 P = 0.21
Sufficient PA	75.03	1.60	71.90	78.17	F(2, 565) = 1.49 P = 0.23
Current smokers	70.60	2.54	65.61	75.59	
Non-smokers	74.38	1.17	72.08	76.68	F(1, 566) = 1.83 P = 0.18

Table V.XV The associations of bodily pain with level of physical activity and smoking status in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	58633.68	413.01	57822.29	59445.06		
Yes	55432.79	1891.97	51715.85	59149.72	$F(1, 515) = 2.72$	$P = 0.10$
Anxiety: No	58678.46	410.90	57871.20	59485.71		
Yes	56077.41	1712.56	52712.95	59441.87	$F(1, 515) = 2.17$	$P = 0.14$
Asthma: No	58524.68	435.03	57670.02	59379.34		
Yes	57635.29	1122.89	55429.30	59841.29	$F(1, 515) = 0.54$	$P = 0.46$
Depression: No	58234.67	422.44	57404.75	59064.58		
Yes	59978.55	1366.27	57294.40	62662.71	$F(1, 515) = 1.48$	$P = 0.22$
Diabetes: No	58354.97	425.74	57518.57	59191.37		
Yes	59313.80	1390.48	56582.10	62045.51	$F(1, 515) = 0.43$	$P = 0.51$
Enlarged prostate: No	58768.77	430.55	57922.93	59614.61		
Yes	54741.32	983.37	52809.40	56673.23	$F(1, 515) = 13.99$	$P = 0.0002$
High cholesterol: No	58877.41	477.54	57939.25	59815.57		
Yes	57403.06	774.16	55882.16	58923.95	$F(1, 515) = 2.60$	$P = 0.11$
High BP: No	58231.55	496.92	57255.30	59207.80		
Yes	58975.34	688.51	57622.72	60327.97	$F(1, 515) = 0.76$	$P = 0.39$
Insomnia: No	58609.89	429.45	57766.20	59453.57		
Yes	56805.76	1264.11	54322.31	59289.21	$F(1, 515) = 1.81$	$P = 0.18$
Osteoarthritis: No	58458.03	430.73	57611.83	59304.23		
Yes	58134.06	1184.23	55807.54	60460.58	$F(1, 515) = 0.07$	$P = 0.80$
Rheumatoid arthritis: No	58431.33	406.33	57633.07	59229.59		
Yes	58419.44	2547.69	53414.30	63424.58	$F(1, 515) = 0.00$	$P = 0.996$
Thyroid problems: No	58543.62	408.66	57740.77	59346.47		
Yes	49666.44	1044.59	47614.26	51718.61	$F(1, 515) = 63.04$	$P < 0.0000$
Prostate cancer: No	58542.86	412.34	57732.80	59352.93		

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	53482.32	1462.92	50608.30	56356.35	F(1, 515) = 11.06	P = 0.0009
Prostate removal: No	58564.00	413.07	57752.49	59375.52		
Yes	53297.52	1365.21	50615.46	55979.59	F(1, 515) = 13.57	P = 0.0003
TURP: No	58605.33	412.54	57794.86	59415.79		
Yes	52726.63	1723.48	49340.71	56112.54	F(1, 515) = 10.99	P = 0.001
Vasectomy: No	58136.42	502.48	57149.27	59123.57		
Yes	59231.46	652.54	57949.48	60513.43	F(1, 515) = 1.75	P = 0.19
Penile surgery: No	58462.96	411.59	57654.37	59271.56		
Yes	56967.89	2461.99	52131.11	61804.68	F(1, 515) = 0.36	P = 0.55
Bladder surgery: No	58490.68	414.72	57675.92	59305.44		
Yes	56130.79	1360.25	53458.48	58803.11	F(1, 515) = 2.75	P = 0.10
Digestive disease: No	58483.40	443.11	57612.87	59353.93		
Yes	57981.10	866.89	56278.02	59684.18	F(1, 515) = 0.26	P = 0.61
Circulatory disease: No	58478.22	429.93	57633.58	59322.86		
Yes	57784.88	998.13	55823.97	59745.79	F(1, 515) = 0.41	P = 0.52
Musculoskeletal disease:	58304.52	416.13	57487.00	59122.05		
Yes	59245.83	1406.91	56481.85	62009.81	F(1, 515) = 0.41	P = 0.52
Neurological disease: No	58510.86	412.80	57699.88	59321.84		
Yes	55228.77	1947.22	51403.29	59054.25	F(1, 515) = 2.71	P = 0.10
Psychological disease: No	58436.83	414.89	57621.74	59251.92		
Yes	58256.78	1924.88	54475.19	62038.37	F(1, 515) = 0.01	P = 0.93
Respiratory disease: No	58545.43	420.46	57719.40	59371.46		
Yes	56338.05	1374.60	53637.54	59038.56	F(1, 515) = 2.36	P = 0.13
Metabolic endo. nut.	58365.43	414.41	57551.29	59179.56		
Yes	60894.57	1645.73	57661.41	64127.74	F(1, 515) = 2.22	P = 0.14

	Mean	S.E.	95% CI		Adj. Wald test	
Urological disease: No	58362.24	408.23	57560.24	59164.25		
Yes	62301.32	3242.84	55930.50	68672.14	F(1, 515) = 1.45	P = 0.23
Medication, general	58949.96	433.44	58098.42	59801.49		
Yes	55992.77	1045.89	53938.03	58047.50	F(1, 515) = 6.80	P = 0.009
Medication, digestive: No	58780.31	425.69	57944.02	59616.61		
Yes	56271.69	1221.17	53872.61	58670.78	F(1, 515) = 3.74	P = 0.05
Medication, circulatory:	58864.69	513.12	57856.61	59872.76		
Yes	57267.89	576.56	56135.18	58400.59	F(1, 515) = 4.23	P = 0.04
Medication,	58666.85	426.37	57829.22	59504.48		
Yes	57173.71	1198.41	54819.33	59528.09	F(1, 515) = 1.37	P = 0.24
Medication, neurological:	58475.84	405.73	57678.76	59272.92		
Yes	57852.11	2136.10	53655.56	62048.65	F(1, 515) = 0.08	P = 0.77
Medication,	58500.00	431.42	57652.45	59347.56		
Yes	57666.98	1135.24	55436.71	59897.26	F(1, 515) = 0.47	P = 0.49
Medication, respiratory:	58677.67	446.04	57801.39	59553.94		
Yes	56787.55	911.19	54997.43	58577.67	F(1, 515) = 3.44	P = 0.06
Medication, metabolic	58766.10	475.69	57831.57	59700.63		
Yes	57281.00	756.52	55794.76	58767.24	F(1, 515) = 2.74	P = 0.10
Medication, urological:	58510.31	408.93	57706.94	59313.67		
Yes	52261.09	1897.58	48533.13	55989.04	F(1, 515) = 10.35	P = 0.001
Medication, male genital:	58556.08	418.34	57734.22	59377.94		
Yes	55444.20	1336.78	52817.99	58070.41	F(1, 515) = 4.91	P = 0.027

Table V.XVI The effect of chronic disease, urogenital surgery and medication use on whole body lean mass (grams) in 568 men, aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide. Data presented are mean \pm S.E. Comparison of means were made using an adjusted Wald test.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	32.10	0.35	31.41	32.79		
Yes	34.03	0.92	32.23	35.83	F(1, 515) = 3.84	P = 0.05
Anxiety: No	32.19	0.35	31.50	32.88		
Yes	32.51	1.13	30.30	34.72	F(1, 515) = 0.07	P = 0.79
Asthma: No	32.21	0.36	31.51	32.91		
Yes	32.33	0.96	30.45	34.20	F(1, 515) = 0.01	P = 0.91
Depression: No	32.23	0.36	31.52	32.94		
Yes	32.13	0.84	30.47	33.79	F(1, 515) = 0.01	P = 0.91
Diabetes: No	32.11	0.36	31.41	32.81		
Yes	33.56	0.88	31.83	35.30	F(1, 515) = 2.34	P = 0.13
Enlarged prostate: No	32.01	0.36	31.31	32.71		
Yes	34.56	0.77	33.05	36.06	F(1, 515) = 9.08	P = 0.003
High cholesterol: No	31.68	0.43	30.83	32.52		
Yes	33.47	0.48	32.53	34.41	F(1, 515) = 7.74	P = 0.006
High BP: No	31.54	0.41	30.74	32.35		
Yes	34.08	0.53	33.04	35.13	F(1, 515) = 14.24	P = 0.0002
Insomnia: No	32.23	0.35	31.54	32.93		
Yes	32.11	1.02	30.10	34.12	F(1, 515) = 0.01	P = 0.91
Osteoarthritis: No	32.18	0.35	31.48	32.88		
Yes	32.68	0.97	30.78	34.58	F(1, 515) = 0.24	P = 0.63
Rheumatoid arthritis: No	32.24	0.34	31.57	32.92		
Yes	31.86	1.48	28.95	34.76	F(1, 515) = 0.06	P = 0.80
Thyroid problems: No	32.17	0.34	31.51	32.83		
Yes	36.24	2.29	31.74	40.73	F(1, 515) = 3.09	P = 0.08
Prostate cancer: No	32.16	0.34	31.49	32.83		
Yes	34.84	1.46	31.96	37.71	F(1, 515) = 3.16	P = 0.08
Prostate removal: No	32.09	0.34	31.42	32.76		
Yes	37.30	1.11	35.12	39.48	F(1, 515) = 20.15	P < 0.0001

	Mean	S.E.	95% CI		Adj. Wald test	
TURP: No	32.26	0.34	31.59	32.94		
Yes	30.91	1.11	28.74	33.09	F(1, 515) = 1.35	P = 0.25
Vasectomy: No	32.13	0.40	31.34	32.92		
Yes	32.47	0.59	31.31	33.63	F(1, 515) = 0.23	P = 0.63
Penile surgery: No	32.22	0.33	31.56	32.87		
Yes	32.39	3.69	25.15	39.63	F(1, 515) = 0.00	P = 0.96
Bladder surgery: No	32.20	0.34	31.52	32.87		
Yes	33.15	1.14	30.92	35.39	F(1, 515) = 0.65	P = 0.42
Digestive disease: No	32.37	0.35	31.69	33.05		
Yes	30.93	1.21	28.57	33.30	F(1, 515) = 1.31	P = 0.25
Circulatory disease: No	32.18	0.35	31.49	32.88		
Yes	32.74	1.03	30.72	34.75	F(1, 515) = 0.26	P = 0.61
Musculoskeletal disease:	32.24	0.37	31.53	32.96		
Yes	32.08	0.81	30.48	33.68	F(1, 515) = 0.03	P = 0.85
Neurological disease: No	32.29	0.34	31.63	32.96		
Yes	29.30	2.39	24.60	34.00	F(1, 515) = 1.53	P = 0.22
Psychological disease: No	32.19	0.34	31.52	32.86		
Yes	33.17	1.93	29.39	36.96	F(1, 515) = 0.25	P = 0.61
Respiratory disease: No	32.44	0.33	31.79	33.10		
Yes	28.16	1.87	24.48	31.84	F(1, 515) = 5.06	P = 0.025
Metabolic endo. nut.	32.14	0.34	31.47	32.81		
Yes	35.38	1.01	33.40	37.35	F(1, 515) = 9.28	P = 0.003
Urological disease: No	32.23	0.34	31.56	32.90		
Yes	31.66	1.74	28.23	35.08	F(1, 515) = 0.10	P = 0.75
Medication, general health:	32.24	0.37	31.52	32.97		
Yes	32.12	0.80	30.54	33.69	F(1, 515) = 0.02	P = 0.89
Medication, digestive: No	32.12	0.37	31.40	32.85		
Yes	32.84	0.77	31.33	34.35	F(1, 515) = 0.71	P = 0.40

	Mean	S.E.	95% CI		Adj. Wald test	
Medication, circulatory:	31.76	0.40	30.96	32.55		
Yes	33.47	0.58	32.33	34.60	F(1, 515) = 5.84	P = 0.016
Medication,	32.07	0.37	31.34	32.80		
Yes	33.01	0.76	31.52	34.50	F(1, 515) = 1.22	P = 0.27
Medication, neurological:	32.06	0.34	31.40	32.73		
Yes	34.27	1.55	31.22	37.33	F(1, 515) = 1.93	P = 0.17
Medication, psychological:	32.06	0.35	31.37	32.75		
Yes	33.97	1.06	31.88	36.05	F(1, 515) = 2.89	P = 0.09
Medication, respiratory:	32.22	0.36	31.50	32.93		
Yes	32.26	0.88	30.54	33.98	F(1, 515) = 0.00	P = 0.96
Medication, metabolic	31.80	0.40	31.02	32.58		
Yes	33.66	0.58	32.52	34.79	F(1, 515) = 6.93	P = 0.009
Medication, urological: No	32.24	0.34	31.57	32.90		
Yes	31.04	1.39	28.32	33.76	F(1, 515) = 0.71	P = 0.40
Medication, male genital:	32.19	0.34	31.51	32.87		
Yes	32.98	1.45	30.12	35.83	F(1, 515) = 0.28	P = 0.61

Table V.XVII The effect of chronic disease, urogenital surgery and medication use on abdominal fat percentage in 568 men, aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide. Data presented are mean \pm S.E. Comparison of means were made using an adjusted Wald test.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	51.68	0.40	50.90	52.46		
Yes	46.30	1.25	43.84	48.76	F(1, 533) = 16.74	P < 0.0001
Anxiety: No	51.54	0.41	50.74	52.35		
Yes	50.17	1.12	47.97	52.38	F(1, 533) = 1.31	P = 0.25
Asthma: No	51.56	0.41	50.75	52.37		
Yes	50.17	1.19	47.84	52.50	F(1, 533) = 1.22	P = 0.27
Depression: No	51.33	0.41	50.52	52.14		
Yes	52.21	1.13	49.99	54.42	F(1, 533) = 0.54	P = 0.46
Diabetes: No	51.85	0.40	51.07	52.62		
Yes	45.76	1.36	43.08	48.44	F(1, 533) = 18.41	P < 0.0001
Enlarged prostate: No	51.97	0.39	51.20	52.74		
Yes	45.34	1.41	42.57	48.11	F(1, 533) = 20.48	P < 0.0001
High cholesterol: No	51.75	0.46	50.85	52.65		
Yes	50.58	0.74	49.13	52.02	F(1, 533) = 1.83	P = 0.18
High BP: No	52.43	0.43	51.58	53.28		
Yes	48.38	0.77	46.86	49.89	F(1, 533) = 20.93	P < 0.0001
Insomnia: No	51.68	0.41	50.87	52.49		
Yes	48.95	1.05	46.89	51.01	F(1, 533) = 5.84	P = 0.016
Osteoarthritis: No	51.61	0.40	50.82	52.40		
Yes	49.01	1.31	46.42	51.59	F(1, 533) = 3.58	P = 0.06
Rheumatoid arthritis: No	51.48	0.40	50.71	52.26		
Yes	50.08	2.02	46.11	54.06	F(1, 533) = 0.46	P = 0.50
Thyroid problems: No	51.50	0.39	50.73	52.27		
Yes	45.97	2.60	40.86	51.09	F(1, 533) = 4.41	P = 0.036
Prostate cancer: No	51.70	0.38	50.95	52.45		

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	37.94	1.18	35.62	40.27	F(1, 533) = 122.81	P < 0.0001
Prostate removal: No	51.66	0.38	50.91	52.41		
Yes	40.35	2.75	34.95	45.74	F(1, 533) = 16.63	P = 0.0001
TURP: No	51.57	0.39	50.80	52.33		
Yes	45.51	2.62	40.37	50.65	F(1, 533) = 5.24	P = 0.023
Vasectomy: No	51.09	0.48	50.14	52.04		
Yes	52.36	0.59	51.20	53.51	F(1, 533) = 2.75	P = 0.10
Penile surgery: No	51.47	0.39	50.70	52.25		
Yes	49.34	2.39	44.64	54.05	F(1, 533) = 0.77	P = 0.38
Bladder surgery: No	51.53	0.39	50.76	52.30		
Yes	46.30	1.75	42.86	49.73	F(1, 533) = 8.50	P = 0.004
Digestive disease: No	51.38	0.41	50.57	52.19		
Yes	51.73	1.14	49.49	53.97	F(1, 533) = 0.08	P = 0.78
Circulatory disease: No	51.59	0.40	50.79	52.38		
Yes	49.09	1.31	46.52	51.67	F(1, 533) = 3.30	P = 0.07
Musculoskeletal disease: No	51.49	0.42	50.66	52.33		
Yes	50.94	0.93	49.12	52.75	F(1, 533) = 0.30	P = 0.58
Neurological disease: No	51.54	0.39	50.76	52.31		
Yes	47.39	2.11	43.25	51.52	F(1, 533) = 3.75	P = 0.05
Psychological disease: No	51.52	0.40	50.74	52.30		
Yes	48.62	1.57	45.54	51.69	F(1, 533) = 3.23	P = 0.07
Respiratory disease: No	51.38	0.40	50.59	52.17		
Yes	52.13	1.52	49.14	55.13	F(1, 533) = 0.23	P = 0.63
Metabolic endo. nut. disease: No	51.48	0.39	50.71	52.25		
Yes	49.11	2.83	43.56	54.67	F(1, 533) = 0.69	P = 0.41

	Mean	S.E.	95% CI		Adj. Wald test	
Urological disease: No	51.43	0.39	50.66	52.21		
Yes	50.73	2.60	45.63	55.83	F(1, 533) = 0.07	P = 0.79
Medication, general health:	51.89	0.42	51.07	52.70		
Yes	48.98	1.01	47.00	50.96	F(1, 533) = 7.11	P = 0.008
Medication, digestive: No	51.94	0.42	51.12	52.76		
Yes	48.25	0.95	46.39	50.12	F(1, 533) = 12.60	P = 0.0004
Medication, circulatory: No	53.04	0.43	52.20	53.87		
Yes	46.65	0.67	45.34	47.97	F(1, 533) = 64.43	P < 0.0001
Medication,	51.95	0.42	51.12	52.78		
Yes	48.35	0.91	46.57	50.14	F(1, 533) = 12.87	P = 0.0004
Medication, neurological:	51.57	0.41	50.77	52.36		
Yes	49.62	1.34	46.99	52.25	F(1, 533) = 1.94	P = 0.16
Medication, psychological:	51.61	0.40	50.82	52.41		
Yes	49.28	1.30	46.72	51.83	F(1, 533) = 2.94	P = 0.09
Medication, respiratory: No	51.48	0.42	50.65	52.31		
Yes	51.00	0.94	49.15	52.86	F(1, 533) = 0.21	P = 0.65
Medication, metabolic endo	52.39	0.42	51.56	53.22		
Yes	47.55	0.82	45.94	49.17	F(1, 533) = 27.29	P < 0.0001
Medication, urological: No	51.50	0.39	50.74	52.27		
Yes	43.97	3.26	37.58	50.37	F(1, 533) = 5.27	P = 0.02
Medication, male genital: No	51.75	0.38	50.99	52.50		
Yes	43.88	2.13	39.70	48.07	F(1, 533) = 13.19	P = 0.0003

Table V.XVIII The effect of chronic disease, urogenital surgery and medication use on maximal handgrip strength (combined hands) in 568 men, aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide. Data presented are mean \pm S.E. Comparison of means were made using an adjusted Wald test.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	80.47	0.89	78.72	82.21		
Yes	56.20	3.44	49.43	62.96	F(1, 566) = 46.50	P < 0.0001
Anxiety: No	79.59	0.92	77.78	81.39		
Yes	73.10	3.48	66.25	79.94	F(1, 566) = 3.24	P = 0.07
Asthma: No	79.66	0.92	77.84	81.47		
Yes	72.85	3.30	66.37	79.33	F(1, 566) = 3.95	P = 0.048
Depression: No	80.05	0.93	78.22	81.88		
Yes	70.84	2.90	65.15	76.54	F(1, 566) = 9.14	P = 0.003
Diabetes: No	80.00	0.92	78.19	81.81		
Yes	67.21	3.28	60.77	73.65	F(1, 566) = 14.10	P = 0.0002
Enlarged prostate: No	80.07	0.92	78.28	81.87		
Yes	67.41	3.15	61.22	73.60	F(1, 566) = 14.89	P = 0.0001
High cholesterol: No	81.57	1.02	79.56	83.58		
Yes	72.96	1.70	69.63	76.30	F(1, 566) = 18.82	P < 0.0001
High BP: No	81.86	0.96	79.97	83.74		
Yes	70.91	1.87	67.23	74.59	F(1, 566) = 27.04	P < 0.0001
Insomnia: No	80.26	0.90	78.49	82.04		
Yes	67.64	3.47	60.82	74.46	F(1, 566) = 12.37	P = 0.0005
Osteoarthritis: No	80.50	0.90	78.73	82.27		
Yes	61.95	3.38	55.31	68.59	F(1, 566) = 28.12	P < 0.0001
Rheumatoid arthritis: No	79.65	0.91	77.87	81.43		
Yes	65.59	3.92	57.88	73.29	F(1, 566) = 12.20	P = 0.0005
Thyroid problems: No	78.96	0.90	77.18	80.73		
Yes	80.88	6.78	67.57	94.20	F(1, 566) = 0.08	P = 0.78
Prostate cancer: No	79.15	0.90	77.38	80.92		

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	70.93	6.53	58.10	83.76	F(1, 566) = 1.56	P = 0.21
Prostate removal: No	79.35	0.90	77.58	81.12		
Yes	64.41	5.18	54.23	74.59	F(1, 566) = 8.07	P = 0.005
TURP: No	79.35	0.91	77.57	81.13		
Yes	66.97	4.51	58.11	75.83	F(1, 566) = 7.24	P = 0.007
Vasectomy: No	77.88	1.11	75.70	80.05		
Yes	82.15	1.36	79.47	84.83	F(1, 566) = 5.92	P = 0.015
Penile surgery: No	78.89	0.91	77.09	80.68		
Yes	82.95	3.94	75.22	90.68	F(1, 566) = 1.01	P = 0.32
Bladder surgery: No	79.53	0.89	77.78	81.27		
Yes	57.24	6.18	45.10	69.39	F(1, 566) = 12.73	P = 0.0004
Digestive disease: No	79.17	0.94	77.32	81.02		
Yes	77.37	2.86	71.75	83.00	F(1, 566) = 0.35	P = 0.55
Circulatory disease: No	79.53	0.93	77.70	81.36		
Yes	71.38	2.99	65.50	77.25	F(1, 566) = 6.77	P = 0.01
Musculoskeletal disease: No	80.21	0.93	78.37	82.04		
Yes	70.78	2.73	65.41	76.15	F(1, 566) = 10.66	P = 0.001
Neurological disease: No	79.48	0.89	77.74	81.23		
Yes	62.75	6.50	49.98	75.51	F(1, 566) = 6.52	P = 0.01
Psychological disease: No	79.30	0.91	77.50	81.09		
Yes	70.46	4.08	62.45	78.48	F(1, 566) = 4.46	P = 0.035
Respiratory disease: No	79.29	0.91	77.51	81.07		
Yes	73.16	5.06	63.22	83.10	F(1, 566) = 1.42	P = 0.23
Metabolic endo. nut. disease:	79.31	0.90	77.55	81.07		
Yes	66.11	6.21	53.92	78.30	F(1, 566) = 4.44	P = 0.036

	Mean	S.E.	95% CI		Adj. Wald test	
Urological disease: No	79.11	0.91	77.33	80.89		
Yes	73.08	5.39	62.50	83.65	F(1, 566) = 1.22	P = 0.27
Medication, general health: No	80.48	0.93	78.65	82.31		
Yes	71.74	2.56	66.71	76.77	F(1, 566) = 10.28	P = 0.001
Medication, digestive: No	80.70	0.92	78.90	82.51		
Yes	68.21	2.61	63.08	73.33	F(1, 566) = 20.39	P < 0.0001
Medication, circulatory: No	82.95	0.94	81.10	84.80		
Yes	68.41	1.79	64.90	71.93	F(1, 566) = 51.62	P < 0.0001
Medication, musculoskeletal:	81.40	0.90	79.63	83.17		
Yes	65.70	2.66	60.47	70.92	F(1, 566) = 31.24	P < 0.0001
Medication, neurological: No	79.34	0.93	77.53	81.16		
Yes	74.54	3.40	67.87	81.21	F(1, 566) = 1.86	P = 0.17
Medication, psychological: No	80.29	0.90	78.52	82.06		
Yes	65.64	3.56	58.64	72.64	F(1, 566) = 15.87	P = 0.0001
Medication, respiratory: No	79.48	0.95	77.62	81.33		
Yes	75.56	2.75	70.17	80.96	F(1, 566) = 1.81	P = 0.18
Medication, metabolic endo	81.82	0.94	79.98	83.67		
Yes	68.84	2.04	64.82	72.85	F(1, 566) = 33.37	P < 0.0001
Medication, urological: No	79.15	0.89	77.40	80.90		
Yes	64.69	15.08	35.07	94.30	F(1, 566) = 0.92	P = 0.34
Medication, male genital: No	79.36	0.90	77.59	81.12		
Yes	69.85	5.48	59.09	80.61	F(1, 566) = 2.93	P = 0.09

Table V.XIX The effect of chronic disease, urogenital surgery and medication use on physical function in 568 men, aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide. Data presented are mean \pm S.E. Comparison of means were made using an adjusted Wald test.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	79.88	1.58	76.76	82.99		
Yes	39.77	7.50	25.03	54.50	F(1, 566) = 27.35	P < 0.0001
Anxiety: No	79.19	1.64	75.98	82.41		
Yes	60.15	6.21	47.96	72.35	F(1, 566) = 8.79	P = 0.003
Asthma: No	78.58	1.66	75.32	81.84		
Yes	66.90	5.85	55.40	78.39	F(1, 566) = 3.69	P = 0.06
Depression: No	80.03	1.64	76.80	83.25		
Yes	57.58	5.30	47.17	67.99	F(1, 566) = 16.38	P = 0.0001
Diabetes: No	79.04	1.65	75.81	82.28		
Yes	58.65	6.23	46.42	70.89	F(1, 566) = 10.01	P = 0.002
Enlarged prostate: No	79.48	1.60	76.33	82.63		
Yes	55.59	6.96	41.92	69.27	F(1, 566) = 11.17	P = 0.0009
High cholesterol: No	82.69	1.75	79.24	86.13		
Yes	65.17	3.21	58.87	71.47	F(1, 566) = 22.94	P < 0.0001
High BP: No	81.24	1.73	77.84	84.63		
Yes	66.72	3.50	59.85	73.59	F(1, 566) = 13.88	P = 0.0002
Insomnia: No	80.91	1.59	77.78	84.04		
Yes	46.53	5.41	35.90	57.16	F(1, 566) = 37.15	P < 0.0001
Osteoarthritis: No	79.86	1.63	76.67	83.05		
Yes	50.10	6.17	37.98	62.22	F(1, 566) = 21.74	P < 0.0001
Rheumatoid arthritis: No	78.63	1.60	75.48	81.77		
Yes	53.25	9.48	34.64	71.87	F(1, 566) = 6.97	P = 0.009
Thyroid problems: No	77.67	1.61	74.51	80.82		
Yes	60.17	17.99	24.83	95.50	F(1, 566) = 0.94	P = 0.33
Prostate cancer: No	77.67	1.62	74.49	80.86		

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	65.43	11.62	42.60	88.26	F(1, 566) = 1.09	P = 0.30
Prostate removal: No	78.10	1.60	74.95	81.25		
Yes	50.30	12.69	25.38	75.22	F(1, 566) = 4.73	P = 0.03
TURP: No	78.04	1.61	74.87	81.21		
Yes	57.39	11.43	34.94	79.85	F(1, 566) = 3.20	P = 0.07
Vasectomy: No	76.23	1.96	72.38	80.07		
Yes	80.86	2.65	75.65	86.07	F(1, 566) = 1.97	P = 0.16
Penile surgery: No	77.52	1.63	74.32	80.72		
Yes	73.80	10.38	53.41	94.19	F(1, 566) = 0.12	P = 0.72
Bladder surgery: No	78.26	1.61	75.09	81.42		
Yes	44.26	9.70	25.21	63.32	F(1, 566) = 11.95	P = 0.0006
Digestive disease: No	77.97	1.69	74.65	81.29		
Yes	72.68	5.25	62.37	82.99	F(1, 566) = 0.92	P = 0.34
Circulatory disease: No	77.33	1.68	74.03	80.62		
Yes	78.86	5.49	68.07	89.65	F(1, 566) = 0.07	P = 0.79
Musculoskeletal disease: No	79.72	1.66	76.45	82.99		
Yes	62.07	5.09	52.06	72.07	F(1, 566) = 10.86	P = 0.001
Neurological disease: No	78.02	1.63	74.83	81.22		
Yes	58.02	8.28	41.76	74.28	F(1, 566) = 5.63	P = 0.018
Psychological disease: No	78.34	1.61	75.17	81.51		
Yes	52.30	9.84	32.97	71.62	F(1, 566) = 6.82	P = 0.009
Respiratory disease: No	78.08	1.62	74.90	81.27		
Yes	64.93	9.08	47.09	82.77	F(1, 566) = 2.04	P = 0.15
Metabolic endo. nut. disease:	78.00	1.61	74.83	81.17		
Yes	54.73	10.71	33.70	75.77	F(1, 566) = 4.62	P = 0.03

	Mean	S.E.	95% CI		Adj. Wald test	
Urological disease: No	77.88	1.61	74.71	81.05		
Yes	55.68	12.76	30.63	80.73	F(1, 566) = 2.98	P = 0.08
Medication, general health: No	80.35	1.65	77.11	83.59		
Yes	63.25	4.64	54.13	72.37	F(1, 566) = 12.04	P = 0.0006
Medication, digestive: No	80.38	1.62	77.19	83.57		
Yes	58.89	5.22	48.63	69.16	F(1, 566) = 15.42	P = 0.0001
Medication, circulatory: No	83.11	1.69	79.79	86.42		
Yes	62.28	3.43	55.54	69.03	F(1, 566) = 29.65	P < 0.0001
Medication, musculoskeletal:	80.60	1.67	77.33	83.88		
Yes	59.97	4.55	51.02	68.91	F(1, 566) = 18.08	P < 0.0001
Medication, neurological: No	78.10	1.66	74.84	81.36		
Yes	69.04	6.09	57.08	81.00	F(1, 566) = 2.06	P = 0.15
Medication, psychological: No	80.23	1.60	77.09	83.38		
Yes	48.66	6.23	36.43	60.89	F(1, 566) = 24.17	P < 0.0001
Medication, respiratory: No	78.36	1.69	75.04	81.69		
Yes	70.90	4.98	61.12	80.67	F(1, 566) = 2.02	P = 0.16
Medication, metabolic endo	82.39	1.65	79.15	85.63		
Yes	59.67	3.90	52.01	67.32	F(1, 566) = 28.87	P < 0.0001
Medication, urological: No	77.96	1.60	74.81	81.11		
Yes	31.96	11.36	9.65	54.27	F(1, 566) = 16.07	P = 0.0001
Medication, male genital: No	77.87	1.63	74.68	81.07		
Yes	66.42	9.34	48.08	84.76	F(1, 566) = 1.46	P = 0.2275

Table V.XX The effect of chronic disease, urogenital surgery and medication use on limitations to usual role activities because of physical problems in 568 men, aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide. Data presented are mean \pm S.E. Comparison of means were made using an adjusted Wald test.

	Mean	S.E.	95% CI		Adj. Wald test	
Angina: No	74.68	1.08	72.55	76.81		
Yes	54.99	3.90	47.33	62.66	F(1, 566) = 23.65	P < 0.0001
Anxiety: No	74.91	1.10	72.75	77.06		
Yes	59.49	3.61	52.40	66.58	F(1, 566) = 16.71	P < 0.0001
Asthma: No	74.22	1.12	72.03	76.41		
Yes	66.69	3.35	60.11	73.27	F(1, 566) = 4.54	P = 0.03
Depression: No	75.34	1.12	73.15	77.53		
Yes	59.25	2.84	53.68	64.82	F(1, 566) = 27.93	P < 0.0001
Diabetes: No	74.36	1.11	72.18	76.54		
Yes	63.20	3.36	56.60	69.79	F(1, 566) = 9.97	P = 0.002
Enlarged prostate: No	74.29	1.10	72.13	76.45		
Yes	64.88	3.92	57.19	72.57	F(1, 566) = 5.36	P = 0.02
High cholesterol: No	76.32	1.24	73.89	78.76		
Yes	66.84	1.92	63.07	70.61	F(1, 566) = 17.23	P < 0.0001
High BP: No	75.45	1.22	73.06	77.84		
Yes	67.92	2.07	63.87	71.98	F(1, 566) = 9.87	P = 0.002
Insomnia: No	75.42	1.10	73.27	77.58		
Yes	56.21	3.08	50.16	62.26	F(1, 566) = 34.54	P < 0.0001
Osteoarthritis: No	75.46	1.09	73.31	77.60		
Yes	51.26	2.83	45.69	56.82	F(1, 566) = 63.44	P < 0.0001
Rheumatoid arthritis: No	74.28	1.07	72.17	76.38		
Yes	57.38	5.04	47.48	67.28	F(1, 566) = 10.77	P = 0.001
Thyroid problems: No	73.50	1.07	71.39	75.61		

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	72.16	7.83	56.78	87.55	F(1, 566) = 0.03	P = 0.87
Prostate cancer: No	73.53	1.07	71.42	75.63		
Yes	71.02	9.03	53.29	88.76	F(1, 566) = 0.08	P = 0.78
Prostate removal: No	73.81	1.06	71.73	75.89		
Yes	59.93	9.60	41.07	78.80	F(1, 566) = 2.06	P = 0.15
TURP: No	73.79	1.08	71.67	75.92		
Yes	63.15	5.32	52.70	73.60	F(1, 566) = 3.84	P = 0.05
Vasectomy: No	73.69	1.30	71.14	76.24		
Yes	72.87	1.76	69.42	76.33	F(1, 566) = 0.14	P = 0.71
Penile surgery: No	73.37	1.09	71.24	75.51		
Yes	77.58	4.34	69.06	86.10	F(1, 566) = 0.88	P = 0.35
Bladder surgery: No	74.05	1.07	71.95	76.15		
Yes	50.52	5.43	39.86	61.18	F(1, 566) = 18.10	P < 0.0001
Digestive disease: No	73.64	1.12	71.44	75.85		
Yes	72.03	3.36	65.43	78.62	F(1, 566) = 0.21	P = 0.65
Circulatory disease: No	73.48	1.12	71.28	75.68		
Yes	73.46	2.95	67.67	79.25	F(1, 566) = 0.00	P = 0.996
Musculoskeletal disease: No	75.38	1.12	73.18	77.58		
Yes	60.70	3.06	54.70	66.71	F(1, 566) = 20.31	P < 0.0001
Neurological disease: No	74.02	1.06	71.94	76.11		
Yes	55.69	7.26	41.43	69.95	F(1, 566) = 6.25	P = 0.013
Psychological disease: No	73.78	1.08	71.66	75.90		
Yes	65.20	6.05	53.32	77.09	F(1, 566) = 1.95	P = 0.16

	Mean	S.E.	95% CI		Adj. Wald test	
Respiratory disease: No	73.70	1.09	71.57	75.84		
Yes	69.15	5.05	59.23	79.08	F(1, 566) = 0.78	P = 0.38
Metabolic endo. nut.	73.76	1.07	71.65	75.86		
Yes	62.41	7.43	47.82	77.01	F(1, 566) = 2.28	P = 0.13
Urological disease: No	73.71	1.07	71.61	75.82		
Yes	62.14	8.21	46.01	78.27	F(1, 566) = 1.95	P = 0.16
Medication, general health:	75.58	1.12	73.38	77.78		
Yes	63.28	2.82	57.74	68.82	F(1, 566) = 16.41	P = 0.0001
Medication, digestive: No	74.92	1.13	72.69	77.15		
Yes	64.42	2.80	58.92	69.91	F(1, 566) = 12.13	P = 0.0005
Medication, circulatory: No	75.61	1.23	73.19	78.02		
Yes	67.80	2.03	63.81	71.80	F(1, 566) = 10.78	P = 0.001
Medication,	76.80	1.09	74.67	78.94		
Yes	55.17	2.64	49.98	60.36	F(1, 566) = 57.36	P < 0.0001
Medication, neurological:	74.24	1.09	72.11	76.38		
Yes	63.99	4.32	55.50	72.48	F(1, 566) = 5.29	P = 0.02
Medication, psychological:	75.11	1.10	72.96	77.26		
Yes	56.71	3.44	49.95	63.46	F(1, 566) = 26.03	P < 0.0001
Medication, respiratory: No	73.84	1.13	71.62	76.07		
Yes	70.92	3.12	64.80	77.04	F(1, 566) = 0.78	P = 0.38
Medication, metabolic endo	75.85	1.19	73.51	78.19		
Yes	64.99	2.17	60.72	69.26	F(1, 566) = 19.21	P < 0.0001
Medication, urological: No	73.72	1.07	71.62	75.82		

	Mean	S.E.	95% CI		Adj. Wald test	
Yes	53.02	7.52	38.25	67.79	F(1, 566) = 7.43	P = 0.007
Medication, male genital:	73.96	1.08	71.84	76.08		
Yes	61.55	5.42	50.91	72.20	F(1, 566) = 5.04	P = 0.025

Table V.XXI The effect of chronic disease, urogenital surgery and medication use on bodily pain in 568 men, aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide. Data presented are mean \pm S.E. Comparison of means were made using an adjusted Wald test.

VI. Chapter 5.3 Bivariate analyses

	No ED	Mild ED	Moderate ED	Severe ED	Design-based F	P
Overall	0.495	0.284	0.136	0.085		
Age group: 35 - 44 years	0.181	0.102	0.029	0.019		
45 - 54 years	0.136	0.079	0.042	0.010		
55 - 64 years	0.089	0.048	0.031	0.021		
65 - 74 years	0.058	0.043	0.024	0.028		
75 - 79 years	0.032	0.012	0.010	0.007	F(11.46, 6369.35) = 1.97	0.025*
School leaving age: 13 years or younger	0.015	0.008	0.006	0.003		
14 years or younger	0.062	0.026	0.018	0.013		
15 years	0.096	0.064	0.036	0.027		
16 years	0.113	0.083	0.034	0.025		
17 years	0.139	0.062	0.027	0.006		
18 years or older	0.072	0.038	0.018	0.010	F(14.79, 8061.65) = 0.96	0.493
Post school qualifications: None	0.141	0.082	0.045	0.022		
Non bachelor qualification	0.292	0.171	0.081	0.055		
Bachelor degree or higher	0.062	0.031	0.010	0.008	F(5.97, 3317.83) = 0.374	0.895
Annual gross household income: Up to \$20,000	0.078	0.051	0.045	0.032		
\$20,001 - \$40,000	0.120	0.063	0.040	0.022		
\$40,001 - \$60,000	0.138	0.069	0.030	0.015		

	No ED	Mild ED	Moderate ED	Severe ED	Design-based F	P
More than \$80,000	0.078	0.054	0.010	0.013	F(11.90, 6568.18) = 2.43	0.0039*
Work status: Full time/part time/casual	0.345	0.182	0.074	0.033		
Retired	0.112	0.064	0.048	0.045		
Other(1)	0.038	0.038	0.014	0.007	F(5.94, 3301.21) = 4.25	0.0003*
DSS pension: Yes	0.119	0.083	0.051	0.040		
No	0.376	0.201	0.084	0.045	F(5.79, 3221.56) = 2.81	0.011*
Marital status: Married/living with a partner	0.390	0.228	0.112	0.075		
Separated/divorced	0.052	0.035	0.010	0.007		
Widowed	0.011	0.010	0.003	0.000		
Never married	0.042	0.011	0.011	0.002	F(8.47, 4708.09) = 0.81	0.603
Country of birth: Australia	0.330	0.192	0.100	0.057		
United Kingdom	0.094	0.051	0.017	0.016		
Other	0.072	0.041	0.020	0.012	F(5.92, 3290.77) = 0.318	0.926

Table VI.I The proportions of men reporting no, mild, moderate and severe ED by age group, school-leaving age, post-secondary qualifications, annual gross household income, work status, DSS pension, marital status and country of birth.

	IIEF_EF			F	P
	Mean	SE	95% CI		
Overall	19.37	0.39	18.60 20.14		
Age group:					
35 - 44 years	19.98	0.75	18.52 21.45		
45 - 54 years	20.69	0.61	19.48 21.89		
55 - 64 years	19.15	0.71	17.76 20.53		
65 - 74 years	16.89	1.10	14.73 19.06		
75 - 79 years	17.24	2.02	13.27 21.21	(4,555) = 2.78	0.026*
School leaving age: 13 years or younger	19.83	2.23	15.46 24.20		
14 years or younger	18.39	1.28	15.88 20.90		
15 years	18.81	0.77	17.29 20.33		
16 years	18.09	0.86	16.40 19.77		
17 years	21.74	0.67	20.42 23.07		
18 years or older	19.20	1.03	17.17 21.23	(5,543) = 3.04	0.010*
	Mean	SE	95% CI		
Post school qualifications: None	19.45	0.73	18.02 20.87		
Non bachelor	19.45	0.51	18.46 20.45		
Bachelor degree	18.71	1.17	16.43 21.00	(2,557) = 0.18	0.837
Annual gross household income: Up to	16.93	0.92	15.12 18.74		
\$20,001 -	19.07	0.80	17.50 20.63		
\$40,001 -	19.72	0.78	18.18 21.26		
\$60,001 -	21.52	0.97	19.62 23.42		
More than	20.66	0.85	18.99 22.32	(4,551) = 3.56	0.007*
Work status: Full time/part time/casual	20.37	0.46	19.46 21.28		

	IIEF_EF			F	P
	Mean	SE	95% CI		
Retired	17.53	0.84	15.88 19.17		
Other(1)	17.10	1.12	15.80 20.20	(2,557) = 5.43	0.005*
DSS pension: Yes	17.59	0.77	16.08 19.10		
No	20.11	0.45	19.24 20.99	(1,558) = 8.09	0.005*
Marital status: Married/living with a	19.56	0.42	18.72 20.39		
Separated/divorced	19.66	1.21	17.29 22.03		
Widowed	18.35	2.86	12.73 23.96		
Never married	17.03	1.82	13.45 20.60	(3,556) = 0.67	0.57
Country of birth: Australia	19.38	0.47	18.45 20.31		
United Kingdom	18.33	1.02	16.32 20.34		
Other	20.61	0.86	18.92 22.31	(2,557) = 1.51	0.22

Table VI.II Mean IIEF erectile function (EF) domain scores by age group, school-leaving age, post-secondary qualifications, annual gross household income, work status, DSS pension, marital status and country of birth.

		IIEF_SD			F	P
		Mean	SE	95% CI		
Overall		6.46	0.09	6.29	6.64	
Age group:	35 - 44 years	6.70	0.17	6.37	7.03	
	45 - 54 years	6.49	0.15	6.21	6.78	
	55 - 64 years	6.32	0.18	5.97	6.67	
	65 - 74 years	6.12	0.25	5.64	6.61	
	75 - 79 years	6.32	0.42	5.49	7.14	(4,557) = 1.17 0.32
School leaving age:	13 years or younger	7.22	0.42	6.40	8.05	
	14 years or younger	6.45	0.26	5.93	6.96	
	15 years	6.27	0.18	5.93	6.61	
	16 years	6.13	0.18	5.78	6.49	
	17 years	7.00	0.18	6.66	7.35	
	18 years or older	6.33	0.26	5.83	6.84	(5,545) = 3.45 0.0044*
Post school qualifications:	None	6.58	0.17	6.24	6.92	
	Non bachelor qualification	6.41	0.11	6.20	6.63	
	Bachelor degree or higher	6.40	0.27	5.88	6.93	(2,559) = 0.36 0.70
Annual gross household income:	Up to					
	\$20,000	6.19	0.19	5.82	6.57	
	\$20,001 - \$40,000	6.19	0.18	5.82	6.55	
	\$40,001 - \$60,000	6.58	0.18	6.23	6.94	
	\$60,001 - \$80,000	6.99	0.23	6.54	7.45	
	More than \$80,000	6.56	0.20	6.16	6.96	(4,553) = 2.51 0.041*

	IIEF_SD			F	P
	Mean	SE	95% CI		
Work status: Full time/part time/casual employment	6.54	0.11	6.33	6.76	
Retired	6.19	0.19	5.82	6.55	
Other(1)	6.70	0.23	6.24	7.15	(2,559) = 1.84 0.16
DSS pension: Yes	6.23	0.17	5.91	6.55	
No	6.56	0.10	6.36	6.77	(1,560) = 2.85 0.092
Marital status: Married/living with a partner	6.47	0.10	6.28	6.66	
Separated/divorced	6.30	0.30	5.71	6.89	
Widowed	6.82	0.59	5.67	7.98	
Never married	6.48	0.38	5.73	7.23	(3,558) = 0.23 0.88
Country of birth: Australia	6.44	0.11	6.23	6.64	
United Kingdom	6.36	0.23	5.91	6.81	
Other	6.70	0.22	6.27	7.14	(2,557) = 1.51 0.22

Table VI.III Mean IIEF sexual desire (SD) domain scores by age group, school-leaving age, post-secondary qualifications, annual gross household income, work status, DSS pension, marital status and country of birth.

		Dyadic SDI-2 score			F	P
		Mean	SE	95% CI		
Overall		36.60	0.62	35.39	37.82	
Age group:	35 - 44 years	42.22	0.87	40.50	43.93	
	45 - 54 years	40.10	0.78	38.56	41.64	
	55 - 64 years	35.73	1.08	33.61	37.85	
	65 - 74 years	27.46	1.55	24.41	30.50	
	75 - 79 years	13.77	2.49	8.87	18.67	(4,547) = 43.48 <0.0001
School leaving age:	13 years or	33.09	3.46	26.30	39.89	
	14 years or	27.24	2.09	23.12	31.35	
	15 years	36.38	1.37	33.68	39.07	
	16 years	36.34	1.13	34.11	38.57	
	17 years	40.18	0.93	38.36	42.00	
	18 years or older	40.07	1.68	36.77	43.36	(5,535) = 7.54 <0.0001
Post school qualifications:	None	35.54	1.27	33.05	38.02	
	Non	36.34	0.79	34.80	37.88	
	Bachelor	40.61	1.42	37.82	43.40	(2,549) = 4.23 0.015
Annual gross household income:		30.11	1.69	26.80	33.42	
		34.22	1.29	31.68	36.76	
		38.25	1.14	36.02	40.48	
		42.32	1.20	39.96	44.69	
	More	40.21	1.03	38.20	42.23	(4,542) = 11.92 <0.0001
Work status:	Full time/part	40.59	0.59	39.44	41.74	
	Retired	26.51	1.31	23.93	29.10	

	Dyadic SDI-2 score				F	P
	Mean	SE	95% CI			
Other(1)	37.56	1.75	34.12	41.01	(2,549) = 47.78	<0.0001
DSS pension: Yes	28.63	1.35	25.99	31.27		
No	39.77	0.59	38.62	40.92	(1,550) = 57.64	<0.0001
Marital status: Married/living with a	36.19	0.65	34.90	37.47		
Separated/divorced	39.15	1.87	35.48	42.82		
Widowed	21.80	6.15	9.71	33.88		
Never married	42.15	2.36	37.51	46.78	(3,548) = 4.49	0.004
Country of birth: Australia	37.02	0.73	35.59	38.45		
United Kingdom	36.14	1.55	33.08	39.19		
Other	35.14	1.68	31.85	38.43	(2,549) = 0.59	0.56

Table VI.IV Mean Dyadic SDI-2 scores by age group, school-leaving age, post-secondary qualifications, annual gross household income, work status, DSS pension, marital status and country of birth.

	Solitary SDI-2 score			F	P
	Mean	SE	95% CI		
Overall	6.15	0.27	5.62 6.67		
Age group:					
35 - 44 years	8.14	0.57	7.02 9.27		
45 - 54 years	7.23	0.43	6.39 8.07		
55 - 64 years	4.60	0.42	3.78 5.42		
65 - 74 years	3.64	0.51	2.65 4.63		
75 - 79 years	1.53	0.46	0.63 2.44	(4,557) = 30.21	<0.0001
School leaving age: 13 years or younger	2.26	0.59	1.10 3.42		
14 years or younger	2.61	0.46	1.70 3.51		
15 years	6.03	0.58	4.90 7.17		
16 years	6.85	0.56	5.75 7.95		
17 years	7.41	0.56	6.31 8.50		
18 years or older	6.91	0.75	5.44 8.37	(5,545) = 17.32	<0.0001
Post school qualifications: None	5.73	0.52	4.70 6.76		
Non bachelor qualification	5.79	0.32	5.16 6.43		
Bachelor degree or higher	9.10	0.90	7.34 10.86	(2,559) = 6.29	0.002
Annual gross household income: Up to	4.17	0.60	2.99 5.34		
\$20,001 - \$40,000	5.32	0.51	4.33 6.31		
\$40,001 - \$60,000	6.65	0.55	5.56 7.74		
\$60,001 - \$80,000	8.37	0.69	7.01 9.73		
More than \$80,000	7.22	0.56	6.11 8.32	(4,552) = 7.05	<0.0001
Work status: Full time/part time/casual	7.06	0.34	6.40 7.73		

	Solitary SDI-2 score			F	P
	Mean	SE	95% CI		
Retired	3.58	0.40	2.79	4.36	
Other(1)	7.27	0.89	5.52	9.02	(2,559) = 23.65 <0.0001
DSS pension: Yes	4.07	0.48	3.13	5.00	
No	7.02	0.31	6.41	7.62	(1,560) = 27.07 <0.0001
Marital status: Married/living with a partner	5.84	0.28	5.28	6.39	
Separated/divorced	7.27	0.89	5.52	9.01	
Widowed	3.38	1.23	0.96	5.80	
Never married	9.10	1.31	6.52	11.67	(3,558) = 4.13 0.0065
Country of birth: Australia	6.31	0.33	5.66	6.97	
United Kingdom	7.03	0.60	5.86	8.21	
Other	4.19	0.57	3.07	5.31	(2,559) = 6.94 0.0011

Table VI.V Mean Solitary SDI-2 scores by age group, school-leaving age, post-secondary qualifications, annual gross household income, work status, DSS pension, marital status and country of birth.

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
<i>SBP (mmHg)</i>						
No ED	126.28	0.92	124.48	128.08		
Mild ED	133.75	1.38	131.05	136.45	F(1, 556) = 20.45	Prob < 0.0001
Moderate ED	141.32	2.03	137.33	145.31	F(2, 555) = 27.44	Prob < 0.0001
Severe ED	143.83	2.83	138.27	149.39	F(3, 554) = 25.57	Prob < 0.0001
<i>DBP (mmHg)</i>						
No ED	82.87	0.54	81.81	83.94		
Mild ED	86.41	0.68	85.07	87.74	F(1, 556) = 16.46	Prob < 0.0001
Moderate ED	86.48	1.17	84.18	88.77	F(2, 555) = 9.82	Prob < 0.0001
Severe ED	82.80	1.46	79.93	85.68	F(3, 554) = 6.96	Prob < 0.0001
<i>Waist circumference</i>						
No ED	98.81	0.79	97.25	100.37		
Mild ED	99.92	0.92	98.11	101.74	F(1, 556) = 0.83	Prob = 0.36
Moderate ED	102.89	1.45	100.05	105.73	F(2, 555) = 3.04	Prob = 0.049
Severe ED	102.32	1.76	98.88	105.77	F(3, 554) = 2.63	Prob = 0.049

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
<i>Serum triglycerides</i>						
No ED	1.66	0.08	1.50	1.82		
Mild ED	1.75	0.13	1.49	2.01	F(1, 554) = 0.30	Prob = 0.58
Moderate ED	1.92	0.16	1.62	2.23	F(2, 553) = 1.11	Prob = 0.33
Severe ED	1.36	0.11	1.14	1.58	F(3, 552) = 3.49	Prob = 0.016
<i>Serum total cholesterol</i>						
No ED	5.52	0.06	5.40	5.65		
Mild ED	5.48	0.08	5.32	5.65	F(1, 554) = 0.16	Prob = 0.69
Moderate ED	5.09	0.14	4.81	5.37	F(2, 553) = 3.99	Prob = 0.019
Severe ED	4.98	0.16	4.66	5.30	F(3, 552) = 5.36	Prob = 0.001
<i>Serum LDL (mmol/L)</i>						
No ED	3.63	0.06	3.51	3.75		
Mild ED	3.58	0.08	3.42	3.74	F(1, 526) = 0.25	Prob = 0.62
Moderate ED	3.04	0.11	2.83	3.24	F(2, 525) = 12.25	Prob < 0.0001

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Severe ED	3.14	0.14	2.86	3.42	F(3, 524) = 10.32	Prob < 0.0001
<i>Serum HDL (mmol/L)</i>						
No ED	1.17	0.02	1.13	1.20		
Mild ED	1.19	0.02	1.14	1.24	F(1, 554) = 0.57	Prob = 0.45
Moderate ED	1.15	0.04	1.08	1.23	F(2, 553) = 0.43	Prob = 0.65
Severe ED	1.24	0.05	1.14	1.33	F(3, 552) = 0.83	Prob = 0.48
<i>Serum glucose (mmol/L)</i>						
No ED	4.48	0.06	4.36	4.60		
Mild ED	4.65	0.09	4.47	4.83	F(1, 554) = 2.38	Prob = 0.12
Moderate ED	5.06	0.14	4.80	5.33	F(2, 553) = 7.95	Prob = 0.0004
Severe ED	5.23	0.19	4.87	5.59	F(3, 552) = 8.97	Prob < 0.0001
<i>HbA1c (?)</i>						
No ED	5.50	0.04	5.43	5.57		
Mild ED	5.69	0.07	5.56	5.82	F(1, 556) = 6.30	Prob = 0.012

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Moderate ED	5.94	0.12	5.72	6.17	F(2, 555) = 8.77	Prob = 0.0002
Severe ED	6.19	0.14	5.90	6.47	F(3, 554) = 11.64	Prob < 0.0001
<i>Daily energy intake</i>						
No ED	9505.90	204.59	9104.04	9907.76		
Mild ED	8830.55	250.43	8338.66	9322.45	F(1, 556) = 4.34	Prob = 0.038
Moderate ED	8782.11	356.52	8081.82	9482.41	F(2, 555) = 2.83	Prob = 0.06
Severe ED	8175.12	447.13	7296.85	9053.39	F(3, 554) = 3.34	Prob = 0.019
<i>Daily fat intake (grams)</i>						
No ED	96.35	2.49	91.46	101.24		
Mild ED	87.73	2.70	82.44	93.03	F(1, 556) = 5.49	Prob = 0.02
Moderate ED	85.93	3.90	78.27	93.60	F(2, 555) = 3.85	Prob = 0.022
Severe ED	82.59	5.56	71.67	93.51	F(3, 554) = 3.29	Prob = 0.02
<i>Daily alcohol intake</i>						
No ED	21.20	1.52	18.21	24.19		

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Mild ED	22.69	1.85	19.05	26.33	F(1, 556) = 0.38	Prob = 0.54
Moderate ED	14.81	1.83	11.21	18.41	F(2, 555) = 5.32	Prob = 0.005
Severe ED	18.65	3.18	12.40	24.89	F(3, 554) = 3.58	Prob = 0.014

Table VI.VI Mean values for chronic disease risk factors, by Global Impotence Rating.

	Sedentary	Insufficient PA	Sufficient PA	Total
No ED	0.22	0.09	0.21	0.52
Mild ED	0.11	0.04	0.11	0.26
Moderate ED	0.07	0.02	0.04	0.13
Severe ED	0.03	0.01	0.04	0.09
Total	0.44	0.16	0.40	1.00

Uncorrected $\chi^2(6) = 5.3378$

Design-based $F(5.96, 3314.27) = 0.8236$ $P = 0.5507$

	Current smoker	Non-smoker	Occasional smoker	Total
No ED	0.12	0.38	0.02	0.52
Mild ED	0.05	0.20	0.01	0.26
Moderate ED	0.02	0.11	0.00	0.13
Severe ED	0.01	0.07	0.00	0.09
Total	0.21	0.76	0.03	1.00

Uncorrected $\chi^2(6) = 9.4814$

Design-based $F(5.87, 3264.79) = 1.4735$ $P = 0.1846$

Table VI.VII Proportions of men with no ED, mild, moderate and severe ED, by physical activity level and smoking status.

	Coefficient	Std.Err.	t	P> t	[95% Conf. Interval]	
SBP	-0.131	0.024	-5.500	0.0000	-0.178	-0.084
DBP	0.005	0.047	0.100	0.9200	-0.088	0.097
Waist circumference	-0.038	0.033	-1.160	0.2480	-0.104	0.027
Serum triglycerides	-0.097	0.261	-0.370	0.7090	-0.610	0.415
Serum total cholesterol	1.500	0.363	4.140	0.0000	0.788	2.212
Serum LDL	2.085	0.396	5.260	0.0000	1.307	2.863
Serum HDL	-0.104	1.447	-0.070	0.9430	-2.947	2.739
Serum glucose	-1.749	0.418	-4.190	0.0000	-2.570	-0.928
HbA1c	-2.480	0.566	-4.380	0.0000	-3.591	-1.368
Daily energy intake	0.000	0.000	2.670	0.0080	0.000	0.001
Daily fat intake	0.026	0.010	2.520	0.0120	0.006	0.046
Daily alcohol intake	0.041	0.018	2.310	0.0210	0.006	0.075

Table VI.VIII Simple linear regression statistics for associations between erectile function scores on the IIEF and chronic disease risk factors.

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Sedentary	19.07	0.60	17.89	20.24		
Insufficient PA	20.06	1.01	18.07	22.05	F(1, 558) = 0.72	Prob = 0.3978
Sufficient PA	19.71	0.59	18.55	20.88	F(2, 557) = 0.48	Prob = 0.6193
Current smokers	19.65	0.87	17.93	21.36		
Non-smokers	19.36	0.45	18.48	20.24	F(1, 558) = 0.09	Prob= 0.7663

Table VI.IX Mean erectile function domain scores from the IIEF by physical activity level and smoking status.

	Coefficient	Std.Err.	t	P> t	[95% Conf. Interval]	
SBP	-0.031	0.005	-5.73	0.0000	-0.042	-0.021
DBP	-0.001	0.01	-0.11	0.913	-0.022	0.019
Waist circumference	-0.016	0.008	-1.92	0.055	-0.032	0.0004
Serum triglycerides	0.002	0.061	0.04	0.969	-0.117	0.122
Serum total cholesterol	0.223	0.088	2.53	0.012	0.050	0.397
Serum LDL	0.290	0.097	2.97	0.003	0.098	0.481
Serum HDL	-0.188	0.351	-0.54	0.592	-0.877	0.501
Serum glucose	-0.246	0.080	-3.08	0.002	-0.402	-0.089
HbA1c	-0.459	0.129	-3.570	0.0004	-0.712	-0.206
Daily energy intake	0.00007	0.00003	2.50	0.013	0.00002	0.0001
Daily fat intake	0.006	0.003	2.460	0.014	0.001	0.011
Daily alcohol intake	0.014	0.004	3.54	0.0004	0.006	0.021

Table VI.X Simple linear regression statistics for associations between sexual desire scores on the IIEF and chronic disease risk factors.

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Sedentary	6.43	0.14	6.15	6.71		
Insufficient PA	6.25	0.22	5.82	6.68	F(1, 560) = 0.49	P = 0.486
Sufficient PA	6.59	0.14	6.31	6.86	F(2, 559) = 0.88	P = 0.414
Current smokers	6.67	0.23	6.22	7.12		
Non-smokers	6.35	0.10	6.15	6.55	F(1, 560) = 1.62	P = 0.204

Table VI.XI Mean sexual desire domain scores from the IIEF by physical activity level and smoking status.

	Coefficient	Std.Err.	t	P> t	[95% Conf. Interval]	
SBP	-0.232	0.037	-6.31	< 0.0001	-0.305	-0.160
DBP	-0.078	0.066	-1.19	0.235	-0.208	0.051
Waist circumference	-0.107	0.049	-2.20	0.028	-0.203	-0.012
Serum triglycerides	0.109	0.387	0.280	0.778	-0.651	0.870
Serum total cholesterol	1.324	0.611	2.17	0.031	0.123	2.524
Serum LDL	1.947	0.646	3.02	0.003	0.679	3.216
Serum HDL	-2.495	2.359	-1.06	0.291	-7.129	2.139
Serum glucose	-1.640	0.560	-2.93	0.004	-2.740	-0.540
HbA1c	-2.893	0.942	-3.07	0.002	-4.744	-1.042
Daily energy intake	0.0006	0.0002	3.35	0.001	0.0003	0.001
Daily fat intake	0.048	0.016	3.04	0.002	0.017	0.079
Daily alcohol intake	0.098	0.025	3.89	0.0001	0.048	0.147

Table VI.XII Simple linear regression statistics for associations between dyadic sexual desire scores on the SDI-2 and chronic disease risk factors.

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Sedentary	36.78	0.99	34.83	38.73		
Insufficient PA	34.97	1.41	32.20	37.74	F(1, 550 = 1.10	P = 0.294
Sufficient PA	37.07	0.93	35.24	38.89	F(2, 549= 0.81	P = 0.446
Current smokers	37.19	1.34	34.56	39.81		
Non-smokers	36.01	0.71	34.62	37.40	F(1, 550 = 0.60	P = 0.437

Table VI.XIII Mean dyadic sexual desire scores from the SDI-2 by physical activity level and smoking status.

	Coefficient	Std.Err.	t	P> t	[95% Conf. Interval]	
SBP	-0.063	0.015	-4.20	<0.0001	-0.092	-0.034
DBP	-0.048	0.028	-1.70	0.09	-0.104	0.008
Waist circumference	-0.038	0.024	-1.60	0.110	-0.085	0.009
Serum triglycerides	-0.094	0.206	-0.45	0.649	-0.498	0.311
Serum total cholesterol	0.021	0.228	0.09	0.926	-0.427	0.470
Serum LDL	0.217	0.276	0.79	0.433	-0.325	0.759
Serum HDL	-1.095	0.872	-1.26	0.210	-2.807	0.618
Serum glucose	-0.636	0.194	-3.27	0.001	-1.018	-0.254
HbA1c	-0.784	0.288	-2.72	0.007	-1.35	-0.217
Daily energy intake	0.0002	0.00009	2.47	0.014	0.00005	0.0004
Daily fat intake	0.025	0.008	3.02	0.003	0.009	0.041
Daily alcohol intake	0.037	0.013	2.72	0.007	0.01	0.063

Table VI.IV Simple linear regression statistics for associations between solitary sexual desire scores on the SDI-2 and chronic disease risk factors.

	Mean	Std.Err.	[95%Conf.	Interval]	Adj. Wald test	
Sedentary	6.26	0.43	5.42	7.10		
Insufficient PA	6.39	0.57	5.27	7.51	F(1, 560) = 0.03	P = 0.852
Sufficient PA	5.93	0.42	5.12	6.75	F(2, 559) = 0.26	P = 0.775
Current smokers	6.44	0.64	5.19	7.69		
Non-smokers	5.98	0.29	5.40	6.55	F(1, 560) = 0.43	P = 0.512

Table VI.XV Mean solitary sexual desire scores from the SDI-2 by physical activity level and smoking status.

Chi-squared tables

Waist > 102 v GIR

pweight:	wt	Number of obs	=	558
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	558
		Population size	=	559.45569

GIR

Waist > 102					
No	0	1	2	3	Total
	.3413	.1565	.0718	.0481	.6177
	[.2995, .3857]	[.1281, .19]	[.0528, .097]	[.0325, .0706]	[.5742, .6594]
Yes	.1818	.1009	.0618	.0377	.3823
	[.1491, .2199]	[.0783, .1293]	[.0451, .0842]	[.0241, .0584]	[.3406, .4258]
Total	.5231	.2575	.1337	.0858	1
	[.4787, .5671]	[.2218, .2967]	[.1078, .1646]	[.0643, .1136]	

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(3)	=	4.2439	
Design-based	F(2.99, 1661.20)	=	1.3245	P = 0.2648

Waist > 102 v ED (yes/no)

pweight:	wt	Number of obs	=	558
Strata:	nwregion	Number of strata	=	2
PSU:	<observations>	Number of PSUs	=	558
		Population size	=	558.19919

Waist > 102			
	No	ED	Total
		Yes	
No	.3125	.3089	.6215
	[.2729, .3551]	[.2691, .3518]	[.578, .663]
Yes	.1826	.1959	.3785
	[.1505, .2198]	[.164, .2323]	[.337, .422]
Total	.4952	.5048	1
	[.4509, .5395]	[.4605, .5491]	

Key: cell proportions
[95% confidence intervals for cell proportions]

Pearson:

Uncorrected	chi2(1)	=	0.2205	
Design-based	F(1, 556)	=	0.1937	P = 0.6600

BMI > 30 v GIR

```

pweight: wt           Number of obs   =      558
Strata:  nwregion     Number of strata  =        2
PSU:    <observations> Number of PSUs   =      558
                               Population size = 559.45569
    
```

BMI > 30	GIR				Total
	0	1	2	3	
No	.3562 [.3138, .401]	.1709 [.1412, .2055]	.0855 [.0644, .1126]	.0531 [.0366, .0764]	.6657 [.6231, .7058]
Yes	.1669 [.1355, .2039]	.0865 [.0658, .113]	.0482 [.0342, .0675]	.0327 [.0202, .0524]	.3343 [.2942, .3769]
Total	.5231 [.4787, .5671]	.2575 [.2218, .2967]	.1337 [.1078, .1646]	.0858 [.0643, .1136]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

```

Pearson:
  Uncorrected  chi2(3)      =  1.0022
  Design-based F(2.98, 1657.18) =  0.3181    P = 0.8110
    
```

BMI > 30 v ED (yes/no)

```

pweight: wt           Number of obs   =      558
Strata:  nwregion     Number of strata  =        2
PSU:    <observations> Number of PSUs   =      558
                               Population size = 558.19919
    
```

BMI > 30	ED		Total
	No	Yes	
No	.3441 [.3031, .3876]	.3234 [.283, .3666]	.6675 [.6248, .7076]
Yes	.151 [.1219, .1856]	.1815 [.1504, .2173]	.3325 [.2924, .3752]
Total	.4952 [.4509, .5395]	.5048 [.4605, .5491]	1

Key: cell proportions
[95% confidence intervals for cell proportions]

```

Pearson:
  Uncorrected  chi2(1)      =  1.8626
  Design-based F(1, 556)   =  1.6439    P = 0.2003
    
```

VII. Chapter 5.4 Bivariate analyses tables

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
Age group: 35 - 44 years	1.07	0.19	0.71	1.44		
45 - 54 years	1.05	0.17	0.72	1.38	F(1, 566) = 0.01	Prob = 0.94
55 - 64 years	1.32	0.19	0.95	1.68	F(2, 565) = 0.66	Prob = 0.52
65 - 74 years	2.64	0.37	1.91	3.38	F(3, 564) = 5.41	Prob = 0.0011
75 - 79 years	3.81	0.69	2.46	5.17	F(4, 563) = 7.41	Prob < 0.0001
School leaving age: 13 years or younger	1.60	0.51	0.59	2.61		
14 years or younger	2.67	0.47	1.74	3.60	F(1, 555) = 2.33	Prob = 0.13
15 years	1.48	0.23	1.03	1.94	F(2, 554) = 2.53	Prob = 0.081
16 years	1.49	0.21	1.08	1.89	F(3, 553) = 1.87	Prob = 0.13
17 years	1.17	0.23	0.73	1.62	F(4, 552) = 2.03	Prob = 0.09
18 years or older	1.19	0.29	0.61	1.77	F(5, 551) = 1.78	Prob = 0.11
Post school qualifications: None	1.47	0.21	1.05	1.89		
Non bachelor qualification	1.63	0.16	1.32	1.94	F(1, 566) = 0.36	Prob = 0.55
Bachelor degree or higher	1.07	0.22	0.63	1.51	F(2, 565) = 2.06	Prob = 0.13
Annual gross household income: Up to \$20,000	1.77	0.24	1.29	2.24		

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
\$20,001 - \$40,000	1.94	0.28	1.38	2.49	F(1, 561) = 0.20	Prob = 0.65
\$40,001 - \$60,000	1.38	0.22	0.95	1.81	F(2, 560) = 1.40	Prob = 0.25
\$60,001 - \$80,000	1.03	0.29	0.46	1.60	F(3, 559) = 2.16	Prob = 0.092
More than \$80,000	1.23	0.24	0.76	1.69	F(4, 558) = 1.94	Prob = 0.10
Work status: Full time/part time/casual						
employment	1.08	0.12	0.85	1.32		
Retired	2.67	0.28	2.11	3.23	F(1, 566) = 26.35	Prob < 0.0001
Other(1)	1.16	0.24	0.69	1.62	F(2, 565) = 13.37	Prob < 0.0001
Country of birth: Australia						
United Kingdom	1.59	0.30	0.99	2.18	F(1, 566) = 0.14	Prob = 0.71
Other	1.71	0.34	1.04	2.38	F(2, 565) = 0.27	Prob = 0.77
DSS pension: Yes						
No	1.19	0.12	0.96	1.42	F(1, 566) = 14.71	Prob = 0.0001
Marital status: Married/living with a						
partner	1.50	0.13	1.25	1.75		
Separated/divorced	1.65	0.36	0.93	2.36	F(1, 566) = 0.14	Prob = 0.71

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
Widowed	3.51	1.20	1.16	5.87	F(2, 565) = 1.44	Prob = 0.24
Never married	0.83	0.25	0.34	1.32	F(3, 564) = 3.16	Prob = 0.024

Table VII.I Obstructive LUTS scores by age, school leaving age, highest post-secondary qualification, gross annual household income, work status, country of birth, DSS pension status and marital status.

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
Age group: 35 - 44 years	2.46	0.22	2.03	2.90		
45 - 54 years	2.95	0.22	2.52	3.37	F(1, 566) = 2.41	Prob > F = 0.1212
55 - 64 years	2.89	0.26	2.38	3.41	F(2, 565) = 1.38	Prob > F = 0.2532
65 - 74 years	4.74	0.44	3.87	5.61	F(3, 564) = 7.04	Prob > F = 0.0001
75 - 79 years	5.63	0.83	3.99	7.26	F(4, 563) = 7.81	Prob > F = 0.0000
School leaving age: 13 years or younger	3.28	1.01	1.30	5.27		
14 years or younger	3.92	0.53	2.87	4.97	F(1, 555) = 0.31	Prob > F = 0.5777
15 years	3.51	0.27	2.99	4.04	F(2, 554) = 0.27	Prob > F = 0.7600
16 years	3.12	0.29	2.55	3.69	F(3, 553) = 0.69	Prob > F = 0.5603
17 years	2.78	0.25	2.29	3.27	F(4, 552) = 1.53	Prob > F = 0.1923
18 years or older	2.98	0.39	2.23	3.74	F(5, 551) = 1.27	Prob > F = 0.2758
Post school qualifications: None	3.08	0.25	2.59	3.57		
Non bachelor qualification	3.37	0.19	2.99	3.75	F(1, 566) = 0.87	Prob > F = 0.3506
Bachelor degree or higher	2.73	0.36	2.02	3.44	F(2, 565) = 1.35	Prob > F = 0.2604
Annual gross household income: Up to						
\$20,000	3.76	0.36	3.05	4.48		

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
\$20,001 - \$40,000	3.80	0.30	3.21	4.38	F(1, 561) = 0.00	Prob > F = 0.9453
\$40,001 - \$60,000	3.16	0.29	2.59	3.74	F(2, 560) = 1.40	Prob > F = 0.2485
\$60,001 - \$80,000	2.22	0.26	1.71	2.72	F(3, 559) = 6.85	Prob > F = 0.0002
More than \$80,000	2.58	0.28	2.03	3.14	F(4, 558) = 5.79	Prob > F = 0.0001
Work status: Full time/part time/casual						
employment	2.61	0.14	2.33	2.89		
Retired	4.58	0.34	3.91	5.25	F(1, 566) = 28.46	Prob > F = 0.0000
Other(1)	3.37	0.46	2.46	4.28	F(2, 565) = 14.68	Prob > F = 0.0000
Country of birth: Australia						
United Kingdom	3.07	0.32	2.44	3.71	F(1, 566) = 0.08	Prob > F = 0.7731
Other	3.57	0.44	2.70	4.44	F(2, 565) = 0.44	Prob > F = 0.6463
DSS pension: Yes						
No	4.21	0.31	3.60	4.81		
	2.81	0.15	2.51	3.10	F(1, 566) = 16.67	Prob > F = 0.0001
Marital status: Married/living with a						
partner	3.09	0.15	2.79	3.38		
Separated/divorced	3.44	0.48	2.49	4.39	F(1, 566) = 0.49	Prob > F = 0.4864

	Mean	Std.Err.	[95% Conf. Interval]	Adjusted Wald test
Widowed	6.43	1.49	3.50 9.36	F(2, 565) = 2.68 Prob > F = 0.0692
Never married	3.28	0.57	2.17 4.39	F(3, 564) = 1.80 Prob > F = 0.1454

Table VII.II Irritative LUTS scores by age, school leaving age, highest post-secondary qualification, gross annual household income, work status, country of birth, DSS pension status and marital status.

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test
Age group: 35 - 44 years	23.31	1.07	21.20	25.43	
45 - 54 years	18.30	0.69	16.93	19.66	F(1, 336) = 15.34 Prob > F = 0.0001
55 - 64 years	17.15	0.69	15.80	18.50	F(2, 335) = 11.92 Prob > F = 0.0000
65 - 74 years	14.91	0.92	13.10	16.72	F(3, 334) = 12.44 Prob > F = 0.0000
75 - 79 years	14.69	1.66	11.42	17.96	F(4, 333) = 10.17 Prob > F = 0.0000
School leaving age: 13 years or younger	18.82	2.11	14.67	22.96	
14 years or younger	17.73	1.26	15.24	20.21	F(1, 330) = 0.20 Prob > F = 0.6581
15 years	17.74	0.91	15.94	19.53	F(2, 329) = 0.12 Prob > F = 0.8898
16 years	19.06	1.11	16.88	21.23	F(3, 328) = 0.36 Prob > F = 0.7842
17 years	19.38	0.96	17.48	21.27	F(4, 327) = 0.54 Prob > F = 0.7091
18 years or older	19.70	1.30	17.14	22.25	F(5, 326) = 0.57 Prob > F = 0.7238
Post school qualifications: None	19.69	1.03	17.65	21.72	
Non bachelor qualification	18.21	0.56	17.11	19.32	F(1, 336) = 1.56 Prob > F = 0.2125
Bachelor degree or higher	20.69	1.66	17.42	23.97	F(2, 335) = 1.54 Prob > F = 0.2169
Annual gross household income: Up to \$20,000	16.82	0.94	14.98	18.67	

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
\$20,001 - \$40,000	17.30	0.74	15.84	18.76	F(1, 333) = 0.16	Prob > F = 0.6905
\$40,001 - \$60,000	19.62	1.07	17.52	21.73	F(2, 332) = 2.19	Prob > F = 0.1137
\$60,001 - \$80,000	21.05	1.60	17.92	24.19	F(3, 331) = 2.78	Prob > F = 0.0410
More than \$80,000	20.70	1.21	18.33	23.08	F(4, 330) = 3.14	Prob > F = 0.0147
Work status: Full time/part time/casual						
employment	20.43	0.64	19.18	21.68		
Retired	15.70	0.67	14.38	17.02	F(1, 336) = 26.06	Prob > F = 0.0000
Other(1)	17.20	1.35	14.55	19.85	F(2, 335) = 13.23	Prob > F = 0.0000
Country of birth: Australia						
United Kingdom	19.39	1.22	16.99	21.79	F(1, 336) = 0.54	Prob > F = 0.4631
Other	20.54	1.35	17.89	23.20	F(2, 335) = 1.20	Prob > F = 0.3011
DSS pension: Yes						
No	16.37	0.73	14.92	17.81		
	19.81	0.59	18.65	20.98	F(1, 336) = 13.37	Prob > F = 0.0003
Marital status: Married/living with a						
partner	19.09	0.54	18.02	20.15		
Separated/divorced	18.88	1.57	15.79	21.97	F(1, 336) = 0.02	Prob > F = 0.9009

	Mean	Std.Err.	[95% Conf.	Interval]	Adjusted Wald test	
Widowed	16.58	2.23	12.20	20.96	F(2, 335) = 0.59	Prob > F = 0.5531
Never married	17.00	1.85	13.35	20.65	F(3, 334) = 0.73	Prob > F = 0.5331

Table VII.III Maximum urine flow rate by age, school leaving age, highest post-secondary qualification, gross annual household income, work status, country of birth, DSS pension status and marital status.